sumatriptan profile

Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5358
CHEMBL ID	128
CHEBI ID	10650
SCHEMBL ID	1482
MeSH ID	M0027392

Synonym
BIDD:GT0248
1-[3-(2-dimethylaminoethyl)-1h-indol-5-yl]-n-methyl-methanesulfonamide
(3-[2-(dimethylamino)ethyl]-1h-indol-5-yl)-n-methylmethanesulfonamide
CHEBI:10650 ,
sumax
3-(2-(dimethylamino)ethyl)-n-methyl-1h-indole-5-methanesulfonamide
sumatran
1-{3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}-n-methylmethanesulfonamide
sumatriptanum
BRD-K50938287-001-01-7
gtpl54
tosymra (nasal spray)
imigran
imitrex
sumatriptanum [inn-latin]
brn 6930870
gr 43175
gr-43175
gr 43175x
1h-indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-n-methyl-
BSPBIO_002304
3-[2-(dimethylamino)ethyl]-n-methylindole-5-methanesulfonamide
MLS001304742
MLS001195659
smr000596517
C07319
sumatriptan
103628-46-2
DB00669
imigran (tn)
sumatriptan (jan/usp/inn)
D00451
imitrex (tn)
NCGC00095838-01
SPECTRUM1505372
NCGC00095838-02
dfn-11 (sumatriptan injection)
dfn-11
CHEMBL128 ,
n02cc01
L000584
bdbm50005835
1-[3-(2-dimethylaminoethyl)-1h-indol-5-yl]-n-methylmethanesulfonamide
dtxsid4023628 ,
dtxcid303628
cas-103628-46-2
tox21_111528
HMS2231B21
zecuity
avp 825
8r78f6l9vo ,
avp-825
avp825
hsdb 7742
sumatriptan [usp:inn:ban]
unii-8r78f6l9vo
FT-0674779
FT-0631027
NCGC00095838-03
sumatriptan [usp monograph]
sumatriptan [usp-rs]
sumatriptan [orange book]
3-[2-(dimethylamino)ethyl]-n-methy-1h-indole-5-methanesulfonamide
tosymra
sumatriptan [who-dd]
sumatriptan [hsdb]
sumatriptan [jan]
sumatriptan [mart.]
sumatriptan [mi]
sumatriptan [inn]
sumatriptan [vandf]
AKOS015894924
HMS3369A05
SCHEMBL1482
tox21_111528_1
NCGC00095838-04
AB00698285-13
AB00698285-12
(3-[2-(dimethylamino)ethyl]-1h-indol-5-yl)-n-methylmethanesulfonamide #
3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5-methanesulphonamide
3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole -5-methanesulphonamide
1-(3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)-n-methylmethanesulfonamide
AB00698285_14
AB00698285_15
STL451003
J-001014
CCG-230331
imigran recovery
1h-indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-n-methyl-
SBI-0206837.P001
{3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}-n-methylmethanesulfonamide
Q416978
1-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]-n-methylmethanesulfonamide
BCP02237
AMY17769
C90357
sumatriptansuccinate
BS164424
sumatriptan- bio-x
EN300-123008
HY-B0121B
CS-0009565
sumatriptanum (inn-latin)
1-(3-(2-dimethylaminoethyl)-1h-indol-5-yl)-n-methyl-methanesulfonamide
sumatriptan (usp:inn:ban)
(3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)-n-methylmethanesulfonamide
sumatriptan (usp monograph)
sumatriptan (mart.)
3-(2-(dimethylamino)ethyl)-n-methy-1h-indole-5-methanesulfonamide
3-(2-(dimethylamino)ethyl)-n-methylindole-5-methanesulfonamide
sumatriptan (usp-rs)

Excerpt	Reference	Relevance
"Sumatriptan is a specific 5-Hydroxytryptamine 1B/1D receptor agonist and has neuroprotective effects in various neuropsychiatric disorders."	( Neuroprotective effect of sumatriptan in pentylenetetrazole-induced seizure is mediated through N-methyl-D-aspartate/nitric oxide and cAMP response element-binding protein signaling pathway. Abdollahi, A; Alotaibi, G; Dehpour, AR; Ghazi-Khansari, M; Imran Khan, M; Mumtaz, F; Rashki, A; Shadboorestan, A, 2022)	1.74
"Sumatriptan (ST) is a commonly prescribed drug for treating migraine. "	( Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine. Akhtari, J; Asadi, P; Assadpour, S; Sahebkar, A; Shiran, MR, 2022)	2.43
"Sumatriptan acts as a synergist of the NTG vasodilating action."	( Duality in response of intracranial vessels to nitroglycerin revealed in rats by imaging photoplethysmography. Iurkova, PM; Kamshilin, AA; Nippolainen, E; Potapenko, AV; Sokolov, AY; Volynsky, MA; Zaytsev, VV, 2023)	1.63
"Sumatriptan is a 5-hydroxytryptamine 1B/1D (5HT1B/1D) agonist used as a treatment for migraine headaches."	( Inhibition of ovalbumin-induced allergic rhinitis by sumatriptan through the nitric oxide pathway in mice. Alaeddini, M; Dabiri, S; Dehpour, AR; Etemad-Moghadam, S; Hemmati, S; Rahimi, N, 2019)	1.48
"Sumatriptan is a serotonin receptor agonist and the most commonly used triptan for the acute treatment of migraine."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	1.51
"Sumatriptan, which is an anti-migraine agent is a specific agonist for 5-hydroxytryptamine 1B, 1D (5HT1B, 1D) receptors."	( The protective effects of sumatriptan on vincristine - induced peripheral neuropathy in a rat model. Abdollahi, A; Afshari, K; Dehpour, AR; Hadian, MR; Khalilzadeh, M; Momeny, M; Norouzi-Javidan, A; Panahi, G; Rahimi, N; Rashidian, A; Shakiba, S, 2018)	1.5
"Sumatriptan TDS is a useful addition to the treatment options available to migraine patients."	( Sumatriptan iontophoretic transdermal system: a review of its use in patients with acute migraine. Garnock-Jones, KP, 2013)	2.55
"Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family."	( Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Derry, CJ; Derry, S; Moore, RA, 2014)	2.57
"Sumatriptan is an effective abortive treatment for acute migraine attacks, but is associated with increased adverse events relative to placebo. "	( Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Derry, CJ; Derry, S; Moore, RA, 2014)	3.29
"Sumatriptan is a tryptamine derivative that acts at 5-HT(1B/1D) receptors and is used for the treatment of migraines."	( Multidrug toxicity involving sumatriptan. Bosy, TZ; Hughes, RL; Knittel, JL; Levine, B; Vorce, SP, )	1.14
"Sumatriptan (Imigran) is a potent and highly selective 5-HT1 receptor agonist often used in treating acute migraine. "	( Effects of sumatriptan nasal spray (Imigran) on isolated rat's tracheal smooth muscle. Chang, YN; Cheng, LH; Chiu, FS; Chu, YH; Liu, SC; Wang, HW; Wu, PC, 2015)	2.25
"Sumatriptan succinate is a drug of choice for migraine."	( Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. Jagdale, SC; Pawar, CR, 2014)	1.34
"Sumatriptan is a 5-HT1B/1D receptor agonist used for the treatment of cluster headaches and migraine which might cause memory impairment as a potential side effect."	( Protective Effects of Lithium on Sumatriptan-Induced Memory Impairment in Mice. Behestani, S; Dehpour, AR; Javadi-Paydar, M; Nikoui, V; Salehi, M, 2016)	1.44
"Sumatriptan is a useful alternative treatment for postcraniotomy headache."	( Sumatriptan improves postoperative quality of recovery and reduces postcraniotomy headache after cranial nerve decompression. Bailey, T; Li, L; Manninen, PH; Tymianski, M; Venkatraghavan, L, 2016)	2.6
"Sumatriptan is a 5-HT-1B/D receptor agonist considered to activate receptors involved in the pathophysiology specific to migraine."	( Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Blumenfeld, A; Cady, R; Gennings, C, 2012)	1.1
"Sumatriptan is an agent effective in treatment of migraine and cluster headache."	( Sumatriptan inhibits TRPV1 channels in trigeminal neurons. Cheng, X; Disney, KE; Evans, MS; Jeffry, JA; Premkumar, LS, 2012)	2.54
"Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family."	( Sumatriptan (oral route of administration) for acute migraine attacks in adults. Derry, CJ; Derry, S; Moore, RA, 2012)	2.54
"Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family."	( Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Derry, CJ; Derry, S; Moore, RA, 2012)	2.54
"Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family."	( Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Derry, CJ; Derry, S; Moore, RA, 2012)	2.54
"Sumatriptan is an abortive medication for migraine attacks, belonging to the triptan family."	( Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Derry, CJ; Derry, S; Moore, RA, 2012)	2.54
"This sumatriptan auto-injector is a single-use system for the rapid subcutaneous delivery of 6 mg of sumatriptan succinate in the acute management of migraine pain. "	( An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Landy, SH; Ramos, E; Schweizer, E; Tepper, SJ; Wein, T, 2013)	1.21
"Sumatriptan is a potent serotonin 5HT(1B/1D) agonist widely used in the treatment of migraine; the effectiveness of the intranasal formulation (20mg) has been well established in several clinical studies."	( Clinical pharmacokinetics of intranasal sumatriptan. Barrow, A; Fuseau, E; Ibbotson, T; Moore, KH; Petricoul, O, 2002)	1.3
"Sumatriptan is a potent and selective vascular 5-HT1 receptor agonist effective for the treatment of migraine. "	( Pharmacokinetics of sumatriptan nasal spray in adolescents. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2003)	2.09
"Sumatriptan is a serotonin1D agonist."	( Pharmacological challenge with a serotonin 1D agonist in alcohol dependence. Hugo, CJ; Maritz, JS; Pienaar, W; Stein, DJ; Vythilingum, B, 2005)	1.05
"Oral sumatriptan (100 mg) is an effective and well tolerated acute treatment for patients who report menstrually related migraine."	( Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. Aurora, SK; Dowson, AJ; Massiou, H, 2005)	0.98
"Sumatriptan is a selective agonist of 5HT1 (1B/1D) receptors, which has proved to be effective and safe for the acute treatment of migraine attacks. "	( Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. Bertolini, A; Coccia, CP; Ferrari, A; Leone, S; Pinetti, D; Sternieri, E, 2005)	2.09
"Sumatriptan is a 5-HT 1,2-serotonin blocker."	( [Particular features of the impact of certain vegetotropic drugs on the excitability of cholinergic structures, contractile myocardial function and electromotive stomach activity]. Lychkova, AE, 2005)	1.05
"Sumatriptan is a serotonin 5-HT(1B/1D) receptor agonist that is used for the acute treatment of migraine attacks. "	( Sumatriptan fast-disintegrating/rapid-release tablets. Keating, GM; Moen, MD, 2006)	3.22
"Sumatriptan is a potent and selective 5-HT(1B) and 5-HT(1D )agonist used in the symptomatic treatment of migraine; it shows poor oral bioavailability ascribed, in part, to its low lipophilicity. "	( Unanticipated acyloxymethylation of sumatriptan indole nitrogen atom and its implications in prodrug design. Guedes, RC; Iley, J; Lopes, F; Moreira, R; Rodrigues, T, 2008)	2.06
"Sumatriptan is a potent and selective agonist at a vascular serotonin1 (5-hydroxytryptamine1; 5-HT1) receptor subtype (similar to 5-HT1D) and is used in acute treatment of migraine and cluster headache. "	( Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. McTavish, D; Plosker, GL, 1994)	3.17
"Sumatriptan is a potent and selective serotonin1D receptor agonist, which can be administered orally and via the subcutaneous or intranasal route."	( Acute treatment of migraine attacks. Ferrari, MD; Haan, J, 1995)	1.01
"Sumatriptan is a new product with a higher acquisition cost than DHE."	( A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Kozma, CM; Lawrence, BJ; Mauch, RP; Reeder, CE, )	1.07
"Sumatriptan is a potent vasoconstrictor of intracranial arteries."	( The mode of action of sumatriptan is vascular? A debate. Goadsby, PJ; Humphrey, PP, 1994)	1.32
"Sumatriptan is a highly cleared compound that is eliminated from the body primarily by metabolism to the pharmacologically inactive indoleacetic acid analogue."	( Single dose pharmacokinetics of sumatriptan in healthy volunteers. Fowler, PA; Hussey, EK; Lacey, LF, 1995)	1.3
"Sumatriptan is a novel serotonin 1 (5-hydroxytryptamine 1; 5-HT1)-like agonist which has been shown to be effective in the treatment of acute migraine. "	( Sumatriptan clinical pharmacokinetics. Scott, AK, 1994)	3.17
"Sumatriptan is a new 5HT1-like agonist that has proved a novel and effective treatment for migraine. "	( Disposition of sumatriptan in laboratory animals and humans. Andrew, PD; Bradbury, A; Dixon, CM; Oxford, J; Saynor, DA; Tarbit, MH, )	1.93
"Sumatriptan is a very effective agent that has joined the ranks of other effective abortive migraine treatments, such as ergotamine, dihydroergotamine, and nonsteroidal anti-inflammatory agents, as well as narcotic analgesics."	( Migraine: a pharmacologic review with newer options and delivery modalities. Baumel, B, 1994)	1.01
"Sumatriptan is a new anti-migraine drug which has been shown in clinical studies to be efficacious in up to 80% of attacks treated."	( [Sumatriptan in the treatment of migraine in general practice]. Midelfart, E; Winnem, M, 1994)	1.92
"Sumatriptan is a selective agonist of 5-hydroxytryptamine receptors, recommended for the acute treatment of migraine. "	( The use of sumatriptan in the treatment of migraine. Gross, M, )	1.96
"Sumatriptan (GR43175) is a selective 5-hydroxytryptamine (5HT1) receptor agonist effective in the acute treatment of migraine. "	( Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Bhargava, B; Gemmill, JD; Hillis, WS; Hogg, KJ; MacIntyre, PD, 1993)	2.04
"Sumatriptan is a selective 5-HT1-like agonist, which is effective in the treatment of migraine and cluster headache. "	( Sumatriptan in the acute treatment of migraine. Lloyd, K; Pilgrim, AJ; Tansey, MJ, 1993)	3.17
"Sumatriptan is a new serotonin receptor agonist that is useful in the treatment of migraine headache. "	( Sumatriptan: a new serotonin agonist for the treatment of migraine headache. Susman, JL, 1993)	3.17
"Sumatriptan is a potent and selective agonist at the vascular 5HT1 receptor which mediates constriction of certain large cranial blood vessels and/or inhibits the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater following activation of the trigeminovascular system. "	( Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. Diener, HC; Pfaffenrath, V; Schoenen, J; Steiner, TJ; Wilkinson, M, 1995)	1.98
"Sumatriptan is a novel drug for migraine headache pain, which, on the basis of its mechanism of action, may have therapeutic potential in other pain states. "	( Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation. Levine, JD; Peroutka, SJ; Pierce, PA; Xie, GX, )	1.85
"Sumatriptan is a selective 5-hydroxytryptamine1d (5-HT1d)-receptor agonist, highly effective in the short-term treatment of migraine headaches. "	( Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. Eichler, HG; Findl, O; Graselli, U; Krejcy, K; Schmetterer, L; Singer, EA; Wolzt, M, 1996)	2
"1 Sumatriptan is a potent and selective 5-HT1 receptor agonist marketed for the treatment of migraine by both oral and subcutaneous routes. "	( The preclinical toxicological evaluation of sumatriptan. Hartley, K; Jackson, MR; Owen, K; Parkinson, MM; Tucker, ML; Tweats, DJ, 1995)	1.27
"Oral sumatriptan is an effective acute treatment for migraine in adults, but its efficacy in children is still undetermined. "	( Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Hämäläinen, ML; Hoppu, K; Santavuori, P, 1997)	2.25
"Sumatriptan is a selective agonist at serotonin 5-HT1-like receptors, including 5-HT1B/1D subtypes. "	( Sumatriptan. An updated review of its use in migraine. Markham, A; Perry, CM, 1998)	3.19
"Sumatriptan is a 5-HT1 receptor agonist which has found widespread use in the treatment of migraine."	( Validation of a liquid chromatographic tandem mass spectrometric method for the determination of sumatriptan in human biological fluids. Barrow, A; Cheng, KN; Redrup, MJ; Williams, PN, 1998)	1.24
"Sumatriptan is an antimigraine agent, which interacts most potently with 5HT1D receptors."	( Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Cohen, R; Sasson, Y; Stern, L; Zohar, J, 1998)	1.24
"Sumatriptan is a 5-HT1B/1D-receptor agonist which also has affinity for 5-HT1F-receptors. "	( Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Beer, MS; Heald, MA; Hill, RG; Longmore, J; Maskell, L; Pickard, JD; Razzaque, Z, 1999)	1.75
"Sumatriptan is an effective and well tolerated agent in the treatment of migraine."	( Sumatriptan. A pharmacoeconomic review of its use in migraine. Coukell, AJ; Lamb, HM, 1997)	2.46
"Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. "	( Intranasal sumatriptan for the acute treatment of migraine in children. Ueberall, MA; Wenzel, D, 1999)	2.14
"Sumatriptan is a specific migraine treatment which has recently become among the most widely prescribed acute migraine therapies."	( Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. , 1999)	1.23
"Sumatriptan is a novel drug for the treatment of acute migraine attacks. "	( [The efficacy of subcutaneous sumatriptan for the treatment of migraine attack]. Stepień, A, 1999)	2.03
"Sumatriptan nasal spray is a single-dose device that delivers 5 mg, 10 mg, or 20 mg of sumatriptan (dosage availability dependent upon country) in a 0.1 ml aqueous solution to one nostril. "	( Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Dahlöf, C, 1999)	3.19
"Sumatriptan is a 5HT1D agonist used in the treatment of migraine. "	( Lack of pharmacokinetic interaction between sumatriptan and naproxen. Rambhau, D; Rao, BR; Rao, YM; Srinivasu, P, 2000)	2.01
"Oral sumatriptan, which is a well tolerated, effective acute treatment for migraine, and is selectively available in different countries in 100 mg, 50 mg, and 25 mg tablets. "	( Defining optimal dosing for sumatriptan tablets in the acute treatment of migraine. Mathew, NT; Salonen, R, 1999)	1.11
"Sumatriptan is an acute treatment for migraine which is often used by women in their child-bearing years, and who become unexpectedly pregnant. "	( Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Davis, RL; Ephross, SA; Fox, AW; Gutterman, DL; O'Quinn, S; Williams, V, 1999)	1.99
"Sumatriptan is a selective 5-HT(1B/D) receptor agonist which does not cross the blood-brain barrier."	( Sumatriptan reduces exercise capacity in healthy males: a peripheral effect of 5-hydroxytryptamine agonism? Cahill, H; Hillis, WS; Hills, WS; Knipe, S; MacIntyre, PD; McCann, GP; Muir, DF, 2000)	2.47
"Sumatriptan is a 5-HT1B/D receptor agonist of documented efficacy in relieving migraine and associated symptoms such as nausea and vomiting. "	( Gastric motor effects of triptans: open questions and future perspectives. Cipolla, G; Crema, F; De Ponti, F; Frigo, G; Moro, E; Sacco, S, 2001)	1.75
"Sumatriptan is a serotonin agonist that has been studied for the acute treatment of migraine and cluster headache. "	( Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Fullerton, T; Gengo, FM, 1992)	3.17
"Sumatriptan is a novel, highly effective drug against migraine and cluster headache attacks. "	( Clinical effects and mechanism of action of sumatriptan in migraine. Ferrari, MD; Saxena, PR, 1992)	1.99
"Sumatriptan is a 5-HT1D agonist of therapeutic use in migraine and cluster headaches. "	( Psychoactivity and abuse potential of sumatriptan. Busch, M; Jasinski, DR; Preston, KL; Sullivan, JT; Testa, MP, 1992)	2
"1. Sumatriptan (GR43175) is a selective 5-HT1-receptor agonist effective in the acute treatment of migraine. "	( The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Bhargava, B; Gemmill, JD; Hillis, WS; Hogg, KJ; Macintyre, PD, 1992)	1.23
"Sumatriptan is an agonist of 5-HT1 -like receptors and exerts a selective vasoconstricting effect on the arteries of the head, particularly in the rami of the carotid artery."	( [Sumatriptan and its use in treatment of migraine and cluster headaches]. Prusiński, A, 1992)	1.92
"Sumatriptan is a highly selective 5 HT1 receptor subtype agonist. "	( [Sumatriptan--future development, alternative features and potential new indications]. Arnold, WS, 1992)	2.64
"Sumatriptan is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache. "	( Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Clissold, SP; Dechant, KL, 1992)	3.17
"Sumatriptan is a highly selective 5-HT1-like receptor agonist which selectively constricts cranial blood vessels (including those in the dura mater)."	( Rationale for the use of 5-HT1-like agonists in the treatment of migraine. Connor, HE; Feniuk, W; Humphrey, PP; Perren, MJ; Whalley, ET, 1991)	1
"Sumatriptan is an effective and well-tolerated treatment for acute attacks of cluster headache."	( Treatment of acute cluster headache with sumatriptan. , 1991)	1.99
"Sumatriptan succinate is a novel compound currently in development for the acute treatment of migraine. "	( Development and validation of a liquid chromatographic-mass spectrometric assay for the determination of sumatriptan in plasma. Lant, MS; Oxford, J, 1989)	1.93

Excerpt	Reference	Relevance
"Sumatriptan has a large apparent volume of distribution (170 l) and an elimination half-life of 2 h."	( Single dose pharmacokinetics of sumatriptan in healthy volunteers. Fowler, PA; Hussey, EK; Lacey, LF, 1995)	1.3
"Sumatriptan has a weak coronary constrictor effect."	( [The migraine remedy sumatriptan (Imigran) and coronary heart disease]. Landmark, K; Nguyen, KN, 1995)	1.33
"Sumatriptan has a low oral bioavailability (14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, the rate of absorption is faster."	( Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. De Vries, P; Saxena, PR; Tfelt-Hansen, P, 2000)	1.03
"Sumatriptan has a rapid onset of action and a large volume of distribution."	( Sumatriptan: a new drug for vascular headache. Hsu, VD, 1992)	2.45
"Sumatriptan has a much more selective pharmacological profile than ergot preparations which are also used in the acute treatment of migraine."	( Rationale for the use of 5-HT1-like agonists in the treatment of migraine. Connor, HE; Feniuk, W; Humphrey, PP; Perren, MJ; Whalley, ET, 1991)	1
"Sumatriptan has been among the top choices in the management of migraine headaches. "	( Biphasic effect of sumatriptan on PTZ-induced seizures in mice: Modulation by 5-HT1B/D receptors and NOS/NO pathway. Aghamollaii, V; Ahmadi, M; Amiri, S; Dehpour, AR; Ghasemi, K; Gooshe, M; Rohani, MM; Tafakhori, A, 2018)	2.25
"SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance of enteral absorption."	( A review of needle-free sumatriptan injection for rapid control of migraine. Farr, SJ; Freitag, FG; Rothrock, JF; Smith, EF, 2013)	1.21
"Sumatriptan succinate has oral bioavailability of 15% and undergoes hepatic metabolism, hence it is suitable for nasal administration."	( Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Chaudhari, PD; Galgatte, UC; Kumbhar, AB, 2014)	1.12
"Sumatriptan succinate has bitter taste, low oral bioavailability, and shorter half-life."	( Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. Jagdale, SC; Pawar, CR, 2014)	1.34
"Sumatriptan has been used for the acute treatment of migraine attacks. "	( Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice. Jand, A; Palizvan, MR, 2017)	3.34
"Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine. "	( WITHDRAWN: Oral sumatriptan for acute migraine. Gray, RN; McCrory, DC, 2012)	1.24
"Sumatriptan has failed to show superiority over more standard and cheaper treatment such as aspirin or aspirin plus metoclopramide."	( Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Hougaard, A; Tfelt-Hansen, P, 2013)	2.55
"Sumatriptan has direct scavenging activity on free radicals and NO. "	( Sumatriptan scavenges superoxide, hydroxyl, and nitric oxide radicals: in vitro electron spin resonance study. Ikeda, Y; Jimbo, H; Satoh, K; Shimazu, M, 2002)	3.2
"With sumatriptan, this finding has proven to be a consequence of the form in which the drug was administered rather than the inherent properties of the drug."	( Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Hämäläinen, M; Jones, M; Loftus, J; Saiers, J, 2002)	2.21
"Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine. "	( Oral sumatriptan for acute migraine. Gray, RN; McCrory, DC, 2003)	1.35
"Sumatriptan tablets have been developed in a fast-disintegrating, rapid-release formulation designed to facilitate tablet disintegration and drug dispersion and to potentially mitigate the effects of gastric stasis that can accompany migraine."	( Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Ahmad, F; Boswell, D; Carpay, J; Kinrade, F; Schoenen, J, 2004)	2.06
"Sumatriptan has been developed as a new tablet formulation to enhance the rate of systemic drug delivery by improving tablet disintegration and drug dispersion relative to those of conventional tablets."	( Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Boswell, D; Bullman, J; Dow, A; Lewis, A; Sidhu, J; Summers, SJ; Walls, C, 2004)	1.31
"Sumatriptan has been used in the treatment of migraine and other vascular headaches since 1993 in the United States. "	( Oral sumatriptan-induced myocardial infarction. Hack, JB, 2004)	2.28
"Sumatriptan (Imitrex) has been available for the longest time within the class, is most flexible in form and has been given successfully to the most number of patients."	( Sumatriptan: a decade of use and experience in the treatment of migraine. Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004)	2.49
"Sumatriptan has been instrumental in defining a biological basis for migraine."	( Sumatriptan: update and review. Cady, R; Schreiber, C, 2006)	2.5
"Only sumatriptan nasal spray has been approved for the treatment of acute migraine with or without aura in adolescents aged 12-17 years in Europe."	( Sumatriptan nasal spray in the acute treatment of migraine in adolescents and children. Brouwer, OF; Callenbach, PM; Gooskens, RH; Linssen, WH; Mulder, PG; Pels, LP; van der Zwan, JL, 2007)	2.24
"Sumatriptan has a large apparent volume of distribution (170 l) and an elimination half-life of 2 h."	( Single dose pharmacokinetics of sumatriptan in healthy volunteers. Fowler, PA; Hussey, EK; Lacey, LF, 1995)	1.3
"Sumatriptan has a weak coronary constrictor effect."	( [The migraine remedy sumatriptan (Imigran) and coronary heart disease]. Landmark, K; Nguyen, KN, 1995)	1.33
"Oral sumatriptan (100 mg) has been evaluated against ergotamine, 2 mg, plus caffeine, 200 mg (as Cafergot); and against aspirin, 900 mg, plus metoclopramide, 10 mg."	( Sumatriptan in the acute treatment of migraine. Lloyd, K; Pilgrim, AJ; Tansey, MJ, 1993)	2.18
"Sumatriptan has shown to be effective in the treatment of an acute migraine- and cluster-headache. "	( [Sumatriptan--side effects and problems in routine clinical practice]. Aull, S; Marterer, A; Schnider, P; Wessely, P; Wöber, C, 1995)	2.64
"Sumatriptan has both vascular and neurogenic effects, both of which may be necessary for a good clinical outcome."	( [Drug treatment of migraine attacks. Pharmacological considerations]. Salvesen, R, 1996)	1.02
"Sumatriptan has been shown to be most effective in migraine attacks, but with transient, slight side effects and high rebound attack rates. "	( Sumatriptan treatment of acute migraine attacks in a Saudi population. al Deeb, S; al Kawi, Z; Bohlega, S; Cheung, P; Yaqub, B, 1997)	3.18
"Sumatriptan has been used successfully in the acute treatment of migraine since 1991. "	( [Evaluation of efficacy and tolerance sumatriptan at a dose of 50 mg in treatment of migraine attack]. Król, F; Prusiński, A, 1998)	2.01
"Thus sumatriptan has become the de facto gold standard and will be thus employed here."	( The scientific basis of medication choice in symptomatic migraine treatment. Goadsby, PJ, 1999)	0.76
"Oral sumatriptan 50 mg has been found to have good efficacy and tolerability in the acute treatment of migraine but has been less well studied than the 100 mg dose."	( A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. Ashford, EA; Brautaset, NJ; Hassani, H; Reunanen, M; Saiers, J; Savani, N; Szirmai, I, 1999)	1.04
"Sumatriptan has been used successfully in patients with postdural puncture headache, however, its use has not been investigated in a controlled fashion."	( Sumatriptan in patients with postdural puncture headache. Connelly, NR; Gibson, CS; Parker, RK; Rahimi, A, 2000)	2.47
"Sumatriptan has also been reported to be effective for the treatment of postdural puncture headache, postictal headache, and headache related to intravenous immunoglobulin infusion."	( Sumatriptan for headache caused by head and neck cancer. Manfredi, PL; Payne, R; Shenoy, S, 2000)	2.47
"Sumatriptan has a low oral bioavailability (14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, the rate of absorption is faster."	( Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. De Vries, P; Saxena, PR; Tfelt-Hansen, P, 2000)	1.03
"Sumatriptan has been used effectively to treat adult patients with migraine headaches, but its efficacy in children has not been established."	( Efficacy of sumatriptan in the treatment of migraine: a review of the literature. McAlhany, A, 2001)	1.41
"Sumatriptan has a rapid onset of action and a large volume of distribution."	( Sumatriptan: a new drug for vascular headache. Hsu, VD, 1992)	2.45
"Sumatriptan has a much more selective pharmacological profile than ergot preparations which are also used in the acute treatment of migraine."	( Rationale for the use of 5-HT1-like agonists in the treatment of migraine. Connor, HE; Feniuk, W; Humphrey, PP; Perren, MJ; Whalley, ET, 1991)	1

Excerpt	Reference	Relevance
"Sumatriptan failed to produce either of these effects due to a poor brain penetration."	( 5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates. Barf, TA; de Boer, P; Ennis, MD; Ghazal, NB; McGuire, JC; Peroutka, SJ; Smith, MW; Swensson, K; Wikström, H, 1996)	1.02
"Sumatriptan can inhibit the electrophysiological activity of ASICs in the trigeminal ganglion (TG) neurons."	( Sumatriptan inhibits the electrophysiological activity of ASICs in rat trigeminal ganglion neurons. Guo, L; Hong, L; Li, R; Liu, A; Ming, P; Zhao, L, 2018)	2.64
"Sumatriptan in lower concentration increases skin flap survival by means of activation of 5-hydroxytryptamine 1b/1d receptors. "	( Sumatriptan Increases Skin Flap Survival through Activation of 5-Hydroxytryptamine 1b/1d Receptors in Rats: The Mediating Role of the Nitric Oxide Pathway. Abbaszadeh-Kasbi, A; Afshari, K; Amirlak, B; Dehdashtian, A; Dehpour, AR; Haddadi, NS; Jazaeri, F; Sheikhi, M; Tavangar, SM; Zarifeh Jazaeri, S, 2019)	3.4
"Sumatriptan can cause myocardial ischaemia and myocardial infarction."	( Amplification of sumatriptan-induced contractions with phenylephrine, histamine and KCl in the isolated human mesenteric artery: in-vitro evidence for sumatriptan-induced mesenteric ischaemia. Gul, H; Yildiz, O, 2002)	1.38
"The sumatriptan-induced increase of growth hormone concentrations was significantly (P < 0.05) blunted in patients with active cluster headache."	( Abnormal 5-HT1D receptor function in cluster headache: a neuroendocrine study with sumatriptan. Arvat, E; Del Rizzo, P; Ferrero, M; Gianotti, L; Limone, P; Lo Giudice, R; Pinessi, L; Rainero, I; Rivoiro, C; Valfrè, W, 2003)	1.02
"The Sumatriptan-induced increase in GH responses to GHRH was dependent on the stimulus tested."	( Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion. Bento, A; Dieguez, C; Mota, A; Peñalva, A; Pombo, M, 1995)	0.77
"Both sumatriptan and 5-HT inhibit adenylate cyclase activity at doses which correlate with the mitogenic effect."	( 5-HT1D receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. Bondiolotti, G; Cattaneo, MG; Palazzi, E; Vicentini, LM, 1994)	0.74
"Sumatriptan appears to cause peripheral venoconstriction only at high doses locally applied (in the hand vein), by acting on 5HT2 receptors."	( Amplifying effect of sumatriptan on noradrenaline venoconstriction in migraine patients. Anselmi, B; Curradi, C; Franchi, G; Panconesi, A; Tarquini, B, 1993)	1.33
"Sumatriptan was found to suppress the CPH attacks as well as indomethacin."	( Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH). Hannerz, J; Jogestrand, T, 1993)	1.3
"Sumatriptan failed to produce a significant reduction in sensory and total pain scores at 60 minutes following treatment, however the result was statistically significant for the affective pain score (P < .05)."	( A double-blind, placebo-controlled, crossover, study to evaluate the efficacy of subcutaneous sumatriptan in the treatment of atypical facial pain. al Balawi, S; Feinmann, C; Tariq, M, 1996)	1.23
"Sumatriptan blunted the increase in blood flow following stimulation of the trigeminal ganglion."	( Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: a novel migraine model. McCall, RB, 1997)	1.02
"Sumatriptan did not cause relaxation."	( Sumatriptan contracts large coronary arteries of beagle dogs through 5-HT1-like receptors. Kaumann, AJ; Parsons, AA; Raval, P; Stutchbury, C, 1992)	2.45

Excerpt	Reference	Relevance
"Sumatriptan treatment significantly reduced the mechanical hypersensitivity induced by IS stimulations and decreased the BBB disruption and VEGF expression."	( Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats. Chen, L; Mi, X; Qin, G; Ran, L, 2018)	1.2
"Sumatriptan/naproxen treatment resulted in significantly higher medication satisfaction scores on the efficacy, functionality, and total efficacy subscales compared with placebo in all attacks in both studies."	( Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Cady, RK; Landy, SH; Nelsen, A; Runken, MC; White, J, 2014)	1.33
"Sumatriptan treatment during the aura preempted the development of headache in 34/38 (89%) attacks. "	( Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Aurora, SK; Barrodale, PM; Burstein, R; Jakubowski, M; McDonald, SA, 2009)	2.09
"Sumatriptan pre-treatment significantly delayed solid but not liquid gastric emptying (t1/2 respectively 159 +/- 11 vs. "	( Influence of delaying gastric emptying on meal-related symptoms in healthy subjects. Coulie, B; Janssens, J; Tack, J; Verbeke, K, 2006)	1.78
"More sumatriptan-treated patients were completely pain free compared with placebo-treated patients at both 2 h (24% versus 12%) and 4 h (48% versus 18)."	( Oral sumatriptan compared with placebo in the acute treatment of migraine. Byrne, M; Nappi, G; Roncolato, M; Sicuteri, F; Zerbini, O, 1994)	1.26
"Sumatriptan also treated nausea and photophobia more effectively in menstrual-migraine patients than did placebo."	( Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Solbach, MP; Waymer, RS, 1993)	1.24
"Sumatriptan-treated patients used rescue medication for 19% of their attacks, compared to 59% for comparator drugs (p = 0.001)."	( Comparison of subcutaneous sumatriptan with usual acute treatments for migraine. French Sumatriptan Study Group. Bertin, L; Boureau, F; Chazot, G; d'Allens, H; Emile, J, 1995)	1.31
"More sumatriptan-treated patients than placebo-treated patients reported adverse events (29% versus 16%) but the difference was not statistically significant."	( [Evaluation of the efficacy of oral sumatriptan in the management of migraine attacks. Clinical results]. Albano, O; Bassi, A; Cassiano, MA; Centonze, V; Di Bari, M; Fabbri, L; Polito, MB, 1995)	1.02
"Sumatriptan is an acute treatment for migraine which is often used by women in their child-bearing years, and who become unexpectedly pregnant. "	( Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Davis, RL; Ephross, SA; Fox, AW; Gutterman, DL; O'Quinn, S; Williams, V, 1999)	1.99
"Sumatriptan treatment tended to reduce median productivity loss 2 hours after injection compared with placebo (25.2 vs 29.9 minutes, respectively; P = .14)."	( Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Batenhorst, AS; Cady, RK; Henry, D; O'Quinn, SO; Putnam, DG; Schulman, EA; Watson, CB, 2000)	1.37
"Sumatriptan treatment had beneficial effects on aspects of health state and mood during the postictal period."	( Effects of medication use on health state in postictal migraineurs. de Geus, EJ; Linssen, WH; Mulder, EJ; Passchier, J, 2001)	1.03
"Sumatriptan treatment was associated with a 3-fold increase in payments for services for painful respiration and other chest pain."	( Cost savings in migraine associated with less chest pain on new triptan therapy. Barr, CE; Goldfarb, SD; Rowland, CR; Torigoe, Y; Wang, E; Wang, JT, 2002)	1.04
"Pre-treatment with sumatriptan attenuated PACAP38-induced headache without affecting PACAP38-induced arterial dilation."	( Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. Al-Karagholi, MA; Amin, FM; Arngrim, N; Ashina, M; Ghanizada, H; Larsson, HBW; Metcalf-Clausen, M; Mørch-Rasmussen, M, 2020)	1.22
"Pre-treatment with sumatriptan decreased 5-hydroxytryptamine (5HT) level by 53%, and significantly decreased calcitonin gene-related peptide (CGRP) levels, lipid pereoxidation, neutrophil infiltration, and level of pro-inflammatory markers in the serum."	( Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats. Abdollahi, A; Dehpour, AR; Gharishvandi, F; Mohammad Jafari, R; Pasalar, P; Shafaroodi, H, 2020)	0.88
"Pre-treatment with sumatriptan prevents cilostazol induced headache from developing. "	( Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers. Falkenberg, K; Olesen, J, 2018)	1.14
"Treatment with sumatriptan significantly increased the endothelial nitric oxide synthase (eNOS) expression consequences nitric oxide metabolites' level in I/R rats."	( Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. Azizi, Y; Dehpour, AR; Dehpour, S; Faghir-Ghanesefat, H; Ghahremani, MH; Keshavarz-Bahaghighat, H; Rahimi, N; Sepand, MR; Sheibani, M, 2019)	2.3
"Treatment with sumatriptan during migraine attacks appeared to be associated with a decrease in 5-HT1B receptor binding, a finding that is most likely associated with the binding of sumatriptan to central 5-HT1B receptors, but the contribution of ongoing cerebral serotonin release to the lower binding cannot be excluded; the migraine attack-associated decrease in binding could indicate that migraine attacks are associated with increases in endogenous serotonin."	( Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding. Ashina, M; Deen, M; Dyssegaard, A; Hansen, HD; Hougaard, A; Knudsen, GM; Schain, M, 2019)	1.19
"Treatment with sumatriptan-naproxen may provide relief of menstrual symptoms and migraine in female migraineurs with dysmenorrhea. "	( Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Ballard, J; Derosier, FJ; Diamond, MP; Krishen, A; Lener, SE; Mannix, LK; Martin, VT; McDonald, SA, 2014)	0.98
"Treatment with sumatriptan repressed NGF- and MAPK-stimulated CGRP promoter activity."	( Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. Durham, PL; Russo, AF, 2003)	0.66
"Pretreatment with sumatriptan increased both pressures and volumes needed to induce first perception and discomfort."	( Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Caenepeel, P; Corsetti, M; Janssens, J; Tack, J, 2004)	0.65
"Treatment with sumatriptan/naproxen sodium allowed significantly more subjects to return to normal or mildly impaired functioning more quickly, and sumatriptan/naproxen sodium patients were significantly more satisfied with their treatment compared with other treatment groups. "	( Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. Ames, MH; Burch, SP; DeRossett, SE; Landy, S; McDonald, SA; Rapoport, A; Rothrock, J, 2007)	0.92
"Treatment with sumatriptan was well tolerated."	( High efficacy and low frequency of headache recurrence after oral sumatriptan. The Oral Sumatriptan Italian Study Group. Bamfi, F; Fabbri, L; Pini, LA; Sternieri, E; Zerbini, O, )	0.71
"Pretreatment with Sumatriptan did not modify the GH response to clonidine or pyridostigmine, as assessed by the peak GH response and the area under the curve."	( Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion. Bento, A; Dieguez, C; Mota, A; Peñalva, A; Pombo, M, 1995)	0.61
"Treatment with sumatriptan during the migraine attack was accompanied by a significant increase in the duration of ES2 (p < or = 0.05), but no significant changes in the durations of the late suppression periods were observed under any other conditions."	( Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan. Dworschak, M; Ensink, FB; Göbel, H; Heuss, D; Krapat, S; Soyka, D, 1994)	0.83
"Treatment with sumatriptan has been well tolerated with only minor, transient, acute side effects reported."	( Sumatriptan in the treatment of migraine. Ferrari, MD, 1993)	2.07
"Treatment with sumatriptan was associated with significant (P < .05) improvements relative to baseline in three of the Short Form-36 Health Survey quality-of-life dimensions (Bodily Pain, General Health Perceptions, and Social Functioning) and three of the Migraine-Specific Quality of Life Questionnaire dimensions (Role Function-Restrictive, Role Function-Preventive, and Emotional Function). "	( Improvements in health-related quality of life with sumatriptan treatment for migraine. Cady, RK; Grice, RB; Gutterman, DL; Jhingran, P; Miller, D; Rubino, J, 1996)	0.9
"Oral treatment with sumatriptan 100 mg tid over a 7-day period was not associated with an increased or altered adverse event profile from that previously reported."	( Preemptive oral treatment with sumatriptan during a cluster period. Cole, J; Krabbe, A; Micieli, G; Monstad, I; Pilgrim, A; Prusinski, A; Shevlin, P, )	0.73
"Treatment with sumatriptan was efficient in 89.5% of the attacks."	( [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks]. Christiani, K; Dworschak, M; Göbel, H; Heinze, A; Heuss, D; Lindner, V; Stolze, H, 1996)	0.87
"Treatment with sumatriptan reduced the numbers of Fos-positive cells found in laminae I and IIo of the TNC and C2 (6, 13 cells and 9 cells, respectively) after mechanical stimulation."	( Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Goadsby, PJ; Hoskin, KL; Kaube, H, 1996)	2.08
"Treatment with sumatriptan was effective in 88% of the attacks and 57% of the patients were pain-free within 15 min after injection; 42% of the patients became painfree within 15 min after at least 90% of their attacks."	( [Acute therapy of episodic and chronic cluster headache with sumatriptan s.c. Results of a one-year long-term study]. Göbel, H; Heinze, A; Lindner, V; Pfaffenrath, V; Ribbat, M; Stolze, H, 1998)	0.88
"Pretreatment with sumatriptan (n = 9) produced a highly significant reduction in the ratio of extravasation within the dura to 1.10 +/- 0.06 (P = 0.002) and in the retina to 0.96 +/- 0.06 (P = 0.001), as did the neurokinin-1 receptor antagonist RP 67580 (n = 12) in the dura (1.04 +/- 0.11, P = 0.002) and retina (1.08 +/- 0.06, P = 0.001)."	( Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Diener, HC; Effert, R; Goadsby, PJ; Hargreaves, RJ; Knorr, M; May, A; Shepheard, SL; Wessing, A, 1998)	0.62
"Pretreatment with sumatriptan is able to restore impaired accommodation and to improve early satiety in patients with functional dyspepsia."	( The physiology and the pathophysiology of the gastric accommodation reflex in man. Tack, J, 2000)	0.63
"Pretreatment with sumatriptan (720 nmol kg-1 x 2, i.v.) did not block c-fos expression in trigeminal nucleus caudalis following formalin application to the nasal mucosa.6."	( CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Boccalini, P; Moskowitz, MA; Nozaki, K, 1992)	1

Excerpt	Reference	Relevance
" Adverse events were dose related; the most common types were injection site reactions and tingling."	( Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Couch, J; Dexter, J; Flamenbaum, W; Goldstein, J; Mathew, NT; Rapoport, A; Saper, J; Sheftell, F; Silberstein, S; Solomon, S, 1992)	0.54
" Safety monitoring involved collection of all adverse events, regardless of their relationship to treatment, and included routine laboratory screening tests and some special investigations."	( The safety and tolerability of sumatriptan: an overview. Brown, EG; Endersby, CA; Smith, RN; Talbot, JC, 1991)	0.57
" The incidence and nature of adverse events in this study were similar to that seen in previous studies."	( The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Bonellie, G; Facchinetti, F; Kangasniemi, P; Pascual, J; Shuaib, A, 1995)	0.56
" Because sumatriptan does not appear to cross the blood-brain barrier and has a short half-life, it was deemed relatively safe to prescribe sumatriptan with antidepressant treatments."	( The safety of concomitant use of sumatriptan and antidepressant treatments. Bergeron, R; Blier, P, 1995)	0.99
" The majority of adverse events (defined as any medical event irrespective of possible causal relationship to treatment) were mild to moderate in intensity, transient and resolved spontaneously."	( The clinical profile of sumatriptan: safety and tolerability. Lloyd, K, 1994)	0.6
" The incidence and nature of adverse events in the asthmatic patient subgroup who received sumatriptan was similar to that in the complete clinical trial population."	( The safety of sumatriptan in asthmatic migraineurs. Lloyd, DK; Pilgrim, AJ, 1993)	0.87
"The study tried to investigate the efficacy, adverse events and possible risk factors of sumatriptan in daily clinical practice."	( [Sumatriptan--side effects and problems in routine clinical practice]. Aull, S; Marterer, A; Schnider, P; Wessely, P; Wöber, C, 1995)	1.42
" Adverse events were reported by 69% of the patients which was more frequent than in most clinic studies described."	( [Sumatriptan--side effects and problems in routine clinical practice]. Aull, S; Marterer, A; Schnider, P; Wessely, P; Wöber, C, 1995)	1.2
" The risk as to severe adverse events, especially cardial adverse events, exists if contraindications for sumatriptan are not considered."	( [Sumatriptan--side effects and problems in routine clinical practice]. Aull, S; Marterer, A; Schnider, P; Wessely, P; Wöber, C, 1995)	1.42
"9% of the patients withdrew from the study because of adverse events and because they felt the treatment was not effective."	( [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks]. Christiani, K; Dworschak, M; Göbel, H; Heinze, A; Heuss, D; Lindner, V; Stolze, H, 1996)	0.53
" They are almost always benign, but can be mistaken for a serious adverse event by the patient."	( The site of common side effects of sumatriptan. Lipton, RB; Newman, LC; Solomon, S, 1997)	0.57
" The suppositories were generally well tolerated; transient asthenia, drowsiness, and headache were the most frequently reported adverse events, and these were not dose-related."	( Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Aubert, B; Fowler, PA; Hussey, EK; Kunka, RL; Pakes, GE; Richard, I; Shaw, S; Warner, P, 1997)	0.56
" Adverse events were mild and consisted mainly of bitter taste at the back of the throat and events typical of sumatriptan administered by other routes (headache, lightheadedness and tingling)."	( Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Duquesnoy, C; Fuseau, E; Hussey, EK; Moore, KH; Pakes, GE; Shaw, S, 1997)	0.77
" For 6 hours after treatment, a continuous electrocardiogram (ECG) was performed, and headache severity, adverse events, and vital signs were recorded."	( Monitoring of acute migraine attacks: placebo response and safety data. Cutler, NR; Ford, NF; Fulmor, IE; Jhee, SS; Salazar, DE; Sramek, JJ, 1998)	0.3
" The incidence of adverse events with 25-mg and 50-mg sumatriptan tablets was similar to the incidence with placebo and lower than the incidence with 100-mg sumatriptan tablets."	( Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Cunin, G; Pfaffenrath, V; Prendergast, S; Sjonell, G, 1998)	0.86
"To evaluate the efficacy, speed of onset, and adverse events of 6 mg subcutaneous, 100 mg oral, and 20 mg intranasal sumatriptan in the treatment of migraine attacks."	( Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen, P, 1998)	0.75
"Numbers needed to treat (NNT) were calculated for relief of headache and for adverse events (when data were available)."	( Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen, P, 1998)	0.54
"Subcutaneous sumatriptan in a dose of 6 mg is significantly more efficacious than 100 mg of oral sumatriptan, but causes more adverse events than oral sumatriptan."	( Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Tfelt-Hansen, P, 1998)	0.91
" Forty-five patients (88%) reported at least one adverse event and 23 (45%) experienced pressure, tightness, and/or pain in the chest, neck, and/or throat after administration of avitriptan."	( Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. Dahlöf, CG; Falk, L; Lewis, CP; Risenfors, M, 1998)	0.49
" However, while effective, it has low oral bioavailability and some problematic adverse effects."	( Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. , 1999)	0.5
" Diclofenac-potassium seemed to be as well tolerated as placebo, with fewer adverse events reported than after sumatriptan treatment and with more patients assessing the overall tolerability of diclofenac-potassium better than that of sumatriptan."	( Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. , 1999)	0.72
" Sumatriptan is more effective, but resulted in more adverse events."	( Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St Diener, HC, 1999)	1.43
"9% of the patients withdrew from the study because of insufficient efficacy or adverse events."	( Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Göbel, H; Heinze, A; Heinze-Kuhn, K; Lindner, V; Stolze, H, 1999)	0.53
" The results show that the overall incidence of adverse events among patients receiving sumatriptan injections for the treatment of cluster headache is low."	( Sumatriptan overuse in episodic cluster headache: lack of adverse events, rebound syndromes, drug dependence and tachyphylaxis. Albano, O; Bassi, A; Cassiano, MA; Causarano, V; Centonze, A; Centonze, V; Dalfino, L; Fabbri, L, )	1.8
"8 mg group is due to the termination of this trial arm after the incidence of a serious adverse event and a subsequent protocol amendment."	( The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Dahlöf, C; de Beukelaar, F; Diener, HC; Ferrari, MD; Mathew, N; Olesen, J; Tfelt-Hansen, P, 2001)	0.57
" Safety and tolerability were assessed through the collection of adverse events, monitoring of heart rate and blood pressure performance of 12-lead electrocardiogram, hematology screen, and blood chemistry studies."	( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Géraud, G; Keywood, C; Spierings, EL, 2002)	0.52
" The incidence of adverse events was higher in the frovatriptan-treated patients than in the patients who took placebo (47% versus 34%) and the spectrum of adverse events was similar."	( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Géraud, G; Keywood, C; Spierings, EL, 2002)	0.52
" Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg."	( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Géraud, G; Keywood, C; Spierings, EL, 2002)	0.72
"To determine the level of concern among migraineurs about migraine prescription medication tolerability and adverse effects and the impact of these concerns on their self-management of migraine."	( Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Gallagher, RM; Kunkel, R, 2003)	0.32
" Of those meeting the criteria, pain relief and speed of onset were important product attributes for 75% to 77% of sufferers, and the absence of adverse effects was important to over 40%."	( Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Gallagher, RM; Kunkel, R, 2003)	0.32
"Adverse effects are an important factor in migraine management, and concern about adverse effects significantly affected patient compliance."	( Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Gallagher, RM; Kunkel, R, 2003)	0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Safety evaluations included adverse events and laboratory tests."	( Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Alexander, WJ; Cady, RK; Frishberg, BM; Kori, SH; Lener, SE; Ruoff, GE; Winner, P; Zhang, Y, 2007)	0.61
" The most common treatment-related adverse events were nausea, muscle tightness, and dizziness."	( Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Alexander, WJ; Cady, RK; Frishberg, BM; Kori, SH; Lener, SE; Ruoff, GE; Winner, P; Zhang, Y, 2007)	0.61
" The adverse events did not differ from those expected for the individual components alone, and no new or unexpected findings occurred."	( Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Alexander, WJ; Cady, RK; Frishberg, BM; Kori, SH; Lener, SE; Ruoff, GE; Winner, P; Zhang, Y, 2007)	0.61
" Safety was evaluated based on the frequency of reported adverse events, and treatment with eASA was associated with lower incidence of adverse events than was with sumatriptan."	( Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. Diener, HC; Lampl, C; Voelker, M, 2007)	0.54
" In addition, the incidence of adverse events with 2 sumatriptan/naproxen sodium tablets administered 2 hours apart was lower than that with the single dose."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.84
" In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression."	( Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Campbell, JC; Hu, X; MacGregor, EA; Pawsey, SP, 2010)	0.36
" Information regarding safety of triptans while breastfeeding is limited but also reassuring, as the minimal amounts excreted into the milk are insufficient to cause any adverse effects on the breastfeeding infant."	( Safety of triptans for migraine headaches during pregnancy and breastfeeding. Bozzo, P; Duong, S; Einarson, A; Nordeng, H, 2010)	0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Adverse events were reported by 80%, 56%, and 60% of BGG492, sumatriptan, and placebo subjects, respectively."	( Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Brand, R; Campos, V; Diener, HC; Evers, S; Göbel, H; Gomez-Mancilla, B; Hariry, S; Johns, D; Jürgens, TP; Kalkman, HO; Pezous, N; Sommer, C; Sommer, M; Straube, A, 2014)	0.64
" Expert commentary: A new formulation of a low-dose sumatriptan intranasal powder administered via a novel breath-powered delivery device appears to be a safe and efficacious option for the acute management of a migraine ideally suited for this situation."	( The efficacy and safety of sumatriptan intranasal powder in adults with acute migraine. Freitag, FG; Shumate, DA, 2016)	0.98
" Safety was evaluated by monitoring of adverse events in addition to laboratory and clinical assessments."	( A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016)	0.66
" All adverse events were mild or moderate, with application-site paresthesia being the most common (32%)."	( A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016)	0.66
" The objective of this study was to evaluate the safety and tolerability of DFN-02 (10 mg) in the acute treatment of episodic migraine with and without aura over a 6-month period based on the incidence of treatment-emergent adverse events and the evaluation of results of clinical laboratory tests, vital signs, physical examination, and electrocardiograms."	( A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017)	0.67
" Adverse events were those expected for triptans, as well as for nasally administered compounds."	( A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017)	0.67
" AVP-825 was well tolerated in controlled trials, with the most common adverse events localized at the administration-site (abnormal taste, nasal discomfort); these were mostly mild, leading to only one discontinuation."	( A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Silberstein, SD, 2018)	0.75
"6% (89/219) of subjects reported treatment-emergent adverse events (TEAE), the most common of which were associated with the injection site: swelling (12."	( Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018)	0.77
"DFN-11 was effective, tolerable, and safe in the acute treatment of 4 migraine attacks over 8 weeks, with consistent responses on pain and associated symptoms."	( Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018)	0.77
"4% (16/119) who received placebo experienced at least 1 treatment-emergent adverse event (TEAE), the most common of which were injection site swelling (7."	( Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. Brand-Schieber, E; Landy, S; Munjal, S; Rapoport, AM, 2018)	0.77
" As of 2018, the FDA Adverse Event Reporting System public dashboard lists a total of 2889 reports of safety problems with the patch, 904 of which were classified as serious."	( Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Burch, RC; Loder, EW; Rayhill, M, 2018)	0.48
" Approval was based on 1 clinical trial and 2 open label studies in which reporting of adverse events was suboptimal."	( Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Burch, RC; Loder, EW; Rayhill, M, 2018)	0.48
" Treatment-emergent adverse events were evaluated up to 30 days after the last dose in the Phase 1 and Phase 3 studies."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	0.79
" No treatment-emergent adverse events were reported with the coadministration of ubrogepant 100 mg and sumatriptan 100 mg in the Phase 1 study."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	1
"We aimed at evaluating adverse drug reactions during the post-marketing phase with erenumab as the suspected/interacting drug in Eudravigilance, with the final goal of investigating the consistency of the disproportionality signals (DS) for erenumab in Eudravigilance and the American Food and Drug Administration Adverse Event Reporting System (FDA FAERS) and undetected DS from Eudravigilance."	( Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Liang, D; Sessa, M, 2022)	0.72
" The three system organ classes with the highest proportion of adverse events were general disorders and administration site conditions (16."	( Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Liang, D; Sessa, M, 2022)	0.72

Excerpt	Reference	Relevance
" There were no significant differences between treatments in relation to Cmax (82."	( Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. De Schepper, PJ; Depré, M; Durham, JM; Fowler, PA; Lacey, LF; Van Hecken, AM, 1992)	0.51
" Pharmacokinetic and pharmacodynamic variables were similar in all groups studied and were not altered by the presence of food, alcohol, dihydroergotamine or prophylactic migraine treatments."	( The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Baber, NS; Fowler, PA; Keene, ON; Lacey, LF; Tanner, RJ; Thomas, M, 1991)	0.52
" There were no statistically significant differences for butorphanol between the 2 treatments on any of the following pharmacokinetic parameters: Cmax, tmax, AUC, t1/2, CL/f, and Vz/f."	( Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate. Barbhaiya, RH; Lee, JS; Shyu, WC; Srinivas, NR; Upmalis, D, 1995)	0.52
" Single-dose pharmacokinetic studies reflect the way that sumatriptan will be used in routine practice, but relatively few studies have been published."	( Sumatriptan clinical pharmacokinetics. Scott, AK, 1994)	1.98
" We studied whether pharmacokinetic or pharmacodynamic differences may explain these different clinical effects."	( Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996)	0.55
"We compared the pharmacokinetic profiles of subcutaneous sumatriptan in 14 patients who consistently had headache relief without headache recurrence, in 12 patients who had headache recurrence in every attack, and in six patients who did not have headache relief after sumatriptan."	( Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996)	0.79
"Despite sufficient power of the study, no important differences in pharmacokinetic and pharmacodynamic profiles between the three patient groups were detected."	( Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996)	0.55
"Headache recurrence and lack of headache relief after sumatriptan do not appear to be explained by pharmacokinetic or pharmacodynamic differences between patients, which may be an important finding for the development of novel antimigraine drugs."	( Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Burggraaf, J; Cohen, AF; Ferrari, MD; Fowler, PA; Muller, LM; Schoemaker, RC; Visser, WH, 1996)	0.8
"We investigated the hypothesis that distributions of continuous pharmacokinetic variables are positively skewed in nature and that logarithmic transformation of these variables restores normality."	( Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? Bye, A; Keene, ON; Lacey, LF; Pritchard, JF, 1997)	0.3
" Pharmacokinetic parameters evaluated after administration of single intravenous and oral doses were very similar and the ANOVA analysis did not show any statistically significant differences for t1/2, Cmax, V or AUC (normalised)."	( A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. David, M; Duléry, BD; Huebert, ND; Petty, MA; Schoun, J, 1997)	0.49
" The elimination half-life (t1/2), approximately 2 h, was unaffected by the magnitude of dose."	( Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Duquesnoy, C; Fuseau, E; Hussey, EK; Moore, KH; Pakes, GE; Shaw, S, 1997)	0.56
"Allometric scaling is an empirical examination of the relationships between the pharmacokinetic parameters and size (usually body weight), but it can also involve brain weight for metabolized drug."	( Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. Bye, A; Cosson, VF; Efthymiopoulos, C; Fuseau, E, 1997)	0.6
" There were no statistical differences between the non-parenteral routes for tmax or Cmax/AUCinfinity."	( Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Duquesnoy, C; Fuseau, E; Mamet, JP; Sumner, D, 1998)	0.55
" Many novel antimigraine compounds are in clinical development, yet full characterization of each one's pharmacodynamic behavior is a formidable task due to the difficulty in studying a migraineur during an attack."	( The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. Forrest, A; Fullerton, T; Gengo, FM; Komorowski-Swiatek, D, 1999)	0.61
" The pharmacokinetic parameters were calculated by using model-independent methods."	( Lack of pharmacokinetic interaction between sumatriptan and naproxen. Rambhau, D; Rao, BR; Rao, YM; Srinivasu, P, 2000)	0.57
" Pharmacokinetic parameters were calculated using noncompartmental methods."	( Chronopharmacokinetics of sumatriptan in healthy human subjects. Boinpally, RR; Devaraj, R; Poondru, S; Yamasani, MR, 2000)	0.61
" As expected for a class of compounds developed for affinity at a specific receptor, there are minor pharmacodynamic differences between the triptans."	( Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. De Vries, P; Saxena, PR; Tfelt-Hansen, P, 2000)	0.31
"In the 24 evaluable subjects (12 men, 12 women) included in the pharmacokinetic analysis, mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively, than the corresponding values after administration of sumatriptan alone."	( The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Bye, C; Gray, P; Leese, PT; McNeal, S; Moore, KH; O'Quinn, S; Sale, M, 2002)	0.84
" However, the possibility of a pharmacokinetic interaction and the safety of this regime have not been examined."	( A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Boulton, DW; Nichola, PS; Shyu, WC; Vachharajani, NN, 2002)	0.56
" The elimination phase half-life is approximately 2 hours, consistent with administration by other routes."	( Clinical pharmacokinetics of intranasal sumatriptan. Barrow, A; Fuseau, E; Ibbotson, T; Moore, KH; Petricoul, O, 2002)	0.58
" A total of 16 subjects (10 males and 6 females) had pharmacokinetic data that could be analyzed, 2 withdrew from the study 30 and 60 minutes after dosing following the loss of venous access for blood sampling, and a bioanalysis failure resulted in loss of data from 3 subjects."	( Pharmacokinetics of sumatriptan nasal spray in adolescents. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2003)	0.64
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" Pharmacokinetic analysis included both noncompartmental and population modeling methods."	( Pharmacokinetics of sumatriptan nasal spray in children. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2004)	0.65
" Potential explanations for differences among triptans in the incidence of CNS side-effects may relate to pharmacological and pharmacokinetic differences, including receptor binding, lipophilicity, and the presence of active metabolites."	( Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Dodick, DW; Martin, V, 2004)	0.32
"This randomized, open-label, 4-way crossover study (n = 32) was conducted to determine whether the new formulation of sumatriptan 50 and 100 mg is bioequivalent to sumatriptan conventional tablets and to compare the pharmacokinetic profiles of the new formulation and the conventional tablet during the early (0-2 h) postdose interval in healthy volunteers."	( Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Boswell, D; Bullman, J; Dow, A; Lewis, A; Sidhu, J; Summers, SJ; Walls, C, 2004)	0.8
" Pharmacokinetic parameters measured early (0-2 h) after dosing reveal slightly faster absorption, on average, of the new sumatriptan formulation than sumatriptan conventional tablets although high intersubject variability was observed."	( Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Boswell, D; Bullman, J; Dow, A; Lewis, A; Sidhu, J; Summers, SJ; Walls, C, 2004)	0.8
" The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine."	( Pharmacokinetic interactions of topiramate. Bialer, M; Curtin, C; Doose, DR; Murthy, B; Schwabe, S; Twyman, RE; Wang, SS, 2004)	0.32
" The analysis was based on phase I pharmacokinetic naratriptan data, sumatriptan pharmacodynamic data, and naratriptan preclinical (animal) potency information, together with general knowledge as to how migraine affects oral absorption."	( Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. Aarons, L; Gueorguieva, I; Nestorov, IA; Rowland, M, 2005)	0.56
"A previously developed pharmacokinetic (PK)/pharmacodynamic (PD) model for naratriptan disposition and effect was used."	( Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. Aarons, L; Gueorguieva, I; Nestorov, IA; Rowland, M, 2005)	0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"(1) To determine whether sumatriptan can be absorbed across the oral mucosa, and, if so; then (2) to describe its pharmacokinetics; and (3) to investigate whether there are pharmacodynamic correlates of such pharmacokinetics in patients experiencing migraine attacks."	( Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Bergstrom, D; Cabana, B; Dilone, E; Fox, AW; Nedumpara, M, )	0.71
" The first, in normal volunteers, compared the pharmacokinetic performance of a lingual spray (LS) formulation of sumatriptan (2 dose sizes, one of which in both the fed and fasted state) with an orthodox 50-mg sumatriptan tablet."	( Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Bergstrom, D; Cabana, B; Dilone, E; Fox, AW; Nedumpara, M, )	0.61
" sumatriptan on pharmacokinetic grounds."	( Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. Fox, AW, 2010)	1.64
"Summary pharmacokinetic data were taken from the literature and from GlaxoSmithKline (GSK) study C92-050."	( Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. Fox, AW, 2010)	0.73
"There are no pharmacokinetic grounds to deter co-administration of an MAOI-A and subcutaneous sumatriptan."	( Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. Fox, AW, 2010)	0.95
"To describe the pharmacokinetic and safety profiles of sumatriptan 85 mg formulated with RT Technology (RT) and naproxen sodium 500 mg in a fixed-dose combination tablet (sumatriptan/naproxen sodium) that targets both serotonergic dysmodulation and inflammation in migraine."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.84
" The pharmacokinetics of 2 sumatriptan/naproxen sodium tablets administered 2 hours apart were consistent with the pharmacokinetic predictions from a single dose of the combination tablet."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.89
"The combination tablet of sumatriptan/naproxen sodium has unique pharmacokinetic properties."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.89
" Blood samples for pharmacokinetic assessment were collected up to 14 hours after the administration of the first dose."	( Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-lab Berges, A; Lener, SE; McDonald, SA; Walls, C, 2010)	0.63
" With S/N + S4, sumatriptan Cmax and AUC(0-14) did not exceed those with S100 + S100."	( Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-lab Berges, A; Lener, SE; McDonald, SA; Walls, C, 2010)	0.98
" Pharmacologically, pharmacokinetic parameters, in particular bioavailability, T(max) and C(max) are responsible for the wide efficacy of the compound and the limited adverse effect (AE) profile."	( Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. Casolla, B; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012)	1.82
" This method was successfully applied to a pharmacokinetic study conducted with 10 healthy volunteers."	( Rapid determination of sumatriptan in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study. Bae, MH; Lee, HW; Lee, J; Lim, MS; Park, J; Park, SM; Seo, JJ; Seong, SJ; Yoon, YR, 2013)	0.7
"The purpose of this study was to directly compare the pharmacokinetic (PK) profile of 22-mg sumatriptan powder delivered intranasally with a novel Breath Powered™ device (11 mg in each nostril) vs a 20-mg sumatriptan liquid nasal spray, a 100-mg oral tablet, and a 6-mg subcutaneous injection."	( Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Carothers, J; Djupesland, PG; Mahmoud, RA; Messina, J; Obaidi, M; Offman, E, 2013)	0.9
" However, the many formulations available are characterized by differences in the pharmacokinetic profile that could affect therapy effectiveness."	( Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. D'Alonzo, L; Lecchi, M; Martelletti, P; Negro, A, 2014)	0.4
"Limited pharmacokinetic sampling strategy may be useful for predicting the area under the curve (AUC) for triptans and may have clinical utility as a prospective tool for prediction."	( Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application. Srinivas, NR; Syed, M, 2016)	0.68
" The validated method was successfully applied to a pharmacokinetic study with simultaneous administration of naproxen sodium and sumatriptan succinate tablet formulations in healthy volunteers."	( Development and validation of an LC-ESI-MS/MS method for the simultaneous quantification of naproxen and sumatriptan in human plasma: application to a pharmacokinetic study. Bellorio, KB; Brêtas, CM; Brêtas, JM; César, IC; Mundim, IM; Pianetti, GA; Teixeira, Lde S, 2016)	0.85
" Blood samples for pharmacokinetic profiling of sumatriptan were obtained prior to dosing and at predetermined time points covering the 12 hours postonset of treatment."	( A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016)	0.91
" Cmax , tmax , AUC0-∞ , and t½ values were all similar between male and female patients and between younger (12-14 years) and older (15-17 years) adolescents."	( A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016)	0.66
"To evaluate the potential for pharmacokinetic interaction and the safety and tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in healthy participants, and to inform the safety and tolerability of ubrogepant alone and in combination with triptans in Phase 3 trials in participants with migraine."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	1
"The Phase 1 study was a single-center, open-label, randomized, 3-way crossover, single-dose, pharmacokinetic interaction study, where participants received each of 3 oral treatments with a 7-day washout period between treatments: single dose of ubrogepant 100 mg, single dose of sumatriptan 100 mg, and ubrogepant 100 mg plus sumatriptan 100 mg."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	0.96
"Although there were slight alterations in ubrogepant pharmacokinetic parameters when coadministered with sumatriptan, such changes are expected to have minimal clinical relevance, especially because no changes were seen in sumatriptan area under the curve and maximum plasma concentration when coadministered with ubrogepant."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	1
" Pharmacokinetic evaluations were also performed during an in-vivo study on Sprague-Dawley rats and neuropharmacokinetic parameters such as drug targeting efficiency (DTE) and direct transport percentage (DTP) were calculated."	( Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: preparation, optimization, characterization and pharmacokinetic evaluation. Azadi, A; Heidari, R; Masjedi, M; Mohammadi-Samani, S, 2020)	0.86

Excerpt	Reference	Relevance
" Drug-drug interactions are further implicated through this study."	( Cerebral blood flow effects of sumatriptan in drug combinations in the baboon model. Dormehl, IC; Hugo, N; Oliver, DW, 1995)	0.58
" This study analyzed the ability of ergotamine, dihydroergotamine, and 5-HT and sumatriptan to interact with the four known human 5-HT1 receptor subtypes."	( Wolff Award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine1 receptor subtypes. Havlik, S; Oksenberg, D; Peroutka, SJ, )	0.36
" This article details those medications that may interact significantly with the SSRIs, and provides clinical guidelines for minimising the likelihood of such complications."	( Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Mitchell, PB, 1997)	0.3
" Nonsteroidal anti-inflammatory drugs (NSAID) such as tolfenamic acid and naproxen sodium combined with sumatriptan have demonstrated efficacy in reducing recurrence observed with the single use of this drug."	( Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. Barbosa, JS; Krymchantowski, AV, 2001)	0.53
"The extent of absorption of sumatriptan was similar after oral administration alone and in combination with clarithromycin dosed to steady state."	( The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Bye, C; Gray, P; Leese, PT; McNeal, S; Moore, KH; O'Quinn, S; Sale, M, 2002)	0.92
" The efficacy of indomethacin, alone and combined with prochlorperazine and caffeine, in abolishing peripheral and central sensitization in in vivo models of hyperalgesia is a further explanation of the clinical efficacy of IndoProCaf in the treatment of migraine."	( Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. Galeotti, N; Ghelardini, C; Grazioli, I; Uslenghi, C, 2004)	0.55
"The authors present a 14-year-old girl with 18q- syndrome combined with cyclic vomiting syndrome."	( Successful treatment with sumatriptan in a case with cyclic vomiting syndrome combined with 18q- syndrome. Haginoya, K; Hirose, M; Kakisaka, Y; Munakata, M; Sato, I; Sato, T; Tsuchiya, S; Uematsu, M; Wakusawa, K, 2009)	0.65
" These data suggest a mechanism of medication overuse headache by which migraine medications combined with repeated episodes of pain may amplify the consequences of nociceptor activation and increase the probability of future migraine attacks as well as risk of medication overuse headache."	( Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Dodick, DW; Nation, KM; Navratilova, E; Porreca, F, 2019)	0.51
"To evaluate the potential for pharmacokinetic interaction and the safety and tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in healthy participants, and to inform the safety and tolerability of ubrogepant alone and in combination with triptans in Phase 3 trials in participants with migraine."	( Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Boinpally, R; Butler, M; Jakate, A; Lu, K; McGeeney, D; Periclou, A, 2020)	1

Excerpt	Reference	Relevance
" Its subcutaneous bioavailability approaches 100%, and its mean terminal half-life is two hours."	( Sumatriptan: a new drug for vascular headache. Hsu, VD, 1992)	1.73
" Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration."	( The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Baber, NS; Fowler, PA; Keene, ON; Lacey, LF; Tanner, RJ; Thomas, M, 1991)	0.52
" The bioavailability is greater than 54% in dog, but lower in rat."	( The kinetics of 14C-GR43175 in rat and dog. Dallas, FA; Dixon, CM; McCulloch, RJ; Saynor, DA, 1989)	0.28
" The drug was rapidly absorbed after oral dosing and had a mean absolute bioavailability of 14% due at least in part to first-pass metabolism."	( Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Andrew, P; Dallas, FA; Fowler, PA; Lacey, LF; Thomas, M, 1989)	0.28
"Sumatriptan exhibits low oral bioavailability partly due to presystemic metabolism, which may vary with regional differences in metabolic activity throughout the gastrointestinal tract."	( Sumatriptan absorption from different regions of the human gastrointestinal tract. Brouwer, KL; Davis, IM; Donn, KH; Dukes, GE; Heizer, WD; Hussey, EK; Powell, JR; Warner, PE, 1995)	3.18
" The objective of this work was to identify potent and selective 5-HT1D receptor agonists with high oral bioavailability and low central nervous system penetration."	( Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors. Baker, R; Beer, MS; Davey, WB; Guiblin, AR; Jelley, RA; Reeve, AJ; Routledge, H; Sternfeld, F; Street, LJ; Watt, AP, 1995)	0.29
" The mean subcutaneous bioavailability is 96% compared to 14% for the oral tablet."	( Single dose pharmacokinetics of sumatriptan in healthy volunteers. Fowler, PA; Hussey, EK; Lacey, LF, 1995)	0.57
" Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism."	( Sumatriptan clinical pharmacokinetics. Scott, AK, 1994)	1.73
" Both 8d,k were found to be well absorbed in the rat with oral bioavailabilities of 66% and 62%, respectively."	( Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor. Baker, R; Beer, MS; Castro, JL; Guiblin, AR; Hargreaves, RJ; Hobbs, SC; Jenkins, MR; Russell, MG; Scholey, K; Stanton, JA, 1994)	0.29
" dose both probably due to extensive and rapid metabolism of the parent drugs as suggested by the low values for bioavailability (range 13."	( A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. David, M; Duléry, BD; Huebert, ND; Petty, MA; Schoun, J, 1997)	0.49
" In conscious rats and dogs, naratriptan has high oral bioavailability (71% and 95%, respectively)."	( Naratriptan: biological profile in animal models relevant to migraine. Beattie, DT; Connor, HE; Feniuk, W; Humphrey, PP; North, PC; Oxford, AW; Saynor, DA, 1997)	0.3
" The overall bioavailability of sumatriptan was 40-50%."	( off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog. Barrow, A; Dixon, CM; Perren, MJ; Saynor, DA; Smith, I; Stowe, R, 1997)	0.82
" A higher lipophilicity explains (except for alniditan) their greater oral bioavailability and better central nervous system penetration."	( Acute migraine therapy: the newer drugs. Schoenen, J, 1997)	0.3
"To cater to the special situation of much reduced oral bioavailability which occurs in severe migraine attacks with pronounced nausea and vomiting, sumatriptan can also be used in a subcutaneous form that can be self-administered."	( Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. Baar, H; Beckmann-Reinhold, A; Beiküfner, HD; Böhme, K; Göbel, H, 1998)	0.72
" Usual absorption parameters were described and the rate of absorption was assessed using deconvolution technics."	( Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Duquesnoy, C; Fuseau, E; Mamet, JP; Sumner, D, 1998)	0.55
"Zolmitriptan (previously known as 311C90) is a serotoninergic 5-HT1B/D agonist with high oral bioavailability with a double, central and peripheral, action mechanism."	( [Clinical efficacy of zolmitriptan in migraine]. Leira, R; Noya, M, 1998)	0.3
" The optimum compound was 1-(3-[5-(1,2, 4-triazol-4-yl)-1H-indol-3-yl]propyl)-4-(2-(3-fluorophenyl)ethyl)p ipe razine (7f) which has excellent selectivity for h5-HT1D receptors over other 5-HT receptor subtypes and good oral bioavailability in three species."	( 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. Beer, MS; Chambers, MS; Goodacre, S; Hobbs, SC; Hunt, P; Jelley, RA; MacLeod, AM; Matassa, VG; Rathbone, D; Reeve, AJ; Stanton, JA; Sternfeld, F; Street, LJ; Watt, AP, 1999)	0.3
" However, while effective, it has low oral bioavailability and some problematic adverse effects."	( Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. , 1999)	0.5
" L-772,405 also shows very good selectivity over a range of other serotonin and nonserotonin receptors and has excellent bioavailability following subcutaneous administration in rats."	( 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. Beer, MS; Broughton, HB; Castro, JL; Hitzel, L; Matassa, VG; Pengilley, RR; Russell, MG; Sohal, B; Stanton, JA; van Niel, MB; Watt, AP, 1999)	0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" 23% bioavailability following oral drug administration."	( The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig. Austin, NE; Gaster, LM; Hagan, JJ; Hatcher, P; Jeffrey, P; Middlemiss, DN; Roberts, C; Routledge, C; Wyman, P, 2000)	0.31
" In early clinical trials, rizatriptan was shown to have good bioavailability and favorable effects on quality of life."	( Rizatriptan versus usual care in long-term treatment of migraine. Silberstein, SD, 2000)	0.31
" Zolmitriptan introduced in 1994 is an agonists of 5-HT 1B/1D receptor, is active both peripherally and centrally, is well absorbed from the digestive tract and has a good bioavailability index /40%/."	( [Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor]. Prusiński, A, 1999)	0.3
" Sumatriptan has a low oral bioavailability (14%) and all the newer triptans have an improved oral bioavailability and for one, risatriptan, the rate of absorption is faster."	( Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. De Vries, P; Saxena, PR; Tfelt-Hansen, P, 2000)	1.22
" Eletriptan has a rapid and complete oral absorption and a good oral bioavailability in migraineurs."	( Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. Diener, HC; McHarg, A, 2000)	0.31
" A qualitative model for pharmacokinetic properties was then used to guide the synthesis toward molecules likely to have oral bioavailability in humans."	( Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation. Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P, 2001)	0.31
"Rizatriptan is a potent, oral, 5-HT1B/1D agonist with more rapid absorption and higher bioavailability than oral sumatriptan."	( Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Block, GA; Giacovazzo, M; Malbecq, W; Paz, J; Reines, SA; Rodriguez, F; Teall, J; Tfelt-Hansen, P; Visser, WH, )	0.63
" Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life."	( An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Centurión, D; De Vries, P; Saxena, PR; Valdivia, LF; Villalón, CM, 2002)	0.68
"5 h) and rizatriptan has greater bioavailability than sumatriptan (45% versus 15%)."	( Rizatriptan: pharmacological differences from sumatriptan and clinical results. Lines, CR; McCarroll, KA; Visser, WH, 2001)	0.82
"The potential advantages of eletriptan lie firstly in its lipophilicity reflected as an increased rate of absorption and Tmax compared to sumatriptan."	( Eletriptan: pharmacological differences and clinical results. Giffin, N, 2001)	0.51
" In adults, intranasal sumatriptan is well absorbed and tolerated."	( Pharmacokinetics of sumatriptan nasal spray in adolescents. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2003)	0.95
" This compound demonstrated favorable in vitro metabolic stability in human and rat liver microsomes and was found to be orally bioavailable in rats (F(po)=51%)."	( Design, synthesis and biological activity of novel dimethyl-[2-[6-substituted-indol-1-yl]-ethyl]-amine as potent, selective, and orally-bioavailable 5-HT(1D) agonists. Arora, J; Demschyshyn, L; Draper, S; Edwards, L; Harrison, S; Isaac, M; Labrie, P; MacLean, N; Maddaford, S; Naismith, A; O'Brien, A; Papac, D; Slassi, M; Tehim, A; Wang, H; Wilson, J; Xin, T, 2003)	0.32
"Onset of effect is related to rate of absorption of sumatriptan."	( Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Fox, AW, 2004)	0.57
" Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus."	( Intranasal medications for the treatment of migraine and cluster headache. Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004)	0.32
" Compared to sumatriptan, the second-generation triptans have a higher oral bioavailability and longer plasma half-life."	( Migraine: pathophysiology, pharmacology, treatment and future trends. Centurión, D; de Vries, P; Saxena, PR; Valdivia, LF; Villalón, CM, 2003)	0.69
" Pharmacokinetic parameters and bioavailability of sumatriptan did not seem to be correlated either to the lack of efficacy or the appearance of side effects."	( Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. Bertolini, A; Coccia, CP; Ferrari, A; Leone, S; Pinetti, D; Sternieri, E, 2005)	0.9
" Based on a population pharmacokinetic model, mean concentration-time profiles were generated by varying the absorption rate constant and lag time."	( Relevance of absorption rate and lag time to the onset of action in migraine. Danhof, M; Della Pasqua, OE; Maas, HJ; Spruit, MA, 2008)	0.35
"Model-based predictions suggest that increases in the absorption rate of the currently marketed oral formulation of sumatriptan result in a gain in the pain-free response that is both clinically and statistically relevant."	( Relevance of absorption rate and lag time to the onset of action in migraine. Danhof, M; Della Pasqua, OE; Maas, HJ; Spruit, MA, 2008)	0.56
"Sumatriptan is a potent and selective 5-HT(1B) and 5-HT(1D )agonist used in the symptomatic treatment of migraine; it shows poor oral bioavailability ascribed, in part, to its low lipophilicity."	( Unanticipated acyloxymethylation of sumatriptan indole nitrogen atom and its implications in prodrug design. Guedes, RC; Iley, J; Lopes, F; Moreira, R; Rodrigues, T, 2008)	2.06
"The absolute bioavailability of subcutaneous (s."	( Subcutaneous sumatriptan pharmacokinetics: delimiting the monoamine oxidase inhibitor effect. Fox, AW, 2010)	0.73
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" In addition, food had no significant effect on the bioavailability of naproxen or sumatriptan after administration of sumatriptan/naproxen sodium but slightly delayed the time to peak plasma concentration of sumatriptan by approximately 40 minutes."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.82
" For oral formulations, these limitations include difficulty in taking an oral medication due to the nausea and vomiting that often accompany migraine, and inconsistent absorption, whereas nasal and subcutaneous formulations may be associated with low bioavailability and an undesirable rate of adverse events, respectively."	( Transdermal delivery of sumatriptan for the treatment of acute migraine. Pierce, MW, 2010)	0.67
" Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy."	( Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012)	0.62
" The new drug formulations that are the most similar to the pharmacokinetics parameters of the subcutaneous one are promising because they both improve pharmacokinetic bioavailability bypassing the first-pass metabolism and increase patient compliance."	( Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. Casolla, B; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2012)	1.82
" BMS-742413 has good intranasal bioavailability in the rabbit and shows a robust, dose-dependent inhibition of CGRP-induced increases in marmoset facial blood flow."	( Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr Cantor, GH; Chaturvedula, PV; Conway, CM; Davis, C; Denton, R; Dubowchik, GM; Keavy, D; Macci, R; Macor, JE; Mathias, N; Mercer, SE; Moench, P; Pin, SS; Schartman, R; Signor, L; Thalody, G; Whiterock, V; Xu, C, 2013)	0.39
"An open-label, cross-over, comparative bioavailability study was conducted in 20 healthy subjects at a single center in the USA."	( Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Carothers, J; Djupesland, PG; Mahmoud, RA; Messina, J; Obaidi, M; Offman, E, 2013)	0.68
" Sumatriptan succinate has oral bioavailability of 15% and undergoes hepatic metabolism, hence it is suitable for nasal administration."	( Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Chaudhari, PD; Galgatte, UC; Kumbhar, AB, 2014)	1.31
"The objective of the investigation was to develop a mucoadhesive in situ gel to improve the bioavailability of the sumatriptan succinate."	( Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Chaudhari, PD; Galgatte, UC; Kumbhar, AB, 2014)	0.61
"5% poloxamer 188 group, with absolute bioavailability 29."	( Non-ionic surfactants as novel intranasal absorption enhancers: in vitro and in vivo characterization. Ding, J; Li, J; Li, Y; Mao, S; Zhang, X, 2016)	0.43
" Intranasal sumatriptan is well absorbed and is generally effective in relieving headache."	( Effects of sumatriptan nasal spray (Imigran) on isolated rat's tracheal smooth muscle. Chang, YN; Cheng, LH; Chiu, FS; Chu, YH; Liu, SC; Wang, HW; Wu, PC, 2015)	1.19
"Sumatriptan succinate (SS) is a 5-HT1 receptor agonist used in the treatment of migraine having poor bioavailability (15%) due to its extensive first-pass effect."	( Sumatriptan succinate sublingual fast dissolving thin films: formulation and in vitro/in vivo evaluation. Abou Ghaly, MH; Amin, MM; El Nabarawi, MA; Tayel, SA, 2016)	3.32
" Absorption of SS delivered by MNs was similar to that observed after subcutaneous injection and was associated with high bioavailability (ca."	( Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats. Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakane, T; Wu, D; Yamamoto, A, 2015)	0.69
" The intestinal absorption rate for each drug was acquired by deconvolution, using historical intravenous data as reference, and used with the intestinal surface area and the dose remaining in the lumen to estimate the Peff."	( Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data. Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E, 2015)	0.42
"The low bioavailability of the anti-migraine drug sumatriptan is partially caused by first-pass hepatic metabolism."	( OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Abu Abed, M; Brockmöller, J; Dos Santos Pereira, JN; Faltraco, F; Knoch, T; Kuron, D; Matthaei, J; Prukop, T; Tzvetkov, MV, 2016)	0.97
"Available formulations of sumatriptan succinate (SS) have low bioavailability or are associated with site reactions."	( Permeation of sumatriptan succinate across human skin using multiple types of self-dissolving microneedle arrays fabricated from sodium hyaluronate. Kamiyama, F; Katsumi, H; Kusamori, K; Quan, YS; Sakane, T; Wu, D; Yamamoto, A, 2016)	1.1
"Sumatriptan succinate (SS) is a selective serotonin receptor agonist used for the treatment of migraine attacks, suffering from extensive first-pass metabolism and low oral bioavailability (∼14%)."	( Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. AbouGhaly, MH; Amin, MM; El Nabarawi, MA; Tayel, SA, 2017)	2.11
" Rapid rate of absorption is suggested to be important for optimal efficacy."	( A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. Allenby, K; Brand-Schieber, E; Cady, RK; Munjal, S; Rapoport, AM; Spierings, ELH, 2017)	0.67
"Nanoformulations in the past few decades have gained tremendous attention owing to their affirmative applications in increasing the bioavailability of poorly soluble drugs."	( Preparation and Characterization of Micelles. Jain, RD; Patravale, VB; Upadhaya, PG, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" SUT bioavailability is low (15%) when it is taken orally owing to its gastric breakdown and bloodstream before reaching the target arteries."	( Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. Ali Hasan, O; El Sisi, AM; Eleraky, NE; Omar, MM, 2019)	0.74
"The aim of the study was to enhance SUT bioavailability through developing an intranasal transferosomal mucoadhesive gel."	( Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. Ali Hasan, O; El Sisi, AM; Eleraky, NE; Omar, MM, 2019)	0.74
"Based on enhancing the bioavailability and sustaining the drug release, it can be concluded that the in-situ gel of SUT-loaded nano-transferosomes were developed as a promising non-invasive drug delivery system for treating migraine."	( Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation. Ali Hasan, O; El Sisi, AM; Eleraky, NE; Omar, MM, 2019)	0.74
" The bioavailability of conventional nasal liquids is low due to the deposition of a large fraction of the delivered dose of a drug in the nasal cavity."	( Harnessing Intranasal Delivery Systems of Sumatriptan for the Treatment of Migraine. Akhtari, J; Asadi, P; Assadpour, S; Sahebkar, A; Shiran, MR, 2022)	0.99
" Sumatriptan belongs to a BCS class III, which exhibits poor oral bioavailability and several side-effects."	( Intranasal drug delivery of sumatriptan succinate-loaded polymeric solid lipid nanoparticles for brain targeting. Dewangan, HK; Shah, K; Yadav, RK, 2022)	1.93
" In vivo pharmacokinetic study demonstrated improved brain bioavailability of SUT-NEsG as compared to orally administered sumatriptan solution (SUT-SL)."	( Quality by design for sumatriptan loaded nano-ethosomal mucoadhesive gel for the therapeutic management of nitroglycerin induced migraine. Alharbi, HM; Almari, AH; Batool, S; Din, FU; Fatease, AA; Lahiq, AA; Shafique, U; Sohail, S, 2023)	1.43

Excerpt	Relevance	Reference
" In the published clinical trials of the oral and subcutaneous dosage forms to date, sumatriptan was effective in reducing headache severity from moderate/severe to mild/absent in approximately 70-80 percent of patients treated with active drug, compared with only 20-30 percent in the placebo groups, and 48 percent in the oral ergotamine tartrate/caffeine (Cafergot)-treated group."	( Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Fullerton, T; Gengo, FM, 1992)	1.95
" Based on this study, a simple, rapid and sensitive voltammetric method was developed for the determination of the drug in a tablet dosage form."	( Differential pulse voltammetric determination of sumatriptan succinate (1:1) in a tablet dosage form. Fernandez Alvarez, JM; Hua, C; Munden, R; Sagar, K; Smyth, MR, 1992)	0.54
"The results of the very first large-scale placebo-controlled dose-response trial with the novel selective 5-hydroxytryptamine1-like (5HT1-like) receptor agonist sumatriptan are presented."	( Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Bayliss, EM; Ferrari, MD; Ludlow, S; Pilgrim, AJ; Visser, WH, 1992)	0.74
" Headache relief rates showed an approximate dose-response relationship and at 1 hour were as follows: placebo, 24%; 1 mg, 43%; 2 mg, 57%; 3 mg, 57%; 4 mg, 50%; 6 mg, 73%; and 8 mg, 80%."	( Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Couch, J; Dexter, J; Flamenbaum, W; Goldstein, J; Mathew, NT; Rapoport, A; Saper, J; Sheftell, F; Silberstein, S; Solomon, S, 1992)	0.54
" In contrast, morphine (the positive control) produced expected dose-response relationships on measures of reinforcing and physiologic effects."	( Psychoactivity and abuse potential of sumatriptan. Busch, M; Jasinski, DR; Preston, KL; Sullivan, JT; Testa, MP, 1992)	0.55
"The role of serotonin in the pathogenesis of migraine is discussed, and the chemistry, pharmacology, pharmacokinetics, efficacy, adverse effects, and dosage and administration of sumatriptan are reviewed."	( Sumatriptan: a new drug for vascular headache. Hsu, VD, 1992)	1.92
" No findings of toxicological significance were observed in rats and dogs after chronic dosing for 1 year or more."	( Preclinical studies on the anti-migraine drug, sumatriptan. Feniuk, W; Humphrey, PP; Jackson, MR; Marriott, AS; Tanner, RJ; Tucker, ML, 1991)	0.54
" The effect of twice-daily dosing with propranolol on the pharmacokinetics and pharmacodynamics of a single oral dose of sumatriptan was investigated in 10 healthy male subjects."	( Lack of an interaction between propranolol and sumatriptan. Breckenridge, AM; Fowler, PA; Lacey, LF; Scott, AK; Walley, T, 1991)	0.75
" Rats and dogs were dosed intravenously (iv) and orally (po) with 1 mg 14C-GR43175 base (as succinate salt)/kg bodyweight."	( The kinetics of 14C-GR43175 in rat and dog. Dallas, FA; Dixon, CM; McCulloch, RJ; Saynor, DA, 1989)	0.28
" The drug was rapidly absorbed after oral dosing and had a mean absolute bioavailability of 14% due at least in part to first-pass metabolism."	( Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Andrew, P; Dallas, FA; Fowler, PA; Lacey, LF; Thomas, M, 1989)	0.28
" Dosing should be individualized according to the needs of the patient."	( Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Clements, B; Cutler, N; Davis, R; Mushet, GR; Whitcher, L, 1995)	0.81
" Moreover, the products are currently marketed in different dosage forms--intramuscular for DHE and subcutaneous for sumatriptan."	( A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Kozma, CM; Lawrence, BJ; Mauch, RP; Reeder, CE, )	0.55
" Following oral dosing up to 400 mg, the pharmacokinetics are also linear, with the exception of rate of absorption, as indicated by a dose dependent increase in time to peak concentration."	( Single dose pharmacokinetics of sumatriptan in healthy volunteers. Fowler, PA; Hussey, EK; Lacey, LF, 1995)	0.57
"Although sumatriptan has proven effective in treating migraine symptoms, there have been no studies comparing this drug with non-steroid anti-inflammatory drugs (NSAIDs) and ergotamine compounds under ideal dosage and delivery conditions."	( [Clinical experience with sumatriptan ++ in the treatment of migraine symptoms]. Pascual, J, )	0.85
" Patients whose headache was completely resolved 90 minutes after subcutaneous dosing received either oral sumatriptan or placebo at the onset of recurrent headache."	( Oral sumatriptan in the treatment of recurrent headache. Cady, RK; Crummett, D; Littlejohn, TW; Rubino, J, 1994)	1.02
" New medications, such as sumatriptan, and new dosage forms of older medications, including dihydroergotamine, NSAIDs, and phenothiazines are available to treat acute attacks."	( Therapeutic advances in migraine. Solomon, GD, 1993)	0.59
" The recommended dosage of sumatriptan at the onset of migraine symptoms is 100 mg orally or 6 mg subcutaneously."	( Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. Diener, HC; Pfaffenrath, V; Schoenen, J; Steiner, TJ; Wilkinson, M, 1995)	0.84
" The patients described had a high frequency of attacks (more than two per day); therefore, far higher dosage of the drug was taken than commonly used in cluster headache."	( Use of high sumatriptan dosages during episodic cluster headache: three clinical cases. Albano, O; Attolini, E; Bassi, A; Cassiano, MA; Cavazzuti, L; Centonze, V; Polito, BM; Ricchhetti, G; Sabbà, C, 1996)	0.67
" Clinical disability scores 120 minutes after dosing showed that 75% and 85% of sumatriptan-treated patients, compared with 30% and 42% of placebo-treated patients, were normal or only mildly impaired (a statistically significant difference)."	( Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Baker, CC; Cady, RK; Clements, B; Davis, R; Gutterman, DL; Mushet, GR, )	0.62
"The proportion of patients whose conditions improved from severe or moderate headache immediately before dosing to mild or no headache at 2 hours after drug administration (ie, headache relief)."	( Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Ferrari, MD; Jiang, K; Lines, CR; Reines, SA; Terwindt, GM; Visser, WH, 1996)	0.65
"2 mumol/kg), GR-127,935 right-shifted the dose-response curve of sumatriptan."	( The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Cutrer, FM; Moskowitz, MA; Waeber, C; Yu, XJ, 1997)	0.77
" The two dosing periods were separated by 3 to 14 days."	( Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Duquesnoy, C; Fuseau, E; Hussey, EK; Moore, KH; Pakes, GE; Shaw, S, 1997)	0.56
"9 h after intravenous or intranasal dosage respectively."	( off absorption, pharmacodynamics, metabolism and excretion of 14C-sumatriptan following intranasal administration to the beagle dog. Barrow, A; Dixon, CM; Perren, MJ; Saynor, DA; Smith, I; Stowe, R, 1997)	0.53
"5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%)."	( Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Sawyer, J; Schoenen, J, 1997)	0.3
" These findings suggest that the leftward shift of the dose-response curve for 5-HT, which plays an important role in the pathogenesis of coronary spasm, is mediated by activation of 5-HT1Dbeta receptor."	( 5-HT1Dbeta receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina. Akita, H; Hirata, K; Ishida, T; Kanazawa, K; Kawashima, S; Sakoda, T; Yokoyama, M, 1998)	0.3
"5 mg or 25 mg) or placebo at home for the treatment of a moderate or severe migraine attack and those who experienced headache recurrence within 24 hours of dosing had the option to repeat the dose."	( Sumatriptan suppositories for the acute treatment of migraine. S2B351 Study Group. Cochran, A; Hobbs, S; Tepper, SJ; Woessner, M, )	1.57
"Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing."	( Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Cady, RC; Jhingran, P; O'Quinn, S; Pait, DG; Ryan, R, 1998)	1.74
"001) greater percentages of patients in the sumatriptan group compared with the placebo group returned to normal work performance by 2 hours after dosing (sumatriptan, 52%; placebo, 9%) and across the work shift (sumatriptan, 66%; placebo, 18%)."	( Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Cady, RC; Jhingran, P; O'Quinn, S; Pait, DG; Ryan, R, 1998)	2
" For their second treatment, patients were evaluated on their response to sumatriptan, number of 25-mg tablets taken, and dosage prescribed for future migraines."	( Dosing of oral sumatriptan: a review of our first 104 patients. Becker, J; Frizelis, K; Kunkel, RS; Solomon, GD, 1998)	0.88
" The majority of patients required more than one 25-mg tablet for a migraine attack, reflecting both inadequacy of dosing for some migraines and recurrence of headache, yet 40% of patients continued on treatment with 25-mg tablets."	( Dosing of oral sumatriptan: a review of our first 104 patients. Becker, J; Frizelis, K; Kunkel, RS; Solomon, GD, 1998)	0.65
"With an onset of headache relief as early as 15 min postdose compared with placebo, sumatriptan nasal spray is an important treatment option for patients who seek rapid headache relief and/or a convenient dosing form, whose migraine-associated nausea and vomiting render the use of an oral medication impractical, and those who prefer not to use an injectable form of migraine medication."	( Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Ashford, E; Saiers, J; Salonen, R; Woessner, M, 1998)	0.82
" For each migraine, patients recorded pain severity scores before and after taking sumatriptan and the time between dosing and onset of meaningful relief."	( Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Batenhorst, A; Beall, D; Beck, A; Clements, B; Cohen, JA; Miller, DW; Pait, DG; Rawlings, J, 1999)	1.97
" Secondary analyses showed that diclofenac-potassium provided significant pain relief from 60 min after dosing and for all remaining endpoints in the 8-h observation period."	( Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. , 1999)	0.5
" dosing and 68."	( Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. Cosson, VF; Fuseau, E, 1999)	0.61
" The results of this study suggest that no alteration in the sumatriptan dosage will be necessary for migraine patients taking naproxen prophylactic therapy."	( Lack of pharmacokinetic interaction between sumatriptan and naproxen. Rambhau, D; Rao, BR; Rao, YM; Srinivasu, P, 2000)	0.81
" Allowed to select dosing themselves, patients tend to migrate to the 100 mg dose."	( Defining optimal dosing for sumatriptan tablets in the acute treatment of migraine. Mathew, NT; Salonen, R, 1999)	0.6
" Overall, the mean percentages of attacks per patient in which headache relief had been obtained 4 h after dosing were 71%, 71%, and 80% for the 25 mg, 50 mg, and 100 mg doses, respectively."	( Patient-selected dosing in a six-month open-label study evaluating oral sumatriptan in the acute treatment of migraine. Sumatriptan Tablets S2CM10 Study Group. Ashford, EA; Dowson, AJ; Flöter, T; Hassani, H; Prendergast, S; Roberts, GW; Szczudlik, A, 1999)	0.54
" Fewer patients required rescue medication in the active groups (1% 100 mg to 13% 6 mg) compared with placebo (17%), and more patients were able to work and function normally two hours after dosing (41%, 100 mg; 20%, placebo)."	( A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Bertin, L; Brion, N; Färkkilä, M; Göbel, H; Wessely, P, 1999)	0.61
" As additional triptans and new dosage formulations are developed and approved, it is anticipated that the treatment of migraine headaches in children may change significantly in the next several years."	( Childhood migraine. Turk, WR, 2000)	0.31
" Each dose of sumatriptan (5 mg, 10 mg, and 20 mg) was superior to placebo with respect to the cumulative percentages of patients first reporting headache relief within 2 hours of dosing (Kaplan-Meier)."	( A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Saper, J; Winner, P, 2000)	0.91
" Therefore, it is quite possible that both drugs produce adverse immunological effects in vivo in cases of high dosage or obstruction of elimination."	( [Effect of migraine medications on monocyte chemotaxis] . Krumholz, W; Menges, T; Ogal, H; Szalay, G, 2000)	0.31
" Pre-incubation with L-NNA abolished the sumatriptan-induced dilation and significantly shifted the dose-response of the constriction curve to the left."	( Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles. Elhusseiny, A; Hamel, E, 2001)	2.02
" Headache response 2 hours after dosing was reported by 76% of patients taking the 10-mg dose and 72% of those taking the 20-mg dose."	( One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Asgharnejad, M; Austin, R; Laurenza, A; Nett, R; Peykamian, M; Rothner, AD; Winner, P, 2000)	0.58
" Headache recurrence, defined as return of moderate or severe headache within 24 hours of dosing and following a headache response at two hours after initial dosing, occurred in 33% of the patients following 100 mg sumatriptan and in 28%, 34% and 32% after 20 mg, 40 mg and 80 mg eletriptan."	( Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. Diener, HC; McHarg, A, 2000)	0.49
" However, sumatriptan injection was perceived as the most effective dosing form by the greatest proportion of patients."	( Sumatriptan injection and tablets in clinical practice: results of a survey of 707 migraineurs. Dahlöf, CG; Saiers, J, )	1.98
" The serious cardiovascular incidents after consuming sumatriptan have been associated mostly with the subcutaneous dosage form of this drug and with patients with underlying cardiovascular risk factors."	( Fatal cardiac arrhythmia after oral sumatriptan. Laine, K; Mäntynen, J; Raasakka, T; Saukko, P, )	0.65
" For each attack, patients rated headache severity, presence of associated symptoms, and functional disability prior to dosing and at intervals through 4 hours thereafter."	( Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Block, GA; Getson, A; Goldstein, J; Jiang, K; Lines, C; Norman, B; Ryan, R, )	0.38
"This study was designed to test the hypothesis that the encapsulation methods used to mask active drug may delay absorption of sumatriptan from dosing to 2 hours after dosing (the traditional end point in clinical trials of migraine treatment), an effect that may be enhanced by migraine-associated gastric stasis."	( Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Coates, P; Fuseau, E; Leibowitz, M; McNeal, S; Metz, A; O'Quinn, S; Pereira, A; Petricoul, O; Purdon, H; Sabin, A; Salonen, R; Thein, S, 2001)	0.78
" Absorption was assessed by calculating the area under the plasma concentration-time curve from dosing to 2 hours after dosing (AUC2) and the times to first measurable plasma concentration, 10 ng/mL, 20 ng/mL, and maximum plasma concentration."	( Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Coates, P; Fuseau, E; Leibowitz, M; McNeal, S; Metz, A; O'Quinn, S; Pereira, A; Petricoul, O; Purdon, H; Sabin, A; Salonen, R; Thein, S, 2001)	0.58
" It produces a dextral shift of the 5-HT dose-response curves for the binding of GTPgamma[35S] to human 5-HT(1B) (pK(b)=9."	( In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist properties. Boot, JR; Carney, SL; Cohen, ML; Colvin, EM; Conway, RG; Hardy, CH; Lucaites, VL; Nelson, DL; Pullar, IA; Schenck, KW; Tomlinson, R; Wedley, S, 2001)	0.31
" However, plasma concentrations increased from the first minute after intranasal dosing suggesting that sumatriptan and naratriptan are absorbed into the general systemic circulation from the nasal cavity in rats in a first-order fashion with no lag time."	( Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. Deprez, S; Einer-Jensen, N; Larsen, L; Schwartz, S; Starns, E, 2001)	0.83
"This study sought to determine the effect of coadministration of clarithromycin dosed to steady state on the pharmacokinetics of a single dose of sumatriptan."	( The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Bye, C; Gray, P; Leese, PT; McNeal, S; Moore, KH; O'Quinn, S; Sale, M, 2002)	0.82
"The extent of absorption of sumatriptan was similar after oral administration alone and in combination with clarithromycin dosed to steady state."	( The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Bye, C; Gray, P; Leese, PT; McNeal, S; Moore, KH; O'Quinn, S; Sale, M, 2002)	0.92
" Studies of frovatriptan in isolated human arteries demonstrated a lower threshold for constriction of cerebral than coronary vasculature and a bell-shaped dose-response curve was apparent in the coronary arteries."	( Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Comer, MB, 2002)	0.31
"In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan."	( Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002)	0.51
" A total of 16 subjects (10 males and 6 females) had pharmacokinetic data that could be analyzed, 2 withdrew from the study 30 and 60 minutes after dosing following the loss of venous access for blood sampling, and a bioanalysis failure resulted in loss of data from 3 subjects."	( Pharmacokinetics of sumatriptan nasal spray in adolescents. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2003)	0.64
" On the cost side of the equation, reflecting the health-care system perspective of the analysis, drug costs for initial dosing, second dosing for nonresponse, and recurrence and rescue medication were taken into account."	( A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Carter, D; DPhil, M; Drummond, M; Hettiarachchi, J; Pang, F; Parpia, T; Wells, N, )	0.37
" The suggested methods were successfully applied for determining sumatriptan succinate in bulk powder, laboratory-prepared mixtures and pharmaceutical dosage forms (Imigran tablet) with good accuracy and precision."	( Stability-indicating methods for the determination of sumatriptan succinate. Abo-Talib, NF; Bebawy, LI; Moustafa, AA, 2003)	0.81
" Trials comparing different doses of sumatriptan or dosing regimens were also included."	( Oral sumatriptan for acute migraine. Gray, RN; McCrory, DC, 2003)	1.11
"To determine the cost-effectiveness of the triptans, a meta-analysis was conducted of the efficacy data from 27 oral triptan trials, using the endpoint of "pain-free" status within 2 hours after initial dosing as the indicator of efficacy."	( Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. Adelman, JU; Belsey, J, )	0.13
" After the perivascular preinjection of 1 nmol/l L-668,169 or 1 nmol/l L-733,060 (NK1 receptor antagonists), the SP dose-response curve was shifted to the right."	( Effects of neuropeptides on the sumatriptan-disturbed circulation in the optic nerve head of rabbits. Cunha-Vaz, JG; Gaspar, MN; Macedo, TR; Ribeiro, CA, 2004)	0.61
" Patients recorded details of the treated migraine on a diary card and rated pain severity immediately before dosing and 30 minutes, 45 minutes, 1 hour, and 2 hours after dosing using a 4-point scale (from 0 = none to 3 = severe)."	( Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Ahmad, F; Boswell, D; Carpay, J; Kinrade, F; Schoenen, J, 2004)	0.61
" The dosing scheme based on age and weight resulted in maximal concentrations (C(max)) and systemic exposure (AUC) that were comparable to those observed in adolescents and adults treated with 20 mg."	( Pharmacokinetics of sumatriptan nasal spray in children. Christensen, ML; Fuseau, E; Jabbour, JT; Mottern, RK, 2004)	0.65
" These findings suggest that effect of NTG on nNOS at a high dosage may involve the cycloxygenase pathway and that activation of the peripheral 5-HT1B/D receptors is not able to modify this effect."	( Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Pardutz, A; Schoenen, J; Szatmári, E; Vecsei, L, 2004)	0.52
" Pharmacokinetic parameters measured early (0-2 h) after dosing reveal slightly faster absorption, on average, of the new sumatriptan formulation than sumatriptan conventional tablets although high intersubject variability was observed."	( Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Boswell, D; Bullman, J; Dow, A; Lewis, A; Sidhu, J; Summers, SJ; Walls, C, 2004)	0.8
" During concomitant treatment with topiramate and carbamazepine or phenytoin, the (oral) clearance of topiramate increases 2-fold and its half-life becomes shorter by approximately 50%, which may require topiramate dosage adjustment when phenytoin or carbamazepine therapy is added or discontinued."	( Pharmacokinetic interactions of topiramate. Bialer, M; Curtin, C; Doose, DR; Murthy, B; Schwabe, S; Twyman, RE; Wang, SS, 2004)	0.32
" In the early treatment group significantly more patients were pain free at all times measured during two hours after dosing than in the late treatment group."	( Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Banik, N; Moeckesch, B; Schellenberg, R; Scholpp, J, 2004)	0.55
" Across all migraines with evaluable efficacy data (n=4334), headache relief was reported in 43% of migraines at 1 hour and in 59% at 2 hours after dosing with sumatriptan nasal spray 20 mg."	( Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Jabbour, JT; Natarajan, S; Richardson, MS; Webster, CJ, )	0.63
"When compared at 2 and 24 hours, aggressive (20 mg dosed up to four times) IV metoclopramide and 6 mg of subcutaneous sumatriptan relieved migraine headache pain comparably."	( A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Bijur, PE; Corbo, J; Esses, D; Friedman, BW; Gallagher, EJ; Lipton, RB; Solorzano, C, 2005)	0.83
" Using a personal digital assistant, patients recorded the time of dosing and the time at which pain severity reached none or mild (ie, pain relief) or none (ie, pain free) in real time so that the time to onset of relief could be measured as a continuous variable."	( Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Agosti, R; Barrett, PS; Brandes, JL; Dahlöf, CG; Jones, MW; Sheftell, FD, 2005)	0.52
"A novel model-based meta-analysis was used to quantify the dose-response relationship of sumatriptan and eletriptan for the proportion of patients that achieve migraine pain relief up to 4 h after treatment."	( Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. Alderman, J; Cox, E; Mandema, JW, 2005)	0.81
"This was a retrospective cohort study conducted in a managed care organization for patients aged 18 years or older who had picked up at least one outpatient prescription for any sumatriptan dosage form at the pharmacy between January 2002 and June 2002."	( Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. Billups, SJ; Carroll, N; Delate, T; Gershovich, OE; Hoffman, CK, 2006)	0.75
" Disease dynamics must be considered to evaluate treatment response adequately and optimise the dosing regimen in migraine."	( A model-based approach to treatment comparison in acute migraine. Danhof, M; Della Pasqua, O; Maas, HJ, 2006)	0.33
"Sumatriptan-naproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<."	( Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Adelman, JU; Alexander, WJ; Barrett, PS; Brandes, JL; Kudrow, D; Lener, SE; O'Carroll, CP; O'Donnell, FJ; Spruill, SE; Stark, SR, 2007)	3.23
"In this double-blind, double-dummy, randomised, parallel group, multicentre study, the efficacy of dosing and re-dosing of a fixed combination of indomethacin, prochlorperazine and caffeine (Indoprocaf) was compared with encapsulated sumatriptan in the acute treatment of two migraine attacks."	( Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007)	0.73
"The study demonstrated that the efficacy of the initial dosing of Indoprocaf was not higher than that of sumatriptan, but that the strategy to use the lowest effective dose as soon as the headache occurred, followed by a second dose if the headache has not relieved or to treat a relapse, was very effective, especially with Indoprocaf."	( Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu Cerbo, R; Del Bene, E; Ferrari, A; Genco, S; Grazioli, I; Martelletti, P; Nappi, G; Pinessi, L; Sandrini, G; Sarchielli, P; Tamburro, P; Uslenghi, C; Zanchin, G, 2007)	0.76
" In an oral formulation, which is the patients' preferred dosing route, sumatriptan FDT/RRT may therefore constitute an advance in the management of acute migraine attacks."	( Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine. Barbanti, P; Cruccu, G; Le Pera, D, 2007)	2.01
"The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan."	( Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Bertolini, A; Coccia, C; Ferrari, A; Pinetti, D; Sternieri, E, 2008)	0.81
" Although at discharge the patient was advised to permanently avoid triptans, she continued the use of oral sumatriptan at low dosage (25-50 mg) without any problems."	( Acute myocardial infarction with sumatriptan: a case report and review of the literature. Chalaupka, FD, 2009)	0.85
"The complete RCT model involved three submodels: i) the input-output submodel for the prediction of events (using the sigmoid dose-response relationship as the basic model), ii) the execution submodel for deviations from a randomized, controlled two-arm parallel trial related to either patient-specific or investigator-specific elements or both: placebo or nocebo effect, errors of measurement, effect of concomitant therapy, regression to the mean phenomenon, blinding process, loss to follow-up and randomization process, iii) the covariate distribution submodel."	( Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach. Bajard, A; Boissel, JP; Chabaud, S; Nony, P; Pérol, D, 2009)	0.35
" The adverse-event profile of the sumatriptan/naproxen sodium combination tablet did not appear to differ from that of the individual components of the same or similar dosage strengths administered alone or in combination."	( Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010)	0.87
" Hence, this method demonstrated to be adequate for in vitro studies of NAP and SUMA in the combinational dosage form, since there is no official monograph, collaborating to the official codes."	( In vitro dissolution profile comparison of an anti-migraine combinational drug in dosage form. Bhojraj, S; Hiremath, VB; Kaliaperumal, K; Nanjan, MJ, 2010)	0.36
" CGRP 8-37 had no significant effects on blood pressure dose-response profiles and individual dose blood pressure responses to any of the vasomodulators tested."	( Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats. Detwiler, TJ; Kane, SA; Lynch, JJ; Regan, CP, 2010)	0.36
" For each drug, 6 healthy male volunteers were dosed with 100 μg (14)C-labelled compound."	( Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Alder, J; Bjerrum, OJ; Brian Houston, J; Garner, C; Gesson, C; Grynkiewicz, G; Jochemsen, R; Lappin, G; Oosterhuis, B; Rowland, M; Shishikura, Y; Weaver, RJ, 2011)	0.59
" Patients were treated with sumatriptan-naproxen using a very early intervention paradigm in 4 test migraines over 12 weeks where dosage occurred within 30 minutes of symptom onset."	( Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention. Hoagland, NA; Hoagland, R; Landy, S, 2012)	2.12
" Trials comparing different doses of sumatriptan or dosing regimens were also included."	( WITHDRAWN: Oral sumatriptan for acute migraine. Gray, RN; McCrory, DC, 2012)	1
"There were insufficient data to evaluate other doses of oral diclofenac, or to compare different formulations or different dosing regimens; only one study compared oral diclofenac with an active comparator (oral sumatriptan 100 mg)."	( Diclofenac with or without an antiemetic for acute migraine headaches in adults. Derry, S; Moore, RA; Rabbie, R, 2012)	0.57
" Subjects reporting headache pain 2 hours after dosing were randomly assigned into a 12-week double-blind phase, treating 1 moderate-to-severe migraine (attack 2) with placebo (n = 145), suma/nap 10/60 mg (n = 96), 30/180 mg (n = 97), or 85/500 mg (n = 152)."	( Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Derosier, FJ; Goodman, DK; Granberry, WK; Hershey, AD; Jimenez, TB; Lewis, D; Linder, SL; Pearlman, E; Rothner, AD; Runken, MC; Winner, PK, 2012)	0.7
" Special clinical trials of the timing of dosage and sumatriptan in combination with other triptans as well as non-triptan drugs are also included."	( Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Hougaard, A; Tfelt-Hansen, P, 2013)	2.08
"There were insufficient data to evaluate other doses of oral diclofenac, or to compare different formulations or different dosing regimens; only one study compared oral diclofenac with an active comparator (oral sumatriptan 100 mg)."	( Diclofenac with or without an antiemetic for acute migraine headaches in adults. Derry, S; Moore, RA; Rabbie, R, 2013)	0.58
" Frequent dosing of SumaRT/Nap or naproxen sodium was well tolerated in this study."	( Treatment of chronic migraine: a 3-month comparator study of naproxen sodium vs SumaRT/Nap. Beach, ME; Cady, R; Dexter, K; Freitag, F; Manley, HR; Nett, R, 2014)	0.4
" Patients recorded details of the treated migraine on a diary card and rated pain severity immediately before dosing and 30 minutes, 1 hour, 2 hours, and 4 hours after dosing using a 4-point scale (0 = none to 3 = severe)."	( Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial. Amini, A; Asadollahi, S; Forouzanfar, MM; Heidari, K; Shahrami, A; Vafaee, R, 2014)	0.74
" Furthermore, in vitro release studies revealed 90% release of drug from developed dosage form within 10 min, thus suggesting rapid drug dissolution followed by faster onset of action, which forms a strong rationale for development of ODTs of sumatriptan succinate."	( Freeze drying: exploring potential in development of orodispersible tablets of sumatriptan succinate. Desai, P; Gugulothu, D; Pandharipande, P; Patravale, V, 2015)	0.83
" As the migraine follows circadian rhythm in which headache is more painful at the awakening time, the dosage form should be given during night time to release drug when pain get worsen."	( Development and optimization of press coated floating pulsatile drug delivery of sumatriptan succinate. Jagdale, SC; Pawar, CR, 2014)	0.63
" This needs administration of dosage form at night time to release drug after lag period when pain gets worse."	( Application of design of experiment for polyox and xanthan gum coated floating pulsatile delivery of sumatriptan succinate in migraine treatment. Jagdale, SC; Pawar, CR, 2014)	0.62
" Blood samples for pharmacokinetic profiling of sumatriptan were obtained prior to dosing and at predetermined time points covering the 12 hours postonset of treatment."	( A Phase I, Open-Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of the Sumatriptan Iontophoretic Transdermal System in Adolescent Migraine Patients. Aycardi, E; Bigal, ME; Chitra, R; Gutman, D; Hellriegel, E; Kansagra, S; Kidron, OS; Knebel, H; Kunta, J; Linder, S; Ma, Y; Pierce, M; Spiegelstein, O; Winner, PK, 2016)	0.91
" Initially dosing with MSM while pain was mild was associated with the lowest daily disability [medication × pain at dosing F (4, 6336."	( Acute migraine medication adherence, migraine disability and patient satisfaction: A naturalistic daily diary study. Nicholson, RA; Robbins, MS; Seng, EK, 2017)	0.46
" Results from the primary endpoint (SPID-30, defined as the sum of pain intensity differences from dosing to 30 minutes), key secondary efficacy endpoints and safety assessments have been reported in the primary publication (Tepper et al."	( Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered Halker, R; Mahmoud, RA; McAllister, PJ; Siffert, J; Silberstein, S; Tepper, SJ; Winner, PK, 2017)	0.46
" Patients recorded ordinal migraine pain intensity and migraine-related disability before dosing (predose), and at 10, 15, 30, 45, 60, 90 and 120 minutes."	( Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO Buse, DC; Lipton, RB; McGinley, JS; Shulman, KJ; Wirth, RJ, 2017)	0.67
"The present study involved segmental testing of hair in two clinical cases with known dosage histories."	( Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment. Johansen, SS; Linnet, K; Nielsen, MKK; Wang, X, 2019)	0.51
" Cluster headache is not optimally treated and few clinical trials are available to model therapy, especially dosing and administration."	( Cluster Headache: Opportunities for Pharmacists to Improve Care. Clark, AS; Smith, TR; Wenzel, R, 2022)	0.72
" Classical oral dosage forms are not frequently workable in migraine because of the associated nausea/vomiting, and no effective fixed dose combination is available."	( Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization. Anwer, UU; Bukhari, NI; Hafiz, MA; Hussain, A; Javed, S; Rasool, F; Raza, SA; Shah, PA; Shamim, R, 2022)	1.02

Role	Description
serotonergic agonist	An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
vasoconstrictor agent	Drug used to cause constriction of the blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
tryptamines	Tryptamine and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	44.6684	0.0447	17.8581	100.0000	AID485294
AR protein	Homo sapiens (human)	Potency	11.8832	0.0002	21.2231	8,912.5098	AID1259243
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0033	0.0013	10.1577	42.8575	AID1259255
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.2391	0.0002	14.3764	60.0339	AID720691
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	0.0024	0.0578	21.1097	61.2679	AID1159526
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 3E	Homo sapiens (human)	IC50 (µMol)	2.5055	0.0004	2.0805	9.0000	AID5956; AID5997
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
5-hydroxytryptamine receptor 3B	Homo sapiens (human)	IC50 (µMol)	2.5055	0.0004	1.9505	9.0000	AID5956; AID5997
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	IC50 (µMol)	0.4497	0.0001	0.6664	10.0000	AID3912; AID3975
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Ki	0.3574	0.0001	0.5326	10.0000	AID3809; AID3829; AID3834; AID3835; AID3849; AID3850; AID3858; AID3860
5-hydroxytryptamine receptor 2C	Rattus norvegicus (Norway rat)	Ki	1.0000	0.0002	0.6677	10.0000	AID5729
Carboxypeptidase M	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0200	0.0200	0.0200	AID4863
D(2) dopamine receptor	Homo sapiens (human)	Ki	0.2180	0.0000	0.6518	10.0000	AID63225
5-hydroxytryptamine receptor 2A	Rattus norvegicus (Norway rat)	IC50 (µMol)	10.0000	0.0004	0.9086	10.0000	AID5606
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6400	0.0002	1.8742	10.0000	AID3731
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.7220	0.0003	1.3833	8.4000	AID3731; AID625190
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.4590	0.0001	0.7396	10.0000	AID625190
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6400	0.0002	1.2704	10.0000	AID3731
5-hydroxytryptamine receptor 1D	Homo sapiens (human)	IC50 (µMol)	0.3091	0.0005	0.2870	2.4000	AID4292; AID4595; AID4596; AID4597; AID4600; AID4601; AID4640; AID4642
5-hydroxytryptamine receptor 1D	Homo sapiens (human)	Ki	0.0077	0.0001	0.8087	10.0000	AID404703; AID4549; AID4615; AID4617; AID4622; AID4626; AID4627; AID4629; AID4632; AID4899; AID4900; AID4908
5-hydroxytryptamine receptor 1B	Homo sapiens (human)	IC50 (µMol)	0.0131	0.0005	0.3975	6.5000	AID4270; AID4510; AID4511; AID4512; AID4514; AID4515; AID4516
5-hydroxytryptamine receptor 1B	Homo sapiens (human)	Ki	0.0188	0.0001	0.5485	9.2100	AID404702; AID4245; AID4248; AID4252; AID4255; AID4256; AID4258; AID4260; AID4569; AID4919; AID4924; AID4929; AID4931
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	IC50 (µMol)	8.9716	0.0001	0.8801	8.8500	AID5366; AID5404
5-hydroxytryptamine receptor 2A	Homo sapiens (human)	Ki	0.6880	0.0000	0.3855	10.0000	AID5201; AID5398
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	5.9835	0.0001	1.0302	9.0000	AID5636; AID5691; AID5956
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8040	0.0005	1.4835	7.8000	AID625190
5-hydroxytryptamine receptor 1B	Rattus norvegicus (Norway rat)	Ki	0.4590	0.0003	1.2967	9.2440	AID625190
5-hydroxytryptamine receptor 1D	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0610	0.0031	1.7360	7.8000	AID4873
5-hydroxytryptamine receptor 1E	Homo sapiens (human)	IC50 (µMol)	5.5000	5.5000	5.5000	5.5000	AID4970
5-hydroxytryptamine receptor 1F	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0878	1.9439	3.8000	AID4977
5-hydroxytryptamine receptor 1F	Homo sapiens (human)	Ki	0.0257	0.0016	1.7865	10.0000	AID4983
5-hydroxytryptamine receptor 7	Homo sapiens (human)	Ki	1.0000	0.0003	0.3806	10.0000	AID1546005
Alpha-1A adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.5614	5.4000	AID5636
5-hydroxytryptamine receptor 3A	Rattus norvegicus (Norway rat)	Ki	1.0000	0.0002	0.4841	10.0000	AID5878
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6400	0.0000	1.8194	10.0000	AID3731
5-hydroxytryptamine receptor 3A	Homo sapiens (human)	IC50 (µMol)	3.3385	0.0001	1.0789	9.0000	AID5956; AID5997; AID6025; AID6358
5-hydroxytryptamine receptor 5A	Homo sapiens (human)	IC50 (µMol)	0.5012	0.5012	0.5012	0.5012	AID3978
5-hydroxytryptamine receptor 1B	Oryctolagus cuniculus (rabbit)	Ki	0.0012	0.0009	0.0464	0.1370	AID404703
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.2180	0.0000	0.4375	10.0000	AID63082
5-hydroxytryptamine receptor 1D	Sus scrofa (pig)	IC50 (µMol)	0.0200	0.0003	0.6496	3.7153	AID4858; AID4863; AID4864
5-hydroxytryptamine receptor 1A	Mus musculus (house mouse)	IC50 (µMol)	0.4500	0.0021	0.3581	2.0000	AID4460
5-hydroxytryptamine receptor 3D	Homo sapiens (human)	IC50 (µMol)	2.5055	0.0004	2.0805	9.0000	AID5956; AID5997
5-hydroxytryptamine receptor 3C	Homo sapiens (human)	IC50 (µMol)	2.5055	0.0004	2.0805	9.0000	AID5956; AID5997
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	6.7000	0.0100	2.7656	10.0000	AID721754
5-hydroxytryptamine receptor 3B	Rattus norvegicus (Norway rat)	Ki	1.0000	0.0002	0.5023	10.0000	AID5878
5-hydroxytryptamine receptor 1B	Gorilla gorilla gorilla (western lowland gorilla)	Ki	0.0064	0.0064	2.8907	5.7750	AID4484
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	EC50 (µMol)	0.0120	0.0008	0.0064	0.0120	AID4575
5-hydroxytryptamine receptor 1A	Homo sapiens (human)	Kd	0.3981	0.0001	0.9528	5.0119	AID438555
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	EC50 (µMol)	1.3000	0.0054	3.2510	20.9400	AID3709
5-hydroxytryptamine receptor 1D	Homo sapiens (human)	EC50 (µMol)	0.0117	0.0008	0.0060	0.0160	AID4571; AID4572; AID4574; AID4575; AID4577; AID4578; AID4581
5-hydroxytryptamine receptor 1B	Homo sapiens (human)	EC50 (µMol)	0.0576	0.0116	0.1388	0.4300	AID4495; AID4496
5-hydroxytryptamine receptor 1D	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0970	0.0013	0.0388	0.0970	AID4872
5-hydroxytryptamine receptor 1F	Homo sapiens (human)	EC50 (µMol)	0.0350	0.0350	0.0350	0.0350	AID4974
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	EC50 (µMol)	0.0120	0.0008	0.0064	0.0120	AID4575
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	EC50 (µMol)	0.0120	0.0008	0.0064	0.0120	AID4575
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	EC50 (µMol)	0.0120	0.0008	0.0064	0.0120	AID4575
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 1	Homo sapiens (human)	Km	55.0000	0.4770	4.0308	9.0000	AID1526737
5-hydroxytryptamine receptor 1D	Homo sapiens (human)	ED50	0.3170	0.0680	0.1925	0.3170	AID4583
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
gamma-aminobutyric acid signaling pathway	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of serotonin secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of vasoconstriction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
exploration behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of dopamine metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin metabolic process	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of hormone secretion	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
anatomical structure morphogenesis	Carboxypeptidase M	Homo sapiens (human)
peptide metabolic process	Carboxypeptidase M	Homo sapiens (human)
protein processing	Carboxypeptidase M	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
temperature homeostasis	D(2) dopamine receptor	Homo sapiens (human)
response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein phosphorylation	D(2) dopamine receptor	Homo sapiens (human)
response to amphetamine	D(2) dopamine receptor	Homo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressure	D(2) dopamine receptor	Homo sapiens (human)
regulation of heart rate	D(2) dopamine receptor	Homo sapiens (human)
regulation of sodium ion transport	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of receptor internalization	D(2) dopamine receptor	Homo sapiens (human)
autophagy	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
neuron-neuron synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
neuroblast proliferation	D(2) dopamine receptor	Homo sapiens (human)
axonogenesis	D(2) dopamine receptor	Homo sapiens (human)
synapse assembly	D(2) dopamine receptor	Homo sapiens (human)
sensory perception of smell	D(2) dopamine receptor	Homo sapiens (human)
long-term memory	D(2) dopamine receptor	Homo sapiens (human)
grooming behavior	D(2) dopamine receptor	Homo sapiens (human)
locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
adult walking behavior	D(2) dopamine receptor	Homo sapiens (human)
protein localization	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell population proliferation	D(2) dopamine receptor	Homo sapiens (human)
associative learning	D(2) dopamine receptor	Homo sapiens (human)
visual learning	D(2) dopamine receptor	Homo sapiens (human)
response to xenobiotic stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to light stimulus	D(2) dopamine receptor	Homo sapiens (human)
response to toxic substance	D(2) dopamine receptor	Homo sapiens (human)
response to iron ion	D(2) dopamine receptor	Homo sapiens (human)
response to inactivity	D(2) dopamine receptor	Homo sapiens (human)
Wnt signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
striatum development	D(2) dopamine receptor	Homo sapiens (human)
orbitofrontal cortex development	D(2) dopamine receptor	Homo sapiens (human)
cerebral cortex GABAergic interneuron migration	D(2) dopamine receptor	Homo sapiens (human)
adenohypophysis development	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cell migration	D(2) dopamine receptor	Homo sapiens (human)
peristalsis	D(2) dopamine receptor	Homo sapiens (human)
auditory behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of synaptic transmission, GABAergic	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of cytokinesis	D(2) dopamine receptor	Homo sapiens (human)
circadian regulation of gene expression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
response to histamine	D(2) dopamine receptor	Homo sapiens (human)
response to nicotine	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of urine volume	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of renal sodium excretion	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of multicellular organism growth	D(2) dopamine receptor	Homo sapiens (human)
response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleep	D(2) dopamine receptor	Homo sapiens (human)
dopamine metabolic process	D(2) dopamine receptor	Homo sapiens (human)
drinking behavior	D(2) dopamine receptor	Homo sapiens (human)
regulation of potassium ion transport	D(2) dopamine receptor	Homo sapiens (human)
response to morphine	D(2) dopamine receptor	Homo sapiens (human)
pigmentation	D(2) dopamine receptor	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of blood pressure	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of innate immune response	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of insulin secretion	D(2) dopamine receptor	Homo sapiens (human)
acid secretion	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to cocaine	D(2) dopamine receptor	Homo sapiens (human)
behavioral response to ethanol	D(2) dopamine receptor	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	D(2) dopamine receptor	Homo sapiens (human)
response to axon injury	D(2) dopamine receptor	Homo sapiens (human)
branching morphogenesis of a nerve	D(2) dopamine receptor	Homo sapiens (human)
arachidonic acid secretion	D(2) dopamine receptor	Homo sapiens (human)
epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of protein secretion	D(2) dopamine receptor	Homo sapiens (human)
release of sequestered calcium ion into cytosol	D(2) dopamine receptor	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
regulation of synapse structural plasticity	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	D(2) dopamine receptor	Homo sapiens (human)
excitatory postsynaptic potential	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of growth hormone secretion	D(2) dopamine receptor	Homo sapiens (human)
prepulse inhibition	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	D(2) dopamine receptor	Homo sapiens (human)
regulation of locomotion involved in locomotory behavior	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cellular response to hypoxia	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor production	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	D(2) dopamine receptor	Homo sapiens (human)
hyaloid vascular plexus regression	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of neuron migration	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of cytosolic calcium ion concentration	D(2) dopamine receptor	Homo sapiens (human)
regulation of dopamine secretion	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of adenylate cyclase activity	D(2) dopamine receptor	Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
negative regulation of voltage-gated calcium channel activity	D(2) dopamine receptor	Homo sapiens (human)
positive regulation of MAPK cascade	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	D(2) dopamine receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of locomotion	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled receptor internalization	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
regulation of dopamine secretion	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
negative regulation of serotonin secretion	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
response to cocaine	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
drinking behavior	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
response to ethanol	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
bone remodeling	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
response to mineralocorticoid	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
cellular response to alkaloid	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
cellular response to xenobiotic stimulus	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
cellular response to temperature stimulus	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
temperature homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
memory	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
regulation of dopamine secretion	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
artery smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
urinary bladder smooth muscle contraction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of heat generation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of potassium ion transport	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of neuron apoptotic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein localization to cytoskeleton	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of glycolytic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of vasoconstriction	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
symbiont entry into host cell	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
sensitization	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral response to cocaine	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of inflammatory response	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of execution phase of apoptosis	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of platelet aggregation	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
positive regulation of DNA biosynthetic process	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
smooth muscle contraction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
circadian rhythm	5-hydroxytryptamine receptor 7	Homo sapiens (human)
blood circulation	5-hydroxytryptamine receptor 7	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 7	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 7	Homo sapiens (human)
MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrine	Alpha-1A adrenergic receptor	Homo sapiens (human)
apoptotic process	Alpha-1A adrenergic receptor	Homo sapiens (human)
smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
activation of phospholipase C activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1A adrenergic receptor	Homo sapiens (human)
adult heart development	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-1A adrenergic receptor	Homo sapiens (human)
response to hormone	Alpha-1A adrenergic receptor	Homo sapiens (human)
negative regulation of autophagy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular signal transduction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of action potential	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
calcium ion transport into cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell growth involved in cardiac muscle cell development	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Alpha-1A adrenergic receptor	Homo sapiens (human)
positive regulation of protein kinase C signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
pilomotor reflex	Alpha-1A adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1A adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1A adrenergic receptor	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
hippocampus development	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
response to estradiol	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
sensory perception of sound	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transporter activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
skeletal system development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
extraocular skeletal muscle development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
striated muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
endoplasmic reticulum organization	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
myoblast fusion	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
neuromuscular junction development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle adaptation	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle fiber development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cellular response to caffeine	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
immune system development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
heart development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
embryonic forelimb morphogenesis	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
camera-type eye development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transport into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channel	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of ventricular cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
monoatomic ion transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory postsynaptic potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
inorganic cation transmembrane transport	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
regulation of membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
receptor-receptor interaction	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
carboxypeptidase activity	Carboxypeptidase M	Homo sapiens (human)
zinc ion binding	Carboxypeptidase M	Homo sapiens (human)
metallocarboxypeptidase activity	Carboxypeptidase M	Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/Go	D(2) dopamine receptor	Homo sapiens (human)
G-protein alpha-subunit binding	D(2) dopamine receptor	Homo sapiens (human)
protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterotrimeric G-protein binding	D(2) dopamine receptor	Homo sapiens (human)
dopamine binding	D(2) dopamine receptor	Homo sapiens (human)
ionotropic glutamate receptor binding	D(2) dopamine receptor	Homo sapiens (human)
identical protein binding	D(2) dopamine receptor	Homo sapiens (human)
heterocyclic compound binding	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor activity	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
virus receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein tyrosine kinase activator activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
protein-containing complex binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor activity	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 7	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 7	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-1A adrenergic receptor	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-gated monoatomic cation channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3E	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
cell surface	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3B	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1A	Homo sapiens (human)
extracellular region	Carboxypeptidase M	Homo sapiens (human)
plasma membrane	Carboxypeptidase M	Homo sapiens (human)
cell surface	Carboxypeptidase M	Homo sapiens (human)
extracellular exosome	Carboxypeptidase M	Homo sapiens (human)
side of membrane	Carboxypeptidase M	Homo sapiens (human)
extracellular space	Carboxypeptidase M	Homo sapiens (human)
Golgi membrane	D(2) dopamine receptor	Homo sapiens (human)
acrosomal vesicle	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
cilium	D(2) dopamine receptor	Homo sapiens (human)
lateral plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
endocytic vesicle	D(2) dopamine receptor	Homo sapiens (human)
axon	D(2) dopamine receptor	Homo sapiens (human)
dendrite	D(2) dopamine receptor	Homo sapiens (human)
synaptic vesicle membrane	D(2) dopamine receptor	Homo sapiens (human)
sperm flagellum	D(2) dopamine receptor	Homo sapiens (human)
dendritic spine	D(2) dopamine receptor	Homo sapiens (human)
perikaryon	D(2) dopamine receptor	Homo sapiens (human)
axon terminus	D(2) dopamine receptor	Homo sapiens (human)
postsynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
ciliary membrane	D(2) dopamine receptor	Homo sapiens (human)
non-motile cilium	D(2) dopamine receptor	Homo sapiens (human)
dopaminergic synapse	D(2) dopamine receptor	Homo sapiens (human)
GABA-ergic synapse	D(2) dopamine receptor	Homo sapiens (human)
G protein-coupled receptor complex	D(2) dopamine receptor	Homo sapiens (human)
glutamatergic synapse	D(2) dopamine receptor	Homo sapiens (human)
presynaptic membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	D(2) dopamine receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1D	Homo sapiens (human)
endoplasmic reticulum	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
calyx of Held	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
serotonergic synapse	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1B	Homo sapiens (human)
neurofilament	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
caveola	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
axon	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cytoplasmic vesicle	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
presynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
neuronal cell body	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendritic shaft	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
cell body fiber	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
glutamatergic synapse	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1E	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 1F	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
trans-Golgi network membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 7	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 7	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 7	Homo sapiens (human)
nucleus	Alpha-1A adrenergic receptor	Homo sapiens (human)
nucleoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytoplasm	Alpha-1A adrenergic receptor	Homo sapiens (human)
cytosol	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
caveola	Alpha-1A adrenergic receptor	Homo sapiens (human)
nuclear membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
intracellular membrane-bounded organelle	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1A adrenergic receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
cleavage furrow	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
perikaryon	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
postsynaptic specialization membrane	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 5A	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3D	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
postsynaptic membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
serotonin-activated cation-selective channel complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
transmembrane transporter complex	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
neuron projection	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 3C	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1345154	Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)	1998	Journal of neurochemistry, Nov, Volume: 71, Issue:5	Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
AID1346739	Human 5-HT1F receptor (5-Hydroxytryptamine receptors)	2005	Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3	[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID1345615	Human 5-HT1A receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346739	Human 5-HT1F receptor (5-Hydroxytryptamine receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346739	Human 5-HT1F receptor (5-Hydroxytryptamine receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Mar-15, Volume: 90, Issue:6	Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes.
AID1345068	Human 5-HT5A receptor (5-Hydroxytryptamine receptors)	2001	European journal of pharmacology, Apr-27, Volume: 418, Issue:3	Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	2004	European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1996	Journal of neurochemistry, Nov, Volume: 67, Issue:5	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID624233	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F	1993	Proceedings of the National Academy of Sciences of the United States of America, Mar-15, Volume: 90, Issue:6	Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes.
AID1346739	Human 5-HT1F receptor (5-Hydroxytryptamine receptors)
AID624212	Agonists at Human 5-Hydroxytryptamine receptor 5-ht5a	2001	European journal of pharmacology, Apr-27, Volume: 418, Issue:3	Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	1992	Proceedings of the National Academy of Sciences of the United States of America, Jun-15, Volume: 89, Issue:12	Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.
AID1345068	Human 5-HT5A receptor (5-Hydroxytryptamine receptors)	1994	FEBS letters, Dec-05, Volume: 355, Issue:3	Cloning and characterisation of the human 5-HT5A serotonin receptor.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	1996	Molecular pharmacology, Dec, Volume: 50, Issue:6	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1345061	Mouse 5-HT5A receptor (5-Hydroxytryptamine receptors)	2001	European journal of pharmacology, Apr-27, Volume: 418, Issue:3	Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	2000	Molecular pharmacology, Nov, Volume: 58, Issue:5	Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
AID1345170	Human 5-HT6 receptor (5-Hydroxytryptamine receptors)	1996	Journal of neurochemistry, Jan, Volume: 66, Issue:1	Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
AID1345061	Mouse 5-HT5A receptor (5-Hydroxytryptamine receptors)	1993	Molecular pharmacology, Mar, Volume: 43, Issue:3	Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization.
AID1345235	Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Sep-15, Volume: 90, Issue:18	Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
AID1345291	Human 5-HT7 receptor (5-Hydroxytryptamine receptors)	1997	British journal of pharmacology, Sep, Volume: 122, Issue:1	Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Sep-10, Volume: 380, Issue:2-3	Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1992	Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	1996	Journal of neurochemistry, Nov, Volume: 67, Issue:5	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	2004	European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	1992	Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8	Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID624233	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	2000	Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID624210	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624233	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1345291	Human 5-HT7 receptor (5-Hydroxytryptamine receptors)	1993	The Journal of biological chemistry, Nov-05, Volume: 268, Issue:31	Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624212	Agonists at Human 5-Hydroxytryptamine receptor 5-ht5a	1994	FEBS letters, Dec-05, Volume: 355, Issue:3	Cloning and characterisation of the human 5-HT5A serotonin receptor.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1996	Molecular pharmacology, Dec, Volume: 50, Issue:6	Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346739	Human 5-HT1F receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346264	Human 5-HT1B receptor (5-Hydroxytryptamine receptors)	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624233	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	1999	European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3	Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	1993	Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2	Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	2000	Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2	Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic tr
AID1346603	Human 5-ht1e receptor (5-Hydroxytryptamine receptors)	1996	Journal of neurochemistry, Nov, Volume: 67, Issue:5	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID624230	Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e	1992	Proceedings of the National Academy of Sciences of the United States of America, Jun-15, Volume: 89, Issue:12	Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.
AID1345235	Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)	1993	The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24	Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID624233	Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F	2005	Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3	[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID1346528	Human 5-HT1D receptor (5-Hydroxytryptamine receptors)	1991	Molecular pharmacology, Aug, Volume: 40, Issue:2	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor.
AID165752	The compound was tested for functional activity by measuring the contraction of saphenous vein from New Zealand white rabbit	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID3835	Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
AID224186	In vitro evaluation in rabbit basilar artery for maximal response	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID1864493	Substrate activity at human OCT3 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID3829	Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID4919	Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID4867	The compound was tested for intrinsic activity against 5-HT1D receptor	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5729	Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID6025	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID3849	In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID63225	The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID4512	Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID395324	Lipophilicity, log D at pH 7.4 by liquid chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID4873	Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID409602	Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID4626	In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID4698	Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID1771268	Toxicity in NewZealand rabbit Saphenous vein rings assessed as induction of vasoconstriction at 1 to 100 uM	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT
AID4269	Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity h5-HT1B/1D ligands.
AID4617	Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity h5-HT1B/1D ligands.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID4581	Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID4865	Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID231640	Binding affinity ratio of cloned human 5-HT1B to that of human 5-HT1D	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID63680	The compound was tested for CNS binding affinity towards Dopamine receptor D4 from cloned Human membranes; Inactive	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID4549	The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID234526	Selectivity of compound towards human 5-HT1D receptor over human 5-HT1B receptor	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
AID409603	Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	Identification of aquaporin 4 inhibitors using in vitro and in silico methods.
AID4779	Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
AID4588	Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID5609	Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4600	Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
AID234875	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235510	Selectivity value is the ratio between EC50 values of 5-HT1A and 5-HT1D receptors	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID4572	Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Design, synthesis and biological activity of novel dimethyl-[2-[6-substituted-indol-1-yl]-ethyl]-amine as potent, selective, and orally-bioavailable 5-HT(1D) agonists.
AID4258	Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID673054	Cardiovascular toxicity in human coronary arteries assessed as induction of vasoconstriction after 30 mins relative to serotonin	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID234716	Relative efficacy in stimulation of [35S]GTP-gamma-S, binding in CHO cells compared to 5-HT	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
AID771317	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID624626	Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID5997	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID3912	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID229104	efficacy relative to 5-HT	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID624628	Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID28233	Fraction ionized (pH 7.4)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1333949	Decrease in plasma protein extravasation in fasted Harlan Sprague-Dawley rat model of migraine compound administered via oral gavage 1 hr prior to electrical stimulation of trigeminal ganglion measured after 15 mins by FITC-BSA based fluorescence assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache.
AID404704	Displacement of [3H]5-hydroxytryptamine from rhesus monkey cloned 5HT1F receptor expressed in African green monkey COS7 cells by liquid scintillation counting	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
AID4591	Intrinsic activity for 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID5081	Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID4642	Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID1918193	Dissociation constant, pKa of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID4750	Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4256	In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID342466	Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 10 uM by stopped-flow light scattering method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID4583	Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID233219	Relative binding to serotonin 5-HT 1B and 5-HT 1D receptors	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID5452	The compound was tested for binding affinity against 5-HT2A receptor	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID4970	Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID4929	Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID395327	Dissociation constant, pKa by capillary electrophoresis	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID4899	Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID342472	Inhibition of AQP4 in mouse erythrocytes assessed as inhibition of osmotic water permeability at 100 uM after 15 mins by stopped-flow light scattering method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID679753	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Sumatriptan: 100 uM) in MDR1-expressing MDCKII cells	2002	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID224012	The compound was tested for its antagonist activity using rabbit saphenous vein (RSV) preparation	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.
AID166850	Binding affinity towards rabbit saphenous vein	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID4869	The compound was tested for binding affinity against 5-HT1D receptor	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID4574	Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID165751	Maximum vein contraction obtained relative to 5-hydroxytryptamine	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID5691	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID91481	Binding constant against human serum albumin (HSA)	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Cheminformatic models to predict binding affinities to human serum albumin.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID624629	Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID395326	Fraction unbound in rat brain	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID234285	Selectivity is the binding affinity towards human 5-HT1B receptor to that of human 5-HT1F receptor	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID4571	Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID342469	Inhibition of AQP4 expressed in rat FRT cells assessed as transepithelial osmotic water permeability at 100 uM by dye dilution method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID438555	Binding affinity to 5HT1A receptor	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Physical binding pocket induction for affinity prediction.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID4908	Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID234525	Selectivity of compound for human 5-HT1D receptor over human 5-HT1B receptor	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
AID4597	Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID342470	Inhibition of AQP4 in wild type mouse brain gilial cells assessed as osmotic water permeability at 10 to 100 uM after 15 mins by calcein quenching assay	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID4596	Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID3860	Binding affinity for cloned human 5-hydroxytryptamine 1A receptor	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID234715	Relative efficacy of compound in stimulation of [35S]GTP gamma-S binding in CHO cells compared to 5-HT	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
AID248822	Compound was tested for serotonergic activity on dual protein extravasation induced by electrical stimulation in guinea-pigs (3-7 nM/kg)	2004	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18	2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands.
AID4622	Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1180756	Antimigraine activity in migraine patient assessed as pain relief incidence at 100 mg after 2 hrs (Rvb = 51.2%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID5636	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID4270	Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID5956	Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID673053	Cardiovascular toxicity in human coronary arteries assessed as induction of vasoconstriction after 30 mins	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
AID234286	Selectivity is the binding affinity towards human 5-HT1D receptor to that of human 5-HT1F receptor	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID4292	Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID4900	Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID681116	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells	2002	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID232942	Binding selectivity for 5-HT 1D receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID4632	Binding affinity for human 5-hydroxytryptamine 1D receptor	2000	Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.
AID4516	Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID4872	Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID4577	Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
AID4496	Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID4484	The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID4510	Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID166996	Ability to contract saphenous vein of New Zealand white rabbit	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID771314	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5201	Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID235511	Selectivity value is the ratio between IC50 values of 5-HT1A and 5-HT1D receptors	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID218766	In vitro evaluation in the dog saphenous vein for maximal response	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID29656	Oral bioavailability in human	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID3709	Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID4863	Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID1221958	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID3809	In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
AID754786	Vasoconstriction of human coronary artery	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID26280	Partition coefficient at pH 7.4	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID234284	Selectivity is the binding affinity towards human 5-HT1A receptor to that of human 5-HT1F receptor	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID404703	Displacement of [3H]5-hydroxytryptamine from human cloned 5HT1D receptor expressed in CHOK1 cells by liquid scintillation counting	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
AID29925	Volume of distribution in man (IV dose)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID76310	The level of 5-HT (prefrontal cortex) measured by means of HPCL with electrochemical detection methods at 25 (umol/kg, sc)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4977	Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID4569	The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1864500	Substrate activity at human OCT1 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID4245	Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT(1B/1D) ligands.
AID4511	Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID3731	Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor	1994	Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16	5-[(3-nitropyrid-2-yl)amino]indoles: novel serotonin agonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity.
AID1864507	Substrate activity at OCT1 (unknown origin) assessed as uptake ratio	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID4931	Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID76293	The level of 5-HIAA (hypothalamus) measured by means of HPCL with electrochemical detection methods at 25 (umol/kg, sc)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID624622	Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5398	The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID4252	Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
AID26304	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID4248	Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity h5-HT1B/1D ligands.
AID26301	Partition coefficient (logD7.4)	1993	Journal of medicinal chemistry, May-28, Volume: 36, Issue:11	Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors.
AID4864	Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane	1993	Journal of medicinal chemistry, May-28, Volume: 36, Issue:11	Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors.
AID233923	Ratio of IC50 for h5-HT1B to h5-HT1D receptors	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID771316	Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID342468	Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 100 uM after 60 mins by stopped-flow light scattering method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID4514	Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5366	Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID29337	Ionisation constant (pKa)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID4575	Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID4627	In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID4260	Binding affinity for human 5-hydroxytryptamine 1B receptor	2000	Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID4578	Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
AID3858	The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID22293	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID3980	Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID4460	Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID4595	Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID1918194	Lipophilicity, log D of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID76303	The level of 5-HT (hypothalamus) measured by means of HPCL with electrochemical detection methods at 25 (umol/kg, sc)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID28235	Unbound fraction (plasma)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID771315	Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1526737	Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis based Michaelis-Menten plot analysis relative to control empty vector transfected cells	2019	Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21	Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
AID1864506	Substrate activity at human OCT2 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID230346	Ratio of receptor binding affinities of 5-hydroxytryptamine 1D receptor alpha vs 5-hydroxytryptamine 1D receptor beta	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID4858	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID3834	Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID218767	Intrinsic activity was measured as maximum contraction relative to 5-HT in dog saphenous vein	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID4255	In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID4924	Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
AID231294	Relative binding affinity for 5-HT1B and 5-HT1D receptor	2000	Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9	5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine.
AID5404	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID74051	Ability to inhibit [125I]- albumin extravasation into dura following electrical stimulation of trigeminal ganglion of Guinea pig	2001	Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5	Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID165754	Functional activity was determined by the contraction of New Zealand white rabbit saphenous vein.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID4515	Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID76288	Effect of 25 (umol/kg, sc) compound on guinea pig rectal temperature (Hypothermia)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID3850	In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID4291	Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.	1999	Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24	3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID4974	In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4975	In vitro agonist potency against human 5-hydroxytryptamine 1F receptor	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID5606	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID77859	The compound (25umol/kg, sc) was tested for hypothermic response for 60 mins in Guinea pig	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
AID63082	Binding affinity for rat dopamine D2 receptor expressed in CHO-K1 cells	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID4495	Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists.
AID404707	Selectivity for human 5HT1D receptor over human 5HT1B receptor	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
AID5878	Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist.
AID4294	5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model	1998	Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6	Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID4601	Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
AID29423	HPLC capacity factor (k')	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID28236	Unbound fraction (tissues)	2002	Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID404708	Selectivity for human 5HT1D receptor over human 5HT1F receptor	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
AID4629	Binding affinity for human 5-hydroxytryptamine 1D receptor	2000	Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15	5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists.
AID4640	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID6281	Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID19418	Partition coefficient (logD7.4)	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID1221964	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID4615	Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT(1B/1D) ligands.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1546005	Displacement of [3H]5-HT from recombinant human 5-HT7 receptor expressed in African green monkey COS7 cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Structure-activity relationships of serotonin 5-HT
AID76298	The level of 5-HIAA (prefrontal cortex) measured by means of HPCL with electrochemical detection methods at 25 (umol/kg, sc)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	5-HT1D receptor agonist properties of novel 2-[5-[[(trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and their use as synthetic intermediates.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID3978	Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Synthesis and biological activity of 3-[2-(dimethylamino)ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin- 2-yl)-methyl]-1H-indole and analogues: agonists for the 5-HT1D receptor.
AID6358	Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
AID3975	Binding activity radioligand.	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptors.
AID1180753	Antimigraine activity in migraine patient assessed as pain freedom incidence at 100 mg after 2 hrs (Rvb = 15.3%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID4983	Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
AID624623	Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID342471	Inhibition of AQP4 in wild type mouse brain gilial cells assessed as reduction of osmotic equilibrium rate at 10 to 100 uM after 15 mins by calcein quenching assay relative to water permeability	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID404702	Displacement of [3H]5-hydroxytryptamine from human cloned 5HT1B receptor expressed in CHOK1 cells by liquid scintillation counting	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID224187	Intrinsic activity was measured as maximum contraction relative to 5-HT in rabbit basilar artery	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13	(+/-) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: a conformationally restricted analogue of 5-carboxamidotryptamine with selectivity for the serotonin 5-HT1D receptor.
AID342467	Inhibition of AQP4 expressed in rat FRT cells assessed as osmotic water permeability at 100 uM after 15 mins by stopped-flow light scattering method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (1.28)	18.7374
1990's	896 (39.45)	18.2507
2000's	805 (35.45)	29.6817
2010's	435 (19.15)	24.3611
2020's	106 (4.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	461 (19.17%)	5.53%
Reviews	435 (18.09%)	6.00%
Case Studies	233 (9.69%)	4.05%
Observational	2 (0.08%)	0.25%
Other	1,274 (52.97%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (109)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Imigran STATdose - Japan Clinical Experience Study for Self-injection [NCT00356603]	Phase 3	75 participants (Actual)	Interventional	2006-06-20	Completed
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine Associated Nausea and Vomiting. [NCT03877718]	Phase 2	475 participants (Actual)	Interventional	2019-02-01	Completed
Investigation of PACAP38-induced Headache and Rosacea-like Symptoms in Patients With Rosacea [NCT03878784]		38 participants (Actual)	Interventional	2018-11-12	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of DFN-02 in Episodic Migraine With or Without Aura [NCT02856802]	Phase 2	107 participants (Actual)	Interventional	2016-07-11	Completed
A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine [NCT00897104]	Phase 3	933 participants (Actual)	Interventional	1995-08-31	Completed
A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects [NCT03310411]	Phase 1	40 participants (Actual)	Interventional	2017-10-17	Completed
Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy [NCT01381497]		1 participants (Actual)	Observational	2010-03-31	Completed
Sumatriptan as Treatment for Moderate to Severe Post-Traumatic Headache [NCT01854385]	Phase 2	40 participants (Actual)	Interventional	2013-06-30	Completed
The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects [NCT03585894]		34 participants (Actual)	Interventional	2018-08-01	Completed
Drug Use Investigation for IMIGRAN Tablet [NCT01376141]		3,571 participants (Actual)	Observational	2001-09-30	Completed
A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data [NCT01381523]		1 participants (Actual)	Observational	2010-11-30	Completed
A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine [NCT00898677]	Phase 3	1,268 participants (Actual)	Interventional	1995-09-30	Completed
Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine [NCT03881644]		37 participants (Actual)	Interventional	2018-07-17	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without [NCT00387881]	Phase 3	679 participants (Actual)	Interventional	2006-09-30	Completed
The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model [NCT02486276]		30 participants (Actual)	Interventional	2015-06-30	Completed
The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model [NCT02485340]		30 participants (Actual)	Interventional	2015-04-30	Completed
A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492 [NCT00892203]	Phase 2	75 participants (Actual)	Interventional	2009-04-30	Completed
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex™) in Healthy Subjects [NCT02741310]	Phase 1	34 participants (Actual)	Interventional	2016-02-22	Completed
Evaluation of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Saliva of Menstrual Migraine Patients Before and After Treatment With Treximet™ [NCT01329562]	Phase 4	41 participants (Actual)	Interventional	2011-05-31	Completed
A Phase I, Open-Label, Two-Part Study of the Effect of Multiple-Dose Evobrutinib on Transporter Substrates Digoxin, Metformin, Rosuvastatin, and Sumatriptan Pharmacokinetics in Healthy Participants [NCT05064488]	Phase 1	40 participants (Actual)	Interventional	2021-10-04	Completed
A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Voluntee [NCT01381796]	Phase 1	63 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized, Double-Blind, Three Period, Cross-Over Study to Evaluate the Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan (Imitrex) in Healthy Male and Female Subjects [NCT03076970]	Phase 1	42 participants (Actual)	Interventional	2017-03-21	Completed
Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine: A Randomized Double-Blind Two-Way Crossover Study [NCT05211050]		20 participants (Anticipated)	Interventional	2022-02-15	Recruiting
Open Label, Randomized, Two Way Crossover, Comparative Evaluation of Relative Bioavailabilities of Two Formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories Limited, India)With the Reference Formulation Imitrex Tablets 100 mg (Gla [NCT01269281]	Phase 1	50 participants (Actual)	Interventional	2005-07-31	Completed
A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan [NCT01086358]	Phase 4	60 participants (Actual)	Interventional	2009-09-30	Completed
A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine [NCT02684409]	Phase 1	37 participants (Actual)	Interventional	2013-08-31	Completed
Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy [NCT01632657]		40 participants (Actual)	Interventional	2012-06-30	Completed
Single-Dose Food In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers [NCT00650247]	Phase 1	57 participants (Actual)	Interventional	2004-11-30	Completed
The Effect of Sumatriptan and Placebo on CGRP Induced Headache [NCT03542357]		30 participants (Actual)	Interventional	2018-02-15	Completed
Prospective Analgesic Compound Efficacy (PACE) Study [NCT02403687]		300 participants (Actual)	Observational [Patient Registry]	2015-06-30	Completed
A Single-Center, Open-label, Single-Arm Study to Evaluate the Effects of Repeat Doses of Subcutaneously Delivered Sumatriptan Via the Intraject System of Local Injection Site Signs in Healthy Adult Subjects. [NCT00620425]	Phase 1	18 participants (Actual)	Interventional	2007-12-31	Completed
Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs [NCT02054299]	Phase 1	48 participants (Actual)	Interventional	2013-04-30	Completed
Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache Following Obstetric Surgery Under Spinal Anesthesia: A Randomized Controlled Trial [NCT05108688]	Phase 4	210 participants (Anticipated)	Interventional	2021-11-15	Recruiting
A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura [NCT00893594]		30 participants (Anticipated)	Interventional	2010-10-31	Recruiting
A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During [NCT00723983]	Phase 1	23 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED) [NCT00449787]	Phase 4	401 participants (Actual)	Interventional	2007-03-31	Completed
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin [NCT05654298]		20 participants (Actual)	Interventional	2022-03-15	Completed
Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache: A Randomized Clinical Trial [NCT04257851]	Phase 4	60 participants (Actual)	Interventional	2020-02-15	Completed
The Sumatriptan and Naratriptan Pregnancy Registry [NCT01059604]		868 participants (Actual)	Observational [Patient Registry]	2001-12-31	Completed
Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents [NCT00488514]	Phase 3	656 participants (Actual)	Interventional	2007-07-13	Completed
Evaluation of a Behavioral Program for Migraineurs in the Emergency Department. [NCT02643719]		0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Study team missed continuing review and study lapsed with out recruiting any subjects.)
TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents [NCT00843024]	Phase 3	589 participants (Actual)	Interventional	2008-12-31	Completed
The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study [NCT00724815]	Phase 3	530 participants (Actual)	Interventional	2009-01-31	Completed
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents [NCT03338920]	Phase 3	159 participants (Actual)	Interventional	2017-11-02	Terminated(stopped due to eDiary data collected not sufficient to utilize in the analysis of protocol endpoints)
Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or [NCT00792636]	Phase 4	407 participants (Actual)	Interventional	2008-11-30	Completed
A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura [NCT00920686]	Phase 2	239 participants (Actual)	Interventional	2009-06-30	Completed
A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers [NCT00720018]	Phase 1	4 participants (Actual)	Interventional	2008-06-30	Completed
Treximet in the Treatment of Chronic Migraine [NCT01090050]	Phase 4	56 participants (Actual)	Interventional	2010-09-30	Completed
A Phase I, Single Center, Open Label, Randomized, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® in Healthy Volunteers [NCT00546650]	Phase 1	25 participants (Actual)	Interventional	2007-11-30	Completed
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) [NCT00382993]	Phase 3	169 participants (Actual)	Interventional	2006-12-31	Completed
Comparison of Treximet and Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache. [NCT01916395]		30 participants (Actual)	Observational	2009-12-31	Completed
An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fed Conditions [NCT00872274]		32 participants (Actual)	Interventional	2008-07-31	Completed
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) Injection 4mg Administered Using the IMITREX STATdose [NCT00875784]	Phase 1	30 participants (Actual)	Interventional	2008-05-06	Completed
Effects of Serotonin Receptor Agonism on Blood Glucose Lowering: Proof of Concept in Humans [NCT04690270]	Early Phase 1	12 participants (Anticipated)	Interventional	2021-01-04	Not yet recruiting
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) [NCT00383162]	Phase 3	173 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migrai [NCT00240630]	Phase 3	646 participants (Actual)	Interventional	2005-10-31	Completed
A Multicentre, Double Blind, Double Dummy, Parallel Group, Placebo Controlled, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels Oral Sumatriptan Given for the Acute Treatment of Migraine(With and Without Aura). [NCT01986088]	Phase 3	1,008 participants (Actual)	Interventional	1996-11-30	Completed
A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine [NCT01986270]	Phase 3	1,141 participants (Actual)	Interventional	1996-12-31	Completed
A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents [NCT00963937]	Phase 3	178 participants (Actual)	Interventional	2009-09-28	Completed
Ictal and Interictal Inflammatory Markers in Migraine [NCT01138150]	Phase 4	36 participants (Actual)	Interventional	2009-09-30	Completed
An Open Label, Single Dose, Randomised, Parallel Group Pharmacokinetic Study to Evaluate a Combination Product Containing Naproxen Sodium and Sumatriptan in Adolescent Subjects With Migraine and Healthy Adult Subjects Administered at Three Doses. [NCT00989625]	Phase 1	50 participants (Actual)	Interventional	2008-11-04	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders [NCT00894556]	Phase 3	109 participants (Actual)	Interventional	2009-06-10	Completed
A Two-Way Crossover, Open-Label, Single-Dose, Fasting Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets Versus Imitrex® 100 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects [NCT00847405]	Phase 1	28 participants (Actual)	Interventional	2003-03-31	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers [NCT00648466]	Phase 1	55 participants (Actual)	Interventional	2004-11-30	Completed
"An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine" [NCT00893737]	Phase 4	147 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pai [NCT00329459]	Phase 3	320 participants (Actual)	Interventional	2006-05-31	Completed
An Evaluation of Treximet in the Treatment of Acute Migraine Headache: A Placebo-Controlled, Double-Blind, Crossover Study, Assessing Cognitive Function. [NCT00837044]		30 participants (Anticipated)	Interventional	2009-02-28	Recruiting
An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fasting Conditions [NCT00872924]		32 participants (Actual)	Interventional	2008-07-31	Completed
A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine [NCT01071317]	Phase 4	50 participants (Actual)	Interventional	2010-02-28	Completed
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction [NCT01053507]	Phase 4	23 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Enrollment rate was slower than anticipated.)
An Open-Label Phase 1 Study to Establish the Pharmacokinetics and Safety of Sumatriptan Succinate Administered Via the Sofusa™ DoseConnect™ System at Escalating Doses Compared to Oral Imitrex® Single 100 mg Dose in Healthy Subjects [NCT03229798]	Phase 1	19 participants (Actual)	Interventional	2018-01-17	Completed
An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months [NCT00442221]	Phase 3	500 participants	Interventional	2004-05-31	Completed
TreximetTM in the Prevention and Modification of Disease Progression in Migraine [NCT01300546]	Phase 4	40 participants (Actual)	Interventional	2010-12-31	Completed
A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine. [NCT01248468]	Phase 4	752 participants (Actual)	Interventional	2010-11-30	Completed
A Randomized, Open Label, Crossover, Bioavailability Study to Compare Omexa Sumatriptan Transmucosal Sublingual Tablet Versus Commercial Imitrex® Sumatriptan Oral Tablet in Healthy Volunteers [NCT02954276]	Phase 1	13 participants (Actual)	Interventional	2016-03-31	Active, not recruiting
Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation [NCT02932488]	Phase 1	17 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to Pilot study with sumatriptan found no significant changes in the primary outcome parameter (change in CBF))
A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches [NCT00433732]	Phase 3	1,400 participants	Interventional	2004-08-31	Completed
A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches [NCT00434083]	Phase 3	1,200 participants	Interventional	2004-07-31	Completed
An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack. [NCT00385008]	Phase 3	20 participants (Actual)	Interventional	2006-09-13	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura [NCT01462812]	Phase 3	223 participants (Actual)	Interventional	2011-01-31	Completed
A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack [NCT00510419]	Phase 3	73 participants (Actual)	Interventional	2007-07-31	Completed
Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine [NCT02571049]	Phase 2	24 participants (Actual)	Interventional	2015-09-30	Completed
A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Sumatriptan Succinate, (100mg), Compared to and Equivalent Dose of a Commercially Available Reference Drug Product (Imitrex®, GlaxoSmithKli [NCT00846885]	Phase 1	28 participants (Actual)	Interventional	2004-08-31	Completed
Neuropeptides in the Humane Intra- og Extracerebral Circulation - in Relation to Sumatriptan in Healthy Volunteers. [NCT00399633]		16 participants (Actual)	Interventional	2007-01-31	Completed
4mg StatDose Imitrex for Acute Treatment of Cluster Headache [NCT00399243]	Phase 4	20 participants (Anticipated)	Interventional	2006-11-30	Recruiting
Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers. Development of a Pragmatic Migraine Model [NCT03156920]		30 participants (Actual)	Interventional	2017-05-23	Completed
A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients [NCT00701389]	Phase 1	24 participants (Actual)	Interventional	2007-11-20	Completed
A Randomized, Open-Label, Single-Dose, Four-way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System Versus IMITREX STATdose at Three Injection Sites in Healthy Adults [NCT00614029]	Phase 1	54 participants (Actual)	Interventional	2006-12-31	Completed
A Safety, Tolerability, and Efficacy Study of LY2590443 in the Treatment of Acute Migraine Headache [NCT00804973]	Phase 2	120 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Due to efficacy results of interim analysis)
Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine [NCT01430442]	Phase 2	1,026 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migra [NCT00240617]	Phase 3	623 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain [NCT00329355]	Phase 3	351 participants (Actual)	Interventional	2006-05-31	Completed
An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX® (Sumatriptan) Nasal Spray, 100 mg IMITREX® (Sumatriptan) Oral Tablet and 6 mg IMITREX [NCT01507610]	Phase 1	20 participants (Actual)	Interventional	2012-01-31	Completed
Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial [NCT01814189]	Phase 3	350 participants (Actual)	Interventional	2013-01-31	Completed
Treximet ™ Pharmacy Budget Impact Model Database Validation Study [NCT01332500]		61,737 participants (Actual)	Observational	2009-07-31	Completed
Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache [NCT01791400]	Phase 2	124 participants (Actual)	Interventional	2009-07-31	Completed
Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly [NCT01450995]	Phase 4	50 participants (Actual)	Interventional	2009-12-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks. [NCT04948164]	Phase 3	240 participants (Anticipated)	Interventional	2018-08-01	Recruiting
A PHASE 1, FIXED-SEQUENCE, OPEN LABEL STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS [NCT04355845]	Phase 1	10 participants (Actual)	Interventional	2020-06-15	Completed
A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Inject [NCT01579383]	Phase 1	104 participants (Actual)	Interventional	2012-04-30	Completed
The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache [NCT03422796]		30 participants (Actual)	Interventional	2017-11-01	Completed
A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acut [NCT01667679]	Phase 3	275 participants (Actual)	Interventional	2012-08-31	Completed
Randomized, Double-Blind, and Placebo-Controlled Study to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination Versus Sumatriptan in the Acute Treatment of Migraine With Nausea [NCT03185143]	Phase 2/Phase 3	36 participants (Actual)	Interventional	2017-06-27	Completed
A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans [NCT01016834]	Phase 4	246 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALD1910, a Humanized Anti-Pituitary Adenylate Cyclase Activating Peptide (PACAP) Monoclonal Antibody [NCT04197349]	Phase 1	96 participants (Actual)	Interventional	2019-09-24	Completed
A Multi-Center, Open-Label, Single-dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject® System in Adult Patients During Acute Migraine Attack [NCT00530517]	Phase 2	54 participants (Actual)	Interventional	2007-09-30	Completed
Multi-Center, Double-Blind, Placebo Controlled Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches [NCT02176655]	Phase 2	31 participants (Actual)	Interventional	2014-07-31	Completed
Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study) [NCT01807234]	Phase 4	72 participants (Actual)	Interventional	2013-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00356603 (3) [back to overview]	Percentage of Participants With Headache Relief at 60 Minutes Post Dose(Migraine) or 30 Minutes Post Dose(Cluster Headache)
NCT00356603 (3) [back to overview]	Percentage of Participants With Investigator/Sub Investigator-rated Successful Self-injection Rate
NCT00356603 (3) [back to overview]	Number of Participants With Subject-rated Acceptability of the Sumatriptan 3mg Kit Product
NCT00382993 (19) [back to overview]	Complete Pain/Symptom-Free Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Migraine Headache Pain Free at 0.5, 1, 4, and 8 Hours Post-Dose
NCT00382993 (19) [back to overview]	Migraine-Associated Nausea Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Migraine-Associated Phonophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Migraine-Associated Photophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Migraine-Associated Sinus Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Migraine-Free Assessment at 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Recurrence of Any Migraine Headache Pain
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine-Associated Neck Pain
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine-Associated Phonophobia
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine-Associated Photophobia
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine-Associated Nausea
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine
NCT00382993 (19) [back to overview]	Sustained Complete Pain/Symptom-Free
NCT00382993 (19) [back to overview]	Rescue Medication Use During 0 - 24 Hours Post-Dose
NCT00382993 (19) [back to overview]	Migraine Headache Pain Free at 2 Hours Post-Dose
NCT00382993 (19) [back to overview]	Migraine-Associated Neck Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00382993 (19) [back to overview]	Sustained Freedom From Migraine-Associated Sinus Pain
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine-Associated Nausea
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine
NCT00383162 (19) [back to overview]	Sustained Complete Pain/Symptom-Free
NCT00383162 (19) [back to overview]	Rescue Medication Used up to 24 Hours Post-dose
NCT00383162 (19) [back to overview]	Pain-Free Assessment at 2 Hours Post-dose
NCT00383162 (19) [back to overview]	Recurrence of Any Migraine Headache Pain
NCT00383162 (19) [back to overview]	Pain-Free Assessment at 1/2, 1, 4, 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Free Assessment at 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Associated Sinus Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Associated Photophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Associated Phonophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Associated Neck Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Migraine-Associated Nausea Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Complete Pain/Symptom-Free Assessed at Baseline, 2, 4, and 8 Hours Post-dose
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine-Associated Sinus Pain
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine-Associated Photophobia
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine-Associated Phonophobia
NCT00383162 (19) [back to overview]	Sustained Freedom From Migraine-Associated Neck Pain
NCT00385008 (15) [back to overview]	Time to First Appearance of Sumatriptan, Naproxen and Eletriptan at the Proximal Small Intestine
NCT00385008 (15) [back to overview]	Cmax for Eletriptan
NCT00385008 (15) [back to overview]	Maximum Observed Drug Concentration (Cmax) for Sumatriptan and Naproxen
NCT00385008 (15) [back to overview]	Mean Area Under the Drug Concentration Time Curve (AUC) From Time of Dosing Through 2 Hour Post-dose [AUC (0-2)], Through 24 Hour [AUC (0-24)] and AUC From Time of Dosing Extrapolated to Infinity [AUC (0-inf)] for Sumatriptan and Naproxen
NCT00385008 (15) [back to overview]	Time of Maximal Drug Concentration (Tmax) for Sumatriptan and Naproxen
NCT00385008 (15) [back to overview]	Small Intestine Transit and Residence (Time to 50% Through Intestine) of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan
NCT00385008 (15) [back to overview]	Small Intestine Transit and Residence (Time to 50% Through Intestine) of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan
NCT00385008 (15) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00385008 (15) [back to overview]	Tmax for Eletriptan
NCT00385008 (15) [back to overview]	Mean AUC (0-inf) and AUC (0-2) for Eletriptan
NCT00385008 (15) [back to overview]	Time to First Appearance of Sumatriptan, Naproxen and Eletriptan at the Proximal Small Intestine
NCT00385008 (15) [back to overview]	Time to Complete Dispersion of the Sumatriptan and Naproxen Portions of the TREXIMA Tablet and of the Relpax Tablet
NCT00385008 (15) [back to overview]	Time to Complete Dispersion of the Sumatriptan and Naproxen Portions of the TREXIMA Tablet and of the Relpax Tablet
NCT00385008 (15) [back to overview]	Time to 10%, 50%, 90% and Complete Gastric Empting of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan
NCT00385008 (15) [back to overview]	Time to 10%, 50%, 90% and Complete Gastric Empting of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan
NCT00387881 (9) [back to overview]	Sustained Headache Relief 2-24 Hours After Treatment
NCT00387881 (9) [back to overview]	Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment
NCT00387881 (9) [back to overview]	Headache Relief at 4, 2, 1 and 0.5 Hours After Treatment
NCT00387881 (9) [back to overview]	Incidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment
NCT00387881 (9) [back to overview]	Intermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours
NCT00387881 (9) [back to overview]	Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment
NCT00387881 (9) [back to overview]	Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.
NCT00387881 (9) [back to overview]	Medication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score
NCT00387881 (9) [back to overview]	Intermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment
NCT00449787 (3) [back to overview]	Headache-related Functional Disability
NCT00449787 (3) [back to overview]	Numerical Rating Scale
NCT00449787 (3) [back to overview]	Patient Satisfaction
NCT00488514 (27) [back to overview]	Number of Treated Migraine Attacks With Photophobia, Phonophobia, Nausea, Neck Pain, Sinus Pain, and Vomiting
NCT00488514 (27) [back to overview]	Number of Treated Migraine Attacks
NCT00488514 (27) [back to overview]	Number of Participants With Hematocrit and Hemoglobin Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit
NCT00488514 (27) [back to overview]	Number of Participants With the Indicated Drug-related Adverse Events
NCT00488514 (27) [back to overview]	Number of Tablets Taken, After Which at Least One Adverse Event Occurred Within 3 or 5 Days of Dosing With That Combination Tablet
NCT00488514 (27) [back to overview]	Mean Body Mass Index (BMI) for All Study Participants at the Indicated Time Points
NCT00488514 (27) [back to overview]	Number of Total Migraines Headaches and Migraines Treated With the Combination Tablet
NCT00488514 (27) [back to overview]	Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 24 Hours of Dosing With the Combination Tablet
NCT00488514 (27) [back to overview]	Number of Treated Attacks Classified as Migraine Pain-Free (MPF) Within 4 Hours of Dosing With a Combination Tablet
NCT00488514 (27) [back to overview]	Average Number of Headaches, Migraine Attacks, and Treated Migraine Attacks Per Month
NCT00488514 (27) [back to overview]	Mean Blood Pressure for All Study Participants at the Indicated Time Points
NCT00488514 (27) [back to overview]	Number of Treated Attacks Classified as Migraine Pain-Free Within 4 Hours That Were Also Pain Free Within 2 Hours of Dosing With the Combination Tablet
NCT00488514 (27) [back to overview]	Mean Change From Baseline in the Migraine Specific Quality of Life (QOL) Questionnaire for Adolescents (MSQ-A) Score at Months 3, 6, 9, and 12
NCT00488514 (27) [back to overview]	Mean Heart Rate for All Study Participants at the Indicated Time Points
NCT00488514 (27) [back to overview]	Mean Height for All Study Participants at the Indicated Time Points
NCT00488514 (27) [back to overview]	Mean Weight for All Study Participants at the Indicated Time Points
NCT00488514 (27) [back to overview]	Number of Migraine Attacks Rated With the Indicated Pain Severity
NCT00488514 (27) [back to overview]	Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionaire-Revised (PPMQ-R) at Month 12
NCT00488514 (27) [back to overview]	Number of Participants Categorized by Response to Each of the 3 Global Satisfaction Questions From the Patient Perception Migraine Questionnaire-Revised (PPMQ-R) at the Screening Visit
NCT00488514 (27) [back to overview]	Number of Participants With Abnormal Electrocardiogram Findings at Screening and at the Final Visit as Assessed by the Investigator
NCT00488514 (27) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Potassium, and Blood Urea Nitrogen (BUN) Values of Interest That Shifted From Normal at Baseline to Abnormal at the End of Study Visit
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event Categorized by Participant Age
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event Categorized by Participant Gender
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event Categorized by Participant Race
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event Categorized by Severity
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event Categorized Over Time
NCT00488514 (27) [back to overview]	Number of Participants With Any Adverse Event That Occurred Within 3 or 5 Days of the First Dose of the Combination Tablet
NCT00620425 (1) [back to overview]	The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema).
NCT00701389 (4) [back to overview]	Number of Participants Who Experienced an Adverse Event During the Study
NCT00701389 (4) [back to overview]	Number of Participants Who Were Discontinued From Any Study Period Due to an Adverse Event
NCT00701389 (4) [back to overview]	Time-weighted Mean Arterial Pressure (Sumatriptan With Telcagepant Versus Sumatriptan Alone)
NCT00701389 (4) [back to overview]	Time-weighted Mean Arterial Pressure (Telcagepant Versus Placebo)
NCT00724815 (4) [back to overview]	Nausea Free at Two Hours
NCT00724815 (4) [back to overview]	Pain Free at Two Hours
NCT00724815 (4) [back to overview]	Phonophobia Free at Two Hours
NCT00724815 (4) [back to overview]	Photophobia Free at Two Hours
NCT00792636 (15) [back to overview]	Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg
NCT00792636 (15) [back to overview]	Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study
NCT00792636 (15) [back to overview]	Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
NCT00792636 (15) [back to overview]	Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure
NCT00792636 (15) [back to overview]	Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure
NCT00792636 (15) [back to overview]	Number of Participants Withdrawn From the Study Due to Blood Pressure Changes
NCT00792636 (15) [back to overview]	Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
NCT00792636 (15) [back to overview]	Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses
NCT00792636 (15) [back to overview]	Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines, 4-6 Migraines, >=4 Migraines, and >6 Migraines Per Month
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine
NCT00792636 (15) [back to overview]	Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen
NCT00804973 (10) [back to overview]	Number of Participants With Recurrent Migraine Headache Within 24 or 48 Hours
NCT00804973 (10) [back to overview]	Number of Participants With Photophobia
NCT00804973 (10) [back to overview]	Number of Participants With Pain Relief Response
NCT00804973 (10) [back to overview]	Number of Participants With Pain Free Response
NCT00804973 (10) [back to overview]	Number of Participants With Nausea
NCT00804973 (10) [back to overview]	Number of Participants With Headache Pain Free Response
NCT00804973 (10) [back to overview]	Number of Participants With Phonophobia
NCT00804973 (10) [back to overview]	Number of Participants With Vomiting
NCT00804973 (10) [back to overview]	Number of Participants With Sustained Pain Relief Response
NCT00804973 (10) [back to overview]	Number of Participants With Sustained Pain Free Response
NCT00843024 (17) [back to overview]	Number of Participants Sustained Pain-free From 2-24 Hours
NCT00843024 (17) [back to overview]	Number of Participants Sustained Phonophobia-free From 2-24 Hours
NCT00843024 (17) [back to overview]	Mean Body Mass Index of Participants at Baseline Categorized by Age Group
NCT00843024 (17) [back to overview]	Mean Age of Participants at Baseline Categorized by Age Group
NCT00843024 (17) [back to overview]	Number of Participants Photophobia-free at 2 Hours Post-dose
NCT00843024 (17) [back to overview]	Number of Female and Male Participants Categorized by Age Group
NCT00843024 (17) [back to overview]	Number of Participants Nausea-free at 2 Hours Post-dose
NCT00843024 (17) [back to overview]	Number of Participants of the Indicated Race Categorized by Age Group
NCT00843024 (17) [back to overview]	Number of Participants Randomized to Double-blind Treatment in the Indicated Age Categories at Baseline
NCT00843024 (17) [back to overview]	Number of Participants Sustained Nausea-free From 2-24 Hours
NCT00843024 (17) [back to overview]	Mean Weight of Participants at Baseline Categorized by Age Group
NCT00843024 (17) [back to overview]	Number of Participants Pain-free at 1 Hour Post-dose
NCT00843024 (17) [back to overview]	Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose
NCT00843024 (17) [back to overview]	Number of Participants Who Were Pain Free at 2 Hours Post-dose
NCT00843024 (17) [back to overview]	Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points
NCT00843024 (17) [back to overview]	Number of Participants Sustained Photophobia-free From 2-24 Hours
NCT00843024 (17) [back to overview]	Number of Participants Phonophobia-free at 2 Hours Post-dose
NCT00846885 (3) [back to overview]	Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00846885 (3) [back to overview]	AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00846885 (3) [back to overview]	AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00847405 (3) [back to overview]	AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00847405 (3) [back to overview]	AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00847405 (3) [back to overview]	Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00893737 (3) [back to overview]	Change in Scores From Completeness of Response Survey (CORS)
NCT00893737 (3) [back to overview]	Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)
NCT00893737 (3) [back to overview]	Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan
NCT00894556 (2) [back to overview]	Pain Relief (PR)
NCT00894556 (2) [back to overview]	Pain Freedom (PF)
NCT00897104 (7) [back to overview]	Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment
NCT00897104 (7) [back to overview]	Pain Relief at 2 Hours After Treatment
NCT00897104 (7) [back to overview]	Pain Free at 2 Hours After Treatment
NCT00897104 (7) [back to overview]	Participants Who Used Escape Medication 2 Hours After the Treatment Dose
NCT00897104 (7) [back to overview]	Time to Relief Within 2 Hours After Treatment
NCT00897104 (7) [back to overview]	Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities
NCT00897104 (7) [back to overview]	Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])
NCT00898677 (5) [back to overview]	Functional Status at 2 Hours After Dose
NCT00898677 (5) [back to overview]	Nausea at 2 Hours After Dose
NCT00898677 (5) [back to overview]	Pain Relief at 2 Hours After Dose
NCT00898677 (5) [back to overview]	Time to Relief Within 2 Hours After Dose
NCT00898677 (5) [back to overview]	Pain Free at 2 Hours After Dose
NCT00920686 (5) [back to overview]	24 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea
NCT00920686 (5) [back to overview]	Time (Hours) to First Use of Rescue Medication
NCT00920686 (5) [back to overview]	2 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea
NCT00920686 (5) [back to overview]	Headache Relief and Recurrence (Observed Cases)
NCT00920686 (5) [back to overview]	4 Hours Post Administration - Incidence of Complete Headache Relief, Photophobia, Phonophobia and Nausea
NCT00963937 (8) [back to overview]	Percentage of Participants Who Used Rescue Medication Between the Time of Dosing and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Were Nausea Free at 30, 60, 120, and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Were Photophobia Free at 30, 60, 120, and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Were Phonophobia Free at 30, 60, 120, and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Were Pain Free at 30, 60, 120, and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Were Free of Vomiting at 30, 60, 120, and 240 Minutes Post-Treatment
NCT00963937 (8) [back to overview]	Percentage of Participants Who Reported Pain Relief at 30, 60, 120, and 240 Minutes Post-Treatment
NCT01016834 (3) [back to overview]	Treatment Preference
NCT01016834 (3) [back to overview]	Overall Satisfaction
NCT01016834 (3) [back to overview]	Treatment Confidence
NCT01053507 (5) [back to overview]	Change in Number of Associated Headache Symptoms
NCT01053507 (5) [back to overview]	Headache Impact Test-6 (HIT-6) Score
NCT01053507 (5) [back to overview]	Mental Efficiency Workload Test (MEWT) Performance Index
NCT01053507 (5) [back to overview]	Migraine Specific Quality of Life Questionnaire (MSQ)
NCT01053507 (5) [back to overview]	Headache Days
NCT01071317 (4) [back to overview]	Number of Participants Who Returned to the Emergency Department for Management of Headache
NCT01071317 (4) [back to overview]	Number of Participants Who Report They Are Comfortable With Disease Management, as Measured by a Three-item Likert Scale
NCT01071317 (4) [back to overview]	Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale
NCT01071317 (4) [back to overview]	Number of Participants Who Report Satisfaction With Treatment, as Measured by a Three Item Likert Scale
NCT01086358 (4) [back to overview]	Lost Activity Time
NCT01086358 (4) [back to overview]	Workplace Productivity and Activity Impairment Scale (WPAI).
NCT01086358 (4) [back to overview]	Lost Workplace Productivity
NCT01086358 (4) [back to overview]	Favorable Response on Migraine-ACT
NCT01090050 (8) [back to overview]	Migraine Headache Days With Greater Than 50% Reduction
NCT01090050 (8) [back to overview]	Migraine Headache Duration From Onset to Pain Free
NCT01090050 (8) [back to overview]	Migraine Headache Duration From Time of Treatment to Pain Free
NCT01090050 (8) [back to overview]	Percent Change of Doses of Study Medication
NCT01090050 (8) [back to overview]	Percent Change of Migraine Headache Days in All Treatment Periods Compared to Baseline
NCT01090050 (8) [back to overview]	Percent Change of Migraine Headache Days Compared to Baseline
NCT01090050 (8) [back to overview]	Migraine Disability Assessment(MIDAS)Questionnaire Total Score
NCT01090050 (8) [back to overview]	Compliance With Lifestyle Changes
NCT01138150 (8) [back to overview]	Change in the Total Serum Adiponectin (T-ADP)
NCT01138150 (8) [back to overview]	High Molecular Weight (HMW)-Adiponectin (ADP)
NCT01138150 (8) [back to overview]	High Molecular Weight (HMW): T-ADP
NCT01138150 (8) [back to overview]	Leptin
NCT01138150 (8) [back to overview]	Low Molecular Weight (LMW)-ADP
NCT01138150 (8) [back to overview]	Low Molecular Weight (LMW):Total (T)-ADP
NCT01138150 (8) [back to overview]	Middle Molecular Weight (MMW)-ADP
NCT01138150 (8) [back to overview]	Resistin
NCT01248468 (4) [back to overview]	Percent of Subjects Who Are Free of Nausea at 2 Hours.
NCT01248468 (4) [back to overview]	Percent of Subjects Who Are Free of Phonophobia at 2 Hours.
NCT01248468 (4) [back to overview]	Percent of Subjects Who Are Free of Photophobia at 2 Hours.
NCT01248468 (4) [back to overview]	Percent of Subjects Who Are Pain Free at 2 Hours.
NCT01300546 (12) [back to overview]	Migraine Attacks With 50% Reduction
NCT01300546 (12) [back to overview]	Compliance With Lifestyle Changes
NCT01300546 (12) [back to overview]	Percent Change of Headache Days Compared to Baseline
NCT01300546 (12) [back to overview]	Doses of Study Medication
NCT01300546 (12) [back to overview]	Migraine Attacks
NCT01300546 (12) [back to overview]	Headache Days With Greater Than 50% Reduction
NCT01300546 (12) [back to overview]	Migraine Disability Assessment Test (MIDAS)
NCT01300546 (12) [back to overview]	Migraine Duration From Onset to Pain Free
NCT01300546 (12) [back to overview]	Percent Change in Headache Days All Treatment Periods Compared to Baseline
NCT01300546 (12) [back to overview]	Percent Change of Doses of Study Medication
NCT01300546 (12) [back to overview]	Migraine Severity
NCT01300546 (12) [back to overview]	Migraine Duration From Time of Treatment to Pain Free
NCT01329562 (18) [back to overview]	CGRP Measured at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	CGRP Measured at Menstrual Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free.
NCT01329562 (18) [back to overview]	CGRP Measured at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post-Treatment in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	CGRP Measured at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment
NCT01329562 (18) [back to overview]	Biomarkers Measured at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free.
NCT01329562 (18) [back to overview]	Biomarkers Measured at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	Biomarkers Measured at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment
NCT01329562 (18) [back to overview]	Time to Pain-Free in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	Migraine Recurrence
NCT01329562 (18) [back to overview]	Biomarkers Measured at Baseline, Menstrual Migraine Onset, and 2 Hours Post Treatment in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	Migraine Recurrence Responders vs Non-Responders
NCT01329562 (18) [back to overview]	α-Amylase Measured at Menstrual Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free.
NCT01329562 (18) [back to overview]	α-Amylase Measured at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	α-Amylase Measured at Baseline, Menstrual Migraine Headache Onset, and 2 Hours Post Treatment
NCT01329562 (18) [back to overview]	Correlation of Mean Estrogen Levels in Saliva and Urine Estradiol at Mid-Luteal and at Menstrual Migraine Headache Free in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	α-Amylase Measured at Menstrual Migraine Headache Onset, Migraine Headache Free, and 24 Hours Migraine Headache Free in Responders vs Non-Responders
NCT01329562 (18) [back to overview]	Time to Pain Free
NCT01329562 (18) [back to overview]	Correlation of Mean Estrogen Levels in Saliva and Urine Estradiol at Mid Luteal and at Menstrual Migraine Headache Free.
NCT01332500 (6) [back to overview]	Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-switch Analysis
NCT01332500 (6) [back to overview]	Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
NCT01332500 (6) [back to overview]	Mean Health Plan Cost Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis
NCT01332500 (6) [back to overview]	Mean Number of Triptan Tablets Per Participant in 6-month Follow-up Period: Treatment-naïve Analysis
NCT01332500 (6) [back to overview]	Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-naïve Analysis
NCT01332500 (6) [back to overview]	Mean Total Cost (Health Plan Plus Participant Copay Costs) Per Participant for Migraine-related Medications in 6-month Follow-up Period: Treatment-switch Analysis
NCT01430442 (5) [back to overview]	Number of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours Post Dose
NCT01430442 (5) [back to overview]	Number of Participants With Total Migraine Freedom at 2 Hours Post Dose
NCT01430442 (5) [back to overview]	Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-dose
NCT01430442 (5) [back to overview]	Number of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours Post Dose
NCT01430442 (5) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuation Due to Adverse Events
NCT01462812 (1) [back to overview]	Headache Relief
NCT01667679 (27) [back to overview]	Change From Baseline in Albumin and Total Protein at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP) and Alanine Aminotransferase (ALT) at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Aspartate Aminotransferase (AST) and Gamma Glutamyl Transferase (GGT) at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Creatinine at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Hematocrit at Visit 3 (up to 12 Weeks) and Visit 4 (up to 24 Weeks)
NCT01667679 (27) [back to overview]	Change From Baseline in Hemoglobin at Visit 3 (up to 12 Weeks) and Visit 4 (up to 24 Weeks)
NCT01667679 (27) [back to overview]	Change From Baseline in Pulse at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Red Blood Cell Count at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Sodium, Potassium, Chloride, Calcium, and Glucose at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Total Bilirubin at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Urea at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in Urinalysis Values by Dipstick Method at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Change From Baseline in White Blood Cell Count, Basinophils, Monocytes, Neutrophils, Lymphocytes, Eosinophils, and Platelets at Visit 3 (up to Week 12) and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Mean Change From Baseline in Clinical Disability Score at 10, 15, 30, 45, 60, 90, and 120 Minutes Post-dose
NCT01667679 (27) [back to overview]	Mean Change in Headache Severity From Baseline to 10, 15, 30, 45, 60, 90, and 120 Minutes Post-dose
NCT01667679 (27) [back to overview]	Mean Sum of Migraine Pain Intensity Differences (SPID)-30 for Headaches With a Baseline Intensity of Mild and Moderate/Severe
NCT01667679 (27) [back to overview]	Number of Participants With Any Treatment-emergent Non-serious and Serious Adverse Event
NCT01667679 (27) [back to overview]	Number of Participants With the Indicated 12-lead Electrocardiogram (ECG) Findings at Baseline, Visit 3 (up to Week 12), and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Number of Participants With the Indicated Concomitant Medications
NCT01667679 (27) [back to overview]	Number of Participants With the Indicated Physical Examination Abnormalities at Baseline, Visit 3 (up to Week 12), and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Percentage of Attacks in Which Pain Freedom Was Achieved
NCT01667679 (27) [back to overview]	Percentage of Attacks in Which Pain Reduction Was Achieved
NCT01667679 (27) [back to overview]	Percentage of Attacks in Which Pain Relief Was Achieved
NCT01667679 (27) [back to overview]	Number of Participants With the Indicated Amounts of Protein, Glucose, Ketones, Blood, and White Blood Cells (WBCs) in Urine at Baseline, Visit 3 (up to Week 12), and Visit 4 (up to Week 24)
NCT01667679 (27) [back to overview]	Mean Sum of Migraine Pain Intensity Differences (SPID)-30
NCT01667679 (27) [back to overview]	Median Time to Pain Freedom
NCT01807234 (10) [back to overview]	Pain Freedom
NCT01807234 (10) [back to overview]	Absence of Photophobia
NCT01807234 (10) [back to overview]	Absence of Nausea
NCT01807234 (10) [back to overview]	Absence of Allodynia
NCT01807234 (10) [back to overview]	2- Hour Pain Relief
NCT01807234 (10) [back to overview]	Time to Pain Relief
NCT01807234 (10) [back to overview]	Absence of Phonophobia
NCT01807234 (10) [back to overview]	Self-assessment of Disability: Percentage of Participants With Moderate or Severe Disability
NCT01807234 (10) [back to overview]	Sustained Pain Freedom (SPF)
NCT01807234 (10) [back to overview]	Sustained Pain Relief (SPR)
NCT01854385 (4) [back to overview]	Change in Headache Relief
NCT01854385 (4) [back to overview]	Adverse Events
NCT01854385 (4) [back to overview]	Headache Diary Compliance
NCT01854385 (4) [back to overview]	Sumatriptan Compliance
NCT02176655 (11) [back to overview]	Number of Headaches Relieved
NCT02176655 (11) [back to overview]	Headache Severity at Treatment, 30 Minutes and 1 Hour Post Treatment
NCT02176655 (11) [back to overview]	Comparing Acute Hangover Scale Individual Symptoms With Headache Severity 2 Hours Post Treatment
NCT02176655 (11) [back to overview]	Acute Hangover Scale Compared to Pain Severity 2 Hours Post Treatment
NCT02176655 (11) [back to overview]	Satisfaction
NCT02176655 (11) [back to overview]	Number of Participants With Consistent Response to VVD-101
NCT02176655 (11) [back to overview]	Number of Headaches With Sustained Pain Freedom at Twenty Four Hours Post Treatment
NCT02176655 (11) [back to overview]	Number of Headaches Relieved to Complete Pain Freedom at Two Hours Post Treatment
NCT02176655 (11) [back to overview]	Number of Drinks Consumed Compared to Pain Severity 2 Hours Post Treatment
NCT02176655 (11) [back to overview]	Meaningful Headache Relief
NCT02176655 (11) [back to overview]	Headache Severity 2 Hours Post Treatment
NCT02571049 (1) [back to overview]	The Percentage of Subjects Reporting Pain Freedom at 60 Minutes Post-treatment
NCT02741310 (6) [back to overview]	Area Under the Concentration-time Curve From Time 0 to 6 Hours for Sumatriptan
NCT02741310 (6) [back to overview]	Time-weighted Averages of Mean Arterial Pressure
NCT02741310 (6) [back to overview]	Number of Participants With Adverse Events
NCT02741310 (6) [back to overview]	Number of Participants Who Developed Anti-erenumab Antibodies
NCT02741310 (6) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Sumatriptan
NCT02741310 (6) [back to overview]	Area Under the Concentration-time Curve From Time 0 to Infinity for Sumatriptan
NCT02856802 (3) [back to overview]	Number of Participants With Absence of Most Bothersome Symptom (MBS) Among Nausea, Photophobia and Phonophobia at 2 Hours (DB1)
NCT02856802 (3) [back to overview]	Number of Participants With Headache Pain Freedom at 2 Hours Postdose in the Double-blind Treatment Period 2 (DB2)
NCT02856802 (3) [back to overview]	Number of Participants Free From Headache Pain at 2 Hours After the First Dose of Study Medication Taken for a Migraine Attack With Moderate to Severe Headache Pain During the Double-blind Treatment Period 1 (DB1).
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcB - Bazett's Correction Formula
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcF - Fridericia's Correction Formula
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) PR Duration
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QRS Duration
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QT Duration
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) RR Duration
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Diastolic Blood Pressure
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Pulse Rate
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Respiratory Rate
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure
NCT03076970 (16) [back to overview]	Pharmacokinetics - AUC0-t
NCT03076970 (16) [back to overview]	Pharmacokinetics - Cmax
NCT03076970 (16) [back to overview]	Pharmacokinetics - Tmax
NCT03076970 (16) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Temperature
NCT03076970 (16) [back to overview]	Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Heart Rate
NCT03310411 (3) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0 ∞]) of Lasmiditan and Sumatriptan
NCT03310411 (3) [back to overview]	Pharmacodynamics (PD): Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP)
NCT03310411 (3) [back to overview]	Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan and Sumatriptan
NCT03338920 (1) [back to overview]	Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment

Percentage of Participants With Headache Relief at 60 Minutes Post Dose(Migraine) or 30 Minutes Post Dose(Cluster Headache)

Headache relief rate was the percentage of participants who showed effectiveness 60 minutes post dose (migraine) or 30 minutes post dose (cluster headache). Data for participants with percentage effectiveness along with 95% confidence interval has been presented. (NCT00356603)
Timeframe: 30 minutes or 60 Minutes after each administration

Intervention	Percentage of participants (Number)
Migraine	93.9
Cluster Headache	93.9
Migraine + Cluster Headache	93.9

Intervention	Participants (Count of Participants)
	Question 1: Yes	Question 1: No	Question 2: Yes	Question 2: No	Question 3: Yes	Question 3: No
Cluster Headache	33	0	31	2	29	4
Migraine	32	1	31	2	31	2
Migraine + Cluster Headache	65	1	62	4	60	6

Intervention	Participants (Number)
	Complete Pain/Symptom-Baseline	Complete Pain/Symptom-2 Hours Post-Dose	Complete Pain/Symptom-4 Hours Post-Dose	Complete Pain/Symptom-8 Hours Post-Dose
Placebo	132	121	114	106
Sumatriptan/Naproxen Sodium	134	94	70	58

Intervention	Participants (Number)
	Pain Free at 0.5 Hour Post-Dose	Pain Free at 1 Hour Post-Dose	Pain Free at 4 Hours Post-Dose	Pain Free at 8 Hours Post-Dose
Placebo	3	12	23	32
Sumatriptan/Naproxen Sodium	3	33	83	88

Intervention	Participants (Number)
	Migraine Associated Nausea at Baseline	Migraine Associated Nausea 2 Hours Post-Dose	Migraine Associated Nausea 4 Hours Post-Dose	Migraine Associated Nausea 8 Hours Post-Dose
Placebo	40	43	35	27
Sumatriptan/Naproxen Sodium	48	33	18	14

Intervention	Participants (Number)
	Migraine Assoc Phonophobia-Baseline	Migraine Assoc Phonophobia 2 Hours Post-Dose	Migraine Assoc Phonophobia 4 Hours Post-Dose	Migraine Assoc Phonophobia 8 Hours Post-Dose
Placebo	75	68	56	42
Sumatriptan/Naproxen Sodium	80	42	27	20

Intervention	Participants (Number)
	Migraine Assoc Photophobia-Baseline	Migraine Assoc Photophobia 2 Hours Post-Dose	Migraine Assoc Photophobia 4 Hours Post-Dose	Migraine Assoc Photophobia 8 Hours Post-Dose
Placebo	100	84	69	51
Sumatriptan/Naproxen Sodium	101	48	31	25

Intervention	Participants (Number)
	Migraine-Assoc Sinus Pain at Baseline	Migraine-Assoc Sinus Pain at 2 Hours Post-Dose	Migraine-Assoc Sinus Pain at 4 Hours Post-Dose	Migraine-Assoc Sinus Pain at 8 Hours Post-Dose
Placebo	47	40	36	27
Sumatriptan/Naproxen Sodium	56	41	27	20

Intervention	Participants (Number)
	Migraine-Free at 2 Hours Post-Dose	Migraine-Free at 4 Hours Post-Dose	Migraine-Free at 8 Hours Post-Dose
Placebo	15	20	30
Sumatriptan/Naproxen Sodium	46	76	83

Intervention	Participants (Number)
	Recurrence by 24 hours post-dose	Recurrence by 48 hours post-dose
Placebo	5	6
Sumatriptan/Naproxen Sodium	13	13

Intervention	Participants (Number)
	Migraine-Assoc Neck Pain at Baseline	Migraine-Assoc Neck Pain at 2 Hours Post-Dose	Migraine-Assoc Neck Pain at 4 Hours Post-Dose	Migraine-Assoc Neck Pain at 8 Hours Post-Dose
Placebo	81	71	65	51
Sumatriptan/Naproxen Sodium	75	52	38	29

Intervention	Participants (Number)
	1/2 hour post-dose	1 hour post-dose	4 hours post-dose	8 hours post-dose
Placebo	2	13	30	32
Sumatriptan-Naproxen Sodium	6	26	80	88

Intervention	Participants (Number)
	2 hours post-dose	4 hours post-dose	8 hours post-dose
Placebo	19	30	29
Sumatriptan-Naproxen Sodium	47	72	80

Intervention	Participants (Number)
	Baseline	2 hours post-dose	4 hours post-dose	8 hours post-dose
Placebo	58	52	39	35
Sumatriptan-Naproxen Sodium	61	31	20	19

Intervention	hr (Median)
	Sumatriptan, Non-migraine	Sumatriptan, Migraine	Naproxen, Non-migraine	Naproxen, Migraine
TREXIMA (Sumatriptan 85 mg + Naproxen 500 mg)	4.365	4.350	4.510	4.350

Intervention	microgramhr per mL (µghr/mL) (Geometric Mean)
	AUC (0-24), Sumatriptan, Non-migraine	AUC (0-24), Sumatriptan, Migraine	AUC (0-inf), Sumatriptan, Non-migraine	AUC (0-inf), Sumatriptan, Migraine	AUC (0-2), Sumatriptan, Non-migraine	AUC (0-2), Sumatriptan, Migraine	AUC (0-24), Naproxen, Non-migraine	AUC (0-24), Naproxen, Migraine	AUC (0-inf), Naproxen, Non-migraine	AUC (0-inf), Naproxen, Migraine	AUC (0-2), Naproxen, Non-migraine	AUC (0-2), Naproxen, Migraine
TREXIMA (Sumatriptan 85 mg + Naproxen 500 mg)	231.526	165.707	231.999	158.036	65.156	54.884	570.54	627.06	901.13	978.39	23.16	24.38

Intervention	hr (Median)
	Eletriptan, Non-Migraine	Eletriptan, Migraine
Relpax (Eletriptan 40 mg)	4.335	4.140

Intervention	Participants (Count of Participants)
	Any AEs	Any SAEs
Relpax (Eletriptan 40 mg)	3	0
TREXIMA (Sumatriptan 85 mg + Naproxen 500 mg)	8	0

Intervention	µg*hr/mL (Geometric Mean)
	AUC (0-inf), Non-migraine	AUC (0-inf), Migraine	AUC (0-2), Non-migraine	AUC (0-2), Migraine
Relpax (Eletriptan 40 mg)	540.669	570.860	70.249	78.092

Intervention	hours (hr) (Median)
	10% gastric emptying, Eletriptan, Non-migraine	10% gastric emptying, Eletriptan, Migraine	50% gastric emptying, Eletriptan, Non-migraine	50% gastric emptying, Eletriptan, Migraine	90% gastric emptying, Eletriptan, Non-migraine	90% gastric emptying, Eletriptan, Migraine	Complete gastric emptying, Eletriptan,Non-migraine	Complete gastric emptying, Eletriptan, Migraine
Relpax (Eletriptan 40 mg)	0.400	0.410	0.590	0.890	2.590	2.490	3.765	3.510

Intervention	hours (hr) (Median)
	10% gastric emptying, Sumatriptan, Non-migraine	10% gastric emptying, Sumatriptan, Migraine	10% gastric emptying, Naproxen, Non-migraine	10% gastric emptying, Naproxen, Migraine	50% gastric emptying, Sumatriptan, Non-migraine	50% gastric emptying, Sumatriptan, Migraine	50% gastric emptying, Naproxen, Non-migraine	50% gastric emptying, Naproxen, Migraine	90% gastric emptying, Sumatriptan, Non-migraine	90% gastric emptying, Sumatriptan, Migraine	90% gastric emptying, Naproxen, Non-migraine	90% gastric emptying, Naproxen, Migraine	Complete gastric emptying,Sumatriptan,Non-migraine	Complete gastric emptying, Sumatriptan, Migraine	Complete gastric emptying, Naproxen, Non-migraine	Complete gastric emptying, Naproxen, Migraine
TREXIMA (Sumatriptan 85 mg + Naproxen 500 mg)	0.100	0.130	1.195	1.300	0.675	1.070	2.260	2.310	3.020	3.440	4.290	4.010	4.505	4.000	4.760	4.500

sumatriptan

Description

Cross-References

Synonyms (112)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Protein Targets (48)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (307)

Molecular Functions (82)

Ceullar Components (72)

Bioassays (359)

Research

Studies (2,271)

Market Indicators

Research Demand Index: 84.63

Study Types

Clinical Trials (109)

Trial Overview

Trial Outcomes

Percentage of Participants With Headache Relief at 60 Minutes Post Dose(Migraine) or 30 Minutes Post Dose(Cluster Headache)

Percentage of Participants With Investigator/Sub Investigator-rated Successful Self-injection Rate

Number of Participants With Subject-rated Acceptability of the Sumatriptan 3mg Kit Product

Complete Pain/Symptom-Free Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine Headache Pain Free at 0.5, 1, 4, and 8 Hours Post-Dose

Migraine-Associated Nausea Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Phonophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Photophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Sinus Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Free Assessment at 2, 4, and 8 Hours Post-dose

Recurrence of Any Migraine Headache Pain

Sustained Freedom From Migraine-Associated Neck Pain

Sustained Freedom From Migraine-Associated Phonophobia

Sustained Freedom From Migraine-Associated Photophobia

Sustained Freedom From Migraine-Associated Nausea

Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose

Sustained Freedom From Migraine

Sustained Complete Pain/Symptom-Free

Rescue Medication Use During 0 - 24 Hours Post-Dose

Migraine Headache Pain Free at 2 Hours Post-Dose

Migraine-Associated Neck Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Sustained Freedom From Migraine-Associated Sinus Pain

Sustained Freedom From Migraine-Associated Nausea

Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose

Sustained Freedom From Migraine

Sustained Complete Pain/Symptom-Free

Rescue Medication Used up to 24 Hours Post-dose

Pain-Free Assessment at 2 Hours Post-dose

Recurrence of Any Migraine Headache Pain

Pain-Free Assessment at 1/2, 1, 4, 8 Hours Post-dose

Migraine-Free Assessment at 2, 4, and 8 Hours Post-dose

Migraine-Associated Sinus Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Photophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Phonophobia Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Neck Pain Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Migraine-Associated Nausea Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Complete Pain/Symptom-Free Assessed at Baseline, 2, 4, and 8 Hours Post-dose

Sustained Freedom From Migraine-Associated Sinus Pain

Sustained Freedom From Migraine-Associated Photophobia

Sustained Freedom From Migraine-Associated Phonophobia

Sustained Freedom From Migraine-Associated Neck Pain

Time to First Appearance of Sumatriptan, Naproxen and Eletriptan at the Proximal Small Intestine

Cmax for Eletriptan

Maximum Observed Drug Concentration (Cmax) for Sumatriptan and Naproxen

Mean Area Under the Drug Concentration Time Curve (AUC) From Time of Dosing Through 2 Hour Post-dose [AUC (0-2)], Through 24 Hour [AUC (0-24)] and AUC From Time of Dosing Extrapolated to Infinity [AUC (0-inf)] for Sumatriptan and Naproxen

Time of Maximal Drug Concentration (Tmax) for Sumatriptan and Naproxen

Small Intestine Transit and Residence (Time to 50% Through Intestine) of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan

Intervention	Participants (Number)
	Pain-free at 4 hours	Pain-free at 1 hour	Pain-free at 0.5 hour
Placebo	60	16	6
Sumatriptan/Naproxen	105	23	5

Intervention	Participants (Number)
	Headache relief at 4 hours	Headache relief at 2 hours	Headache relief at 1 hour	Headache relief at 0.5 hour
Placebo	108	113	73	39
Sumatriptan/Naproxen	153	124	85	41

Intervention	Participants (Number)
	Headache-Assoc. Neck Pain at 4 hours	Headache-Assoc. Neck Pain at 2 hours	Headache-Assoc. Sinus Pain at 4 hours	Headache-Assoc. Sinus Pain at 2 hours	Headache-Assoc. Photophobia at 4 hours	Headache-Assoc. Photophobia at 2 hours	Headache-Assoc. Phonophobia at 4 hours	Headache-Assoc. Phonophobia at 2 hours	Headache-Assoc. Nausea at 4 hours	Headache-Assoc. Nausea at 2 hours
Placebo	93	68	88	49	87	60	83	53	82	37
Sumatriptan/Naproxen	63	59	49	36	60	46	59	54	51	36

Intervention	Participants (Number)
	Intermed. Sustained Pain-free, 2-4 hrs post-dose	Intermed. Sustained Pain-free, 1-2 hrs post-dose
Placebo	22	11
Sumatriptan/Naproxen	61	23

Intervention	Participants (Number)
	Pain-Free (2 hours)	Sustained Pain-Free (2-24 hours)
Placebo	25	20
Sumatriptan/Naproxen	64	54

Intervention	Score in scale (Mean)
	Efficacy Adjusted Mean	Functionality Adjusted Mean	Ease-of-Use Adjusted Mean	Bothersome-of-Side Effects Adjusted Mean	Total Score adjusted Mean
Placebo	53	56	84	94	64
Sumatriptan/Naproxen	67	70	88	91	75

Intervention	Participants (Number)
	Intermed. Sustained Pain Relief, 2-4 hrs post-dose	Intermed. Sustained Pain Relief, 1-2 hrs post-dose
Placebo	92	67
Sumatriptan/Naproxen	118	84

Intervention	treated migraine attacks (Number)
	Photophobia	Phonophobia	Nausea	Neck pain	Sinus pain	Vomiting
12 Month Completer Population	4064	3725	2173	2172	1424	375
6 Month Completer Population	5608	5221	3120	3050	2052	555
ITT Population	6528	6063	3690	3540	2428	682

Intervention	treated migraine attacks (Number)
	All Migraines	Migraines Without Rescue Medication	Migraines Without Rescue or Prohibited Medication
85 mg Sumatriptan/500 mg Naproxen Sodium	8517	7791	7657

Intervention	participants (Number)
	Hemoglobin, normal to high, n=318,176, 546	Hemoglobin, normal to low, n=318,176, 546	Hematocrit, normal to high, n=318,176, 546	Hematocrit, normal to low, n=318,176, 546
12 Month Completer Population	0	6	0	10
6 Month Completer Population	6	10	2	17
Safety Population	9	20	4	29